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Abstract 
Ovarian cancer is the 5
th
 most common cancer in females and the UK has one of the highest incident rates 
in Europe. In the UK only 36% of patients will live for at least 5 years after diagnosis. The number of 
prognostic markers, treatments and the sequences of treatments in ovarian cancer are rising. Therefore, it 
is getting more difficult for the human brain to perform clinical decision making. There is a need for an 
expert computer system (e.g. Artificial Intelligence (AI)), which is capable of investigating the possible 
outcomes for each marker, treatment and sequence of treatment. Such expert systems may provide a tool 
which could help clinicians to analyse and predict outcome using different treatment pathways. 
 Whilst prediction of overall survival of a patient is difficult there may be some benefits, as this not only 
is useful information for the patient but may also determine treatment modality.  
In this project a dataset was constructed of 352 patients who had been treated at a single centre. Clinical 
data were extracted from the health records. Expert systems were then investigated to determine the 
optimum model to predict overall survival of a patient. The five year survival period (a standard survival 
outcome measure in cancer research) was investigated; in addition, the system was developed with the 
flexibility to predict patient survival rates for many other categories. Comparisons with currently used 
prognostic models in ovarian cancer demonstrated a significant improvement in performance for the AI 
model (Area under the Curve (AUC) of 0.72 for AI and AUC of 0.62 for the statistical model). Using 
various methods, the most important variables in this prediction were identified as: FIGO stage, outcome 
of the surgery and CA125. This research investigated the effects of increasing the number of cases in 
prediction models. Results indicated that by increasing the number of cases, the prediction performance 
improved. Categorization of continuous data did not improve the prediction performance. 
The project next investigated the possibility of predicting surgical outcomes in ovarian cancer using AI, 
based on the variables that are available for clinicians prior to the surgery. Such a tool could have direct 
clinical relevance. Diverse models that can predict the outcome of the surgery were investigated and 
developed. The developed AI models were also compared against the standard statistical prediction 
model, which demonstrated that the AI model outperformed the statistical prediction model: the 
prediction of all outcomes (complete or optimal or suboptimal) (AUC of AI: 0.71 and AUC of statistical 
model: 0.51), the prediction of complete or optimal cytoreduction versus suboptimal cytoreduction (AUC 
of AI: 0.73 and AUC of statistical model: 0.50) and finally the prediction of complete cytoreduction 
versus optimal or suboptimal cytoreduction (AUC of AI: 0.79 and AUC of statistical model: 0.47). The 
most important variables for this prediction were identified as: FIGO stage, tumour grade and histology.  
The application of transcriptomic analysis to cancer research raises the question of which genes are 
significantly involved in a particular cancer and which genes can accurately predict survival outcomes in 
a given cancer. Therefore, AI techniques were employed to identify the most important genes for the 
prediction of Homologous Recombination (HR), an important DNA repair pathway in ovarian cancer, 
identifying LIG1 and POLD3 as novel prognostic biomarkers.  Finally, AI models were used to predict 
the HR status for any given patient (AUC: 0.87).  
This project has demonstrated that AI may have an important role in ovarian cancer.  AI systems may 
provide tools to help clinicians and research in ovarian cancer and may allow more informed decisions 
resulting in better management of this cancer. 
  
iv 
Acknowledgements 
This thesis would not have been possible without the assistance and support of many 
great people. I would like to express my deep gratitude to my supervisor Dr. Richard 
Edmondson for his enthusiastic guidance in this research. Many thanks go to Dr. Joe 
Faith for his help and guidance.  
I am also grateful to all the staff at the Northern Institute for Cancer Research for 
helping and supporting in any form. I also thank to all my friends and colleagues who 
have supported me and helped me. 
I give my deepest love and appreciation to my mother, and my family for their 
unconditional love and support. Finally, I am deeply indebted to my dear partner Juila 
for her love, patience and encouragement all these years. 
 
v 
Abbreviations 
AI Artificial Intelligence  
ANN Artificial Neural Network 
AUC Area Under Curve 
BN Bayesian Network 
CT Computed tomography  
DNA Deoxyribonucleic Acid 
DT Decision tree 
FIGO International Federation of Gynecology and Obstetrics 
FN False negative  
FP False positive  
FS Feature Selection 
GA Genetic algorithm  
HR Homologous recombination  
IG Information Gain 
KNN K- Nearest Neighbour  
LOOCV Leave One Out Cross Validation  
MAE Mean Absolute Error  
MDT Multi-disciplinary team 
ML Machine learning  
MRI Ultrasound and Magnetic Resonance Imaging  
OS Overall survival  
OV_TMA_2000 Newcastle ovarian cancer tissue micro array 2000  
OV_TMA_2005 Newcastle ovarian cancer tissue micro array 2005 
vi 
PARP Poly (ADP-ribose) polymerase  
PC Principal component  
PCA Principal Component Analysis  
RMSE Root Mean Squared Error  
RNN Recurrent Neural Network  
ROC Receiver Operating Characteristic  
RPP Relative Projection Pursuit  
TN True negative  
TP True positive  
TPP Targeted Projection Pursuit  
vii 
 
Table of Contents 
 
Declaration ....................................................................................................................... ii 
Abstract ........................................................................................................................... iii 
Acknowledgements ......................................................................................................... iv 
Abbreviations .................................................................................................................. v 
Table of Contents .......................................................................................................... vii 
List of Figures .................................................................................................................. x 
List of Tables ................................................................................................................ xiii 
List of Equations ........................................................................................................... xv 
Chapter 1 Introduction ................................................................................................... 1 
1.1 Introduction ............................................................................................................. 2 
1.2 Ovarian cancer ........................................................................................................ 2 
1.2.1 Current understanding ...................................................................................... 2 
1.2.1.1 Stage .......................................................................................................... 2 
1.2.1.2 Grade ......................................................................................................... 5 
1.2.1.3 CA125 Biomarker ..................................................................................... 6 
1.2.1.4 Tumour Histology ..................................................................................... 7 
1.2.1.5 Radiography .............................................................................................. 7 
1.2.1.6 Age ............................................................................................................ 8 
1.2.1.7 Physical examination ................................................................................ 9 
1.2.1.8 Surgery .................................................................................................... 10 
1.2.1.9 Other possible contributors ..................................................................... 12 
1.2.1.10 Standard management ........................................................................... 12 
1.2.1.11 Outcomes of the management ............................................................... 13 
1.2.2 Clinical decision making ................................................................................ 14 
1.2.3 Future paths .................................................................................................... 15 
1.3 Computing approaches .......................................................................................... 16 
1.3.1 Machine learning (ML) .................................................................................. 17 
1.3.1.1 Nearest Neighbour approach (Decision tree) .......................................... 18 
1.3.1.2 Neural networks ...................................................................................... 25 
1.3.1.3 Bayesian Networks ................................................................................. 32 
1.3.2 Feature Selection ............................................................................................ 37 
1.3.2.1 Principal Component Analysis (PCA) .................................................... 38 
1.3.2.2 Information Gain (IG) ............................................................................. 44 
1.3.2.3 Targeted Projection Pursuit (TPP) .......................................................... 47 
1.3.2.4 Genetic algorithm (GA) .......................................................................... 51 
1.4 Research outline .................................................................................................... 58 
1.4.1 Statement of the problem ............................................................................... 58 
1.4.1.1 Complexity of the ovarian cancer management ...................................... 58 
1.4.1.2 Prediction of survival .............................................................................. 58 
1.4.1.3 Surgical prediction .................................................................................. 59 
1.4.2 Research questions ......................................................................................... 59 
1.4.3 Structure of the thesis ..................................................................................... 59 
Chapter 2 Data and Data handling ............................................................................. 61 
2.1 Introduction ........................................................................................................... 62 
viii 
2.2 Datasets ................................................................................................................. 62 
2.2.1 Newcastle ovarian cancer tissue micro array 2000 (OV_TMA_2000) .......... 62 
2.2.2 Newcastle ovarian cancer tissue micro array 2005 (OV_TMA_2005) .......... 67 
2.3 Data pre-processing ............................................................................................... 72 
2.3.1 Handling missing values ................................................................................ 72 
2.3.2 Outliers ........................................................................................................... 72 
2.3.3 Coding the input values .................................................................................. 74 
2.3.4. Normalization and scaling............................................................................. 74 
2.4 Comparison of datasets ......................................................................................... 75 
2.5 Summary of chapter .............................................................................................. 78 
Chapter 3 Experimental methodology ........................................................................ 79 
3.1 Introduction ........................................................................................................... 80 
3.2 Estimates of prediction performance .................................................................... 80 
3.2.1 Resubstitution Validation ............................................................................... 80 
3.2.2 Hold-out validation ........................................................................................ 81 
3.2.3 K-Fold Cross-Validation ................................................................................ 82 
3.2.4 Leave-One-Out Cross-Validation (LOOCV) ................................................. 83 
3.2.5 Repeated k-fold Cross-Validation .................................................................. 84 
3.2.6 Evaluation of the estimates ............................................................................ 84 
3.3 Prediction performance measurements ................................................................. 85 
3.3.1 Possible outcomes of a model ........................................................................ 85 
3.3.2 Accuracy ........................................................................................................ 86 
3.3.3 Recall.............................................................................................................. 87 
3.3.4 Precision ......................................................................................................... 87 
3.3.5 Mean Absolute Error (MAE) ......................................................................... 88 
3.3.6 Root Mean Squared Error (RMSE) ................................................................ 88 
3.3.7 Receiver Operating Characteristic (ROC) ..................................................... 89 
3.4 Over fitting ............................................................................................................ 90 
3.5 Process definition .................................................................................................. 92 
3.6 Summary of the chapter ........................................................................................ 94 
Chapter 4 Prognostic Data ........................................................................................... 95 
4.1 Introduction ........................................................................................................... 96 
4.2 Finding the best feature set ................................................................................... 96 
4.2.1 The optimum feature set size ......................................................................... 96 
4.2.2 The most important features in the dataset .................................................... 99 
4.2.2.1 One feature sets ....................................................................................... 99 
4.4.2.2 Two features sets ................................................................................... 101 
4.4.2.3 Three features sets ................................................................................. 103 
4.4.2.4 Four features sets................................................................................... 105 
4.4.2.5 Five features sets ................................................................................... 107 
4.4.3 Discovering best features using feature selection techniques ...................... 109 
4.3 Prediction of survival for many categories ......................................................... 110 
4.3.1 Analysis of 64 survival categories ............................................................... 110 
4.3.2 Analysis of Overall Survival (OS) ............................................................... 115 
4.4 Categorization of the continues data ................................................................... 117 
4.5 Model analysis by increasing the number of data ............................................... 119 
4.6 The best model .................................................................................................... 120 
4.7 Comparison with conventional statistics ............................................................. 123 
4.8 Comparison with pervious work ......................................................................... 125 
4.9 Summary of the chapter ...................................................................................... 125 
Chapter 5 Surgical Prediction ................................................................................... 128 
5.1 Introduction ......................................................................................................... 129 
ix 
5.2 Statement of the problem .................................................................................... 129 
5.3 Residual prediction.............................................................................................. 131 
5.3.1 Residual prediction: Complete/Optimal/Sub-optimal cytoreduction ........... 132 
5.3.2 Residual prediction: Complete and Optimal versus Suboptimal cytoreduction
 ............................................................................................................................... 139 
5.3.3 Residual prediction: Complete versus Optimal or Sub-optimal cytoreduction
 ............................................................................................................................... 145 
5.4 Discovering important factors ............................................................................. 151 
5.5 Summary of the chapter .................................................................................. 151 
Chapter 6 Gene analysis for classification of Homologous recombination ........... 153 
6.1 Introduction ......................................................................................................... 154 
6.2 statement of the problem ..................................................................................... 154 
6.3 Dataset ................................................................................................................. 156 
6.4 Most important Genes ......................................................................................... 160 
6.5 HR prediction models ......................................................................................... 162 
6.6 Summary of the chapter ...................................................................................... 165 
Chapter 7 Conclusion and Future Works ................................................................. 166 
7.1 Introduction ......................................................................................................... 167 
7.2 Conclusions of the Thesis ................................................................................... 167 
7.3 Summary of main contributions .......................................................................... 167 
7.3.1 The review of related problems ................................................................... 167 
7.3.2 The solution for prediction ........................................................................... 168 
7.3.3 The prototype implementation and evaluation ............................................. 169 
7.4 Further work ........................................................................................................ 170 
7.5 The overall achievement of the thesis ................................................................. 171 
Appendices ................................................................................................................... 173 
Appendix 1 Prototype snapshot ................................................................................ 173 
Appendix 2 class diagrams ....................................................................................... 174 
References .................................................................................................................... 178 
 
 
 
  
x 
List of Figures 
Figure 1-1 Age associated incidence of ovarian cancer .................................................... 9 
Figure 1-2 KNN method example (artificial dataset) ..................................................... 20 
Figure 1-3 Decision Tree example .................................................................................. 24 
Figure 1-4 Biological neuron .......................................................................................... 27 
Figure 1-5 Artificial model of a neuron .......................................................................... 27 
Figure 1-6 Feed Forward ANN model ............................................................................ 29 
Figure 1-7 Neural network for AND function ................................................................ 31 
Figure 1-8 Connections in Bayesian network ................................................................. 35 
Figure 1-9 Bayesian network of probability of raining today and tomorrow ................. 36 
Figure 1-10 Transformation of dataset using PCA ......................................................... 39 
Figure 1-11 The TPP process .......................................................................................... 48 
Figure 1-12 original view of SRBCT dataset using TPP ................................................ 50 
Figure 1-13 separated class view of SRBCT dataset using TPP ..................................... 50 
Figure 1-14 Significant variables in SRBCT discovered using TPP .............................. 50 
Figure 1-15 GA process .................................................................................................. 55 
Figure 1-16 GA process example .................................................................................... 56 
Figure 2-1The issue of outliers in the dataset ................................................................. 73 
Figure 2-2 Two datasets comparison .............................................................................. 77 
Figure 2-3 Survival vs. Outcome of surgery 2000-2005................................................. 77 
Figure 3-1 Resubstitution Validation .............................................................................. 81 
Figure 3-2 Hold-out Validation ....................................................................................... 82 
Figure 3-3  4-fold Cross-Validation ................................................................................ 83 
Figure 3-4 Leave-One-Out Cross-Validation.................................................................. 84 
Figure 3-5 The possible outcomes of prediction ............................................................. 86 
Figure 3-6 Receiver operating characteristic (ROC) ...................................................... 89 
Figure 3-7 Stop training time .......................................................................................... 92 
Figure 3-8 Process definition .......................................................................................... 93 
Figure 4-1 the optimum feature set size (Accuracy) ....................................................... 98 
Figure 4-2 the optimum feature set size (MAE) ............................................................. 98 
Figure 4-3 the optimum feature set size (RMSE) ........................................................... 98 
Figure 4-4 one feature sets performance results ........................................................... 100 
Figure 4-5 two features sets performance results .......................................................... 102 
Figure 4-6 three features sets performance results ........................................................ 104 
Figure 4-7 four features sets performance results ......................................................... 106 
xi 
Figure 4-8 five features sets performance results ......................................................... 108 
Figure 4-9 Prediction performance results for 64 categories of survival ...................... 112 
Figure 4-10 ROC curves: 2 survival categories ............................................................ 114 
Figure 4-11 ROC curves: 4 survival categories ............................................................ 114 
Figure 4-12 OS prediction performance: ROC curves .................................................. 116 
Figure 4-13 Effects of increasing number of cases on accuracy of the model ............. 120 
Figure 4-14 Prediction performance comparison (ANN, DT and BN) ......................... 122 
Figure 4-15 Model comparison using ROC curve ........................................................ 122 
Figure 4-16 ANN vs. Logistic Regression .................................................................... 124 
Figure 4-17 ANN vs. Logistic Regression (ROC curves)............................................. 124 
Figure 5-1 ROC curve (ANN): Complete / Optimal /Sub-optimal cytoreduction (CA125 
not categorized) ............................................................................................................. 135 
Figure 5-2 ROC Curve (Logistic Regression): Complete / Optimal /Suboptimal 
cytoreduction (CA125 not categorized) ........................................................................ 135 
Figure 5-3 ROC curve (ANN): Complete / Optimal /Suboptimal cytoreduction (CA125 
categorized) ................................................................................................................... 138 
Figure 5-4 ROC Curve (Logistic Regression): Complete / Optimal /Suboptimal 
cytoreduction (CA125 categorized) .............................................................................. 138 
Figure 5-5 ROC curve (ANN): (Complete or Optimal) cytoreduction versus Sub-
optimal cytoreduction (CA125 not categorized) ........................................................... 141 
Figure 5-6 ROC curve (Logistic Regression): (Complete or Optimal) cytoreduction 
versus Sub-optimal cytoreduction (CA125 not categorized) ........................................ 141 
Figure 5-7 ROC curve (ANN): (Complete or Optimal) cytoreduction versus Sub-
optimal cytoreduction (CA125 categorized) ................................................................. 144 
Figure 5-8 ROC curve (Logistic Regression): (Complete or Optimal) cytoreduction 
versus Sub-optimal cytoreduction (CA125 not categorized) ........................................ 144 
Figure 5-9 ROC curve (ANN): Complete cytoreduction versus (Optimal or Sub-
optimal) cytoreduction (CA125 not categorized) ......................................................... 147 
Figure 5-10 ROC curve (Logistic Regression): Complete cytoreduction versus (Optimal 
or Sub-optimal) cytoreduction (CA125 not categorized).............................................. 147 
Figure 5-11 ROC curve (ANN): Complete cytoreduction versus (Optimal or Sub-
optimal) cytoreduction (CA125 categorized)................................................................ 150 
Figure 5-12  ROC curve (Logistic Regression): Complete cytoreduction versus 
(Optimal or Sub-optimal) cytoreduction (CA125 categorized) .................................... 150 
Figure 6-1 Selective cytotoxity of PARP inhibitors ..................................................... 155 
xii 
Figure 6-2 First view of dataset using TPP ................................................................... 161 
Figure 6-3 Separated class view of the dataset using TPP ............................................ 161 
Figure 6-4 HR prediction ROC curves using ANN ...................................................... 162 
Figure 6-5 HR prediction ROC curves using BN ......................................................... 163 
Figure 6-6 HR prediction ROC curves using DT ......................................................... 164 
  
xiii 
List of Tables 
Table 1-1 International Federation of Gynecology and Obstetrics (FIGO) staging system 
for Ovarian cancer ............................................................................................................. 4 
Table 1-2 Five year survival rate for different stages of Ovarian cancer.......................... 5 
Table 1-3 Grading of ovarian cancer ................................................................................ 6 
Table 1-4 Radiographic characteristics of Adnexel masses .............................................. 8 
Table 1-5 Characteristics of Pelvic mass on physical examination ................................ 10 
Table 1-6 Outcomes of the surgery ................................................................................. 12 
Table 1-7 Outcomes of the management ........................................................................ 14 
Table 1-8 Play Golf dataset ............................................................................................. 22 
Table 1-9 AND function truth table ................................................................................ 31 
Table 1-10 Joint probability results using Bayesian theory ............................................ 36 
Table 1-11 Artificial dataset for explaining PCA process .............................................. 40 
Table 1-12 Normalized artificial dataset for explaining PCA process ........................... 40 
Table 1-13 The amount of information required to assign objects to each class for 
variable ‘Outlook’ ........................................................................................................... 45 
Table 1-14 Artificial dataset as an example for GA process .......................................... 55 
Table 2-1 OV_TMA_2000 .............................................................................................. 63 
Table 2-2 OV_TMA_2000 Age ...................................................................................... 64 
Table 2-3 OV_TMA_2000 FIGO stage .......................................................................... 64 
Table 2-4 OV_TMA_2000 Grade ................................................................................... 65 
Table 2-5 OV_TMA_2000 Histological subtype ............................................................ 65 
Table 2-6 OV_TMA_2000 CA125 ................................................................................. 66 
Table 2-7 OV_TMA_2000 Outcome of the surgery ....................................................... 66 
Table 2-8 Analysed data for collection of OV_TMA_2005 dataset ............................... 67 
Table 2-9 OV_TMA_2005 .............................................................................................. 68 
Table 2-10 OV_TMA_2005 Age .................................................................................... 69 
Table 2-11 OV_TMA_2005 FIGO stage ........................................................................ 69 
Table 2-12 OV_TMA_2005 Grade ................................................................................. 70 
Table 2-13 OV_TMA_2005 Histological subtype .......................................................... 70 
Table 2-14 OV_TMA_2005 CA125 ............................................................................... 71 
Table 2-15 OV_TMA_2005 Outcome of the surgery ..................................................... 71 
Table 3-1 AUC results interpretation .............................................................................. 90 
Table 4-1 Important features using feature selection techniques .................................. 109 
Table 4-2 Prediction performance results for 64 survival categories (Accuracy) ........ 112 
xiv 
Table 4-3 OS prediction performance ........................................................................... 116 
Table 4-4 Prediction performance: Categorized data versus Continuous data ............. 118 
Table 5-1 Prediction performance of results for complete/optimal/sub-optimal 
cytoreduction when CA125 is not categorized using ANN .......................................... 134 
Table 5-2 Prediction performance results for complete/optimal/suboptimal 
cytoreduction when CA125 is not categorized using Logistic Regression ................... 134 
Table 5-3 Prediction performance results for complete/optimal/sub-optimal 
cytoreduction when CA125 is categorized using ANN ................................................ 137 
Table 5-4 Prediction performance results for complete/optimal/sub-optimal 
cytoreduction when CA125 is categorized using Logistic Regression ......................... 137 
Table 5-5 Prediction performance results for (complete or optimal) cytoreduction versus 
sub-optimal cytoreduction when CA125 is not categorized using ANN ...................... 140 
Table 5-6 Prediction performance results for (complete or optimal) cytoreduction versus 
sub-optimal cytoreduction when CA125 is not categorized using Logistic Regression
 ....................................................................................................................................... 140 
Table 5-7 Prediction performance results for (complete or optimal) cytoreduction versus 
sub-optimal cytoreduction when CA125 is categorized using ANN ............................ 143 
Table 5-8 Prediction performance results for (complete or optimal) cytoreduction versus 
suboptimal cytoreduction when CA125 is categorized using Logistic Regression ...... 143 
Table 5-9 Prediction performance results for complete cytoreduction versus (optimal or 
sub-optimal) cytoreduction when CA125 is not categorized using ANN..................... 146 
Table 5-10 Prediction performance results for complete cytoreduction versus (optimal 
or sub-optimal) cytoreduction when CA125 is not categorized using Logistic 
Regression ..................................................................................................................... 146 
Table 5-11 Prediction performance results for complete cytoreduction versus (optimal 
or sub-optimal) cytoreduction when CA125 is categorized using ANN ...................... 149 
Table 5-12 Prediction performance results for complete cytoreduction versus (optimal 
or sub-optimal) cytoreduction when CA125 is categorized using Logistic Regression149 
Table 5-13 The most important variable identified using feature selection methods ... 151 
Table 6-1 Gene analysis dataset .................................................................................... 159 
Table 6-2 12 most differentially regulated genes identified between 4 HR competent and 
4 HR deficient tumours using three methods ................................................................ 161 
Table 6-3 ANN prediction performance results (HR)................................................... 162 
Table 6-4 BN prediction performance results (HR) ...................................................... 163 
Table 6-5 DT prediction performance results (HR) ...................................................... 164 
xv 
List of Equations 
Equation 1-1 Entropy using the frequency table of one variable .................................... 21 
Equation 1-2 Entropy using frequency table of two variables ........................................ 21 
Equation 1-3 Information Gain of variable X ................................................................. 21 
Equation 1-4 The value of the net (artificial neuron) ...................................................... 26 
Equation 1-5 The output of the net ................................................................................. 26 
Equation 1-6 Sum of Squared Error (SSE) ..................................................................... 28 
Equation 1-7 Calculating the error of the neuron............................................................ 29 
Equation 1-8 Adjusting the weights ................................................................................ 30 
Equation 1-9 Bayesian theory ......................................................................................... 33 
Equation 1-10 Covariance of X and Y ............................................................................ 41 
Equation 1-11 Covariance matrix ................................................................................... 41 
Equation 1-12 Amount of information required to assign an object to class P or N ...... 44 
Equation 1-13 the entropy needed to classify objects in Si subsets ................................ 44 
Equation 1-14 Information gained by dividing on attribute A ........................................ 45 
Equation 1-15 definition of projection p in TPP ............................................................. 49 
Equation 1-16 Euclidean norm........................................................................................ 49 
Equation 2-1 zero-mean normalization ........................................................................... 75 
Equation 2-2 max-min normalization ............................................................................. 75 
Equation 3-1 True error rate of k-fold cross-validation .................................................. 82 
Equation 3-2 True Negative Rate .................................................................................... 86 
Equation 3-3 False Negative Rate ................................................................................... 86 
Equation 3-4 Accuracy .................................................................................................... 87 
Equation 3-5 Recall of given class a ............................................................................... 87 
Equation 3-6 Precision of given class a .......................................................................... 88 
Equation 3-7 Mean Absolute Error ................................................................................. 88 
Equation 3-8 Root Mean Squared Error ......................................................................... 89 
Equation 3-9 Area under ROC curve (AUC) .................................................................. 90 
1 
 
Chapter 1 Introduction 
  
2 
1.1 Introduction  
This chapter of the thesis introduces ovarian cancer. The disease is briefly described  
along with a discussion of the current understanding of the disease. Furthermore, the 
standard management of this cancer is introduced and the process of clinical decision 
making process is discussed. Finally, current challenges in ovarian cancer are 
highlighted.  
The second section of this chapter then discusses artificial intelligence, specifically, 
machine learning and feature selection techniques. The relative merits of different 
methods are outlined. 
Finally this chapter draws these two areas into a series of research questions.  
1.2 Ovarian cancer 
According to Cancer Research UK (2008a), 190,000 new cases of ovarian cancer are 
reported each year worldwide; representing about 4% of all cancers diagnosed in 
women.  In the past 30 years there has been an 18% increase in ovarian cancer patients 
reported in the UK (Cancer Research UK, 2008a). Ovarian cancer is the 5th most 
common cancer in females in UK, with 6,800 cases each year, the UK has one of the 
highest incident rates in Europe (Cancer Research UK, 2008b). Although there has been 
a modest improvement in ovarian cancer treatments in the past 20 years, the long term 
survival rates have changed very little. In the UK only 36% of the patients will live for 
at least 5 years after diagnosis (Cancer Research UK, 2008c), although this rate varies 
for different stages of the cancer and the survival rate is around 90% in early stages 
compared to 15% at the late stages (Ghaemmghami, Orton and Soutter, 2003).  The cost 
of ovarian cancer treatment in the UK and other European countries is unclear; however 
as an example, the Australian government estimates a lifetime treatment cost per case of 
$19,677 in 2000-01 (AIHW, 2006).  
1.2.1 Current understanding 
This section of the thesis investigates the current understanding of ovarian cancer. The 
different characteristics of the cancer and the standard management of this cancer are 
included in the following sections.  
1.2.1.1 Stage 
Ovarian cancer has been divided into four categories based on anatomical distribution of 
the disease, called stages by the ‘International Federation of Gynecology and Obstetrics’ 
(FIGO) (Chi and Hoskins, 2000). These stages are expressed in Roman numerals from 
3 
stage I (the least advanced stage) to stage IV (the most advanced stage). Stage is a 
useful classification as it dictates not only prognosis but is used to determine treatment 
Leitao and Barakat (2009).  
Table 1-1 summarizes the characteristics of different stages of ovarian cancer (Chi and 
Hoskins, 2000).    
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Stage Characteristics 
I Growth limited to the ovaries 
A Growth limited to one ovary; no ascites; no tumour on the external surface; 
capsule intact 
B Growth limited to both ovaries; no ascites; no tumour on the external 
surfaces; capsule intact.  
C Tumour either Stage I A or I B. but with tumour on the external surface of 
one or both ovaries; or with capsule ruptured; or with malignant cells in 
ascites or peritoneal washings.  
II Growth involving one or both ovaries with pelvic extension. 
A Extension and/or metastases to the uterus and/or tubes 
B Extension to other pelvic tissues 
C Tumour either stage II A or II B, but with tumour on the surface of one or 
both ovaries; or capsule ruptured; or with malignant cells in ascites or 
peritoneal washings.  
III  Tumour involving one or both ovaries with peritoneal implants outside the 
pelvis and/or positive retroperitoneal or inguinal lymph nodes. Superficial 
liver metastasis equals stage III. Tumour is limited to the true pelvis but with 
histologically verified malignant extension small bowel or omentum. 
A Tumour grossly limited to the true pelvis but with histologically confirmed 
microscopic of abdominal peritoneal surfaces  
B Tumour involving one or both ovaries with histologically confirmed 
implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter. 
Nodes are negative.  
C Abdominal implants greater than 2 cm in diameter and/or positive 
retroperitoneal or inguinal nodes. 
IV Growth involving one or both ovaries with distant metastases. If pleural 
effusion is present there must be positive cytology to allot a case to stage IV. 
Parenchymal liver metastases equals stage IV. 
 
Table 1-1 International Federation of Gynecology and Obstetrics (FIGO) staging system for 
Ovarian cancer  
(Chi and Hoskins, 2000) 
 
5 
The majority of cases present at high (FIGO III/IV) stage, Simon (2005). The 5 year 
survival rate varies for different stages of the cancer. Patients with early stage (I) 
ovarian cancer have 80-90% chance of five year survival (Table 1-2).  
 
Table 1-2 summarizes the five year survival chance for different stages of ovarian 
cancer (Chi and Hoskins, 2000).  
Stage Five year survival 
I 80-90% 
II 80% 
III 15-40% 
IV 5-20% 
Table 1-2 Five year survival rate for different stages of Ovarian cancer  
(Chi and Hoskins, 2000) 
1.2.1.2 Grade  
Grade is an important prognostic factor for ovarian cancer and refers to how abnormal 
the cancer cells look when viewed through a microscope (Larma and Gardner, 2006). 
Normal cells grow and develop into mature cells capable of undertaking their 
physiological role. This process is referred to as differentiation (Smith et al., 2009). 
Cancer cells may look similar to normal cells (or well differentiated) or underdeveloped 
(or poorly differentiated). Grade generally correlates with outcome, poorly 
differentiated tumours being associated with a worse outcome than well differentiated 
tumours (Smith et al., 2009). Based on ovarian cancer grade categories, the higher the 
grade, the more likely it is that cancer will spread (Larma and Gardner, 2006).  
Table 1-3 summarizes the characteristics of different grades of ovarian cancer (Larma 
and Gardner, 2006). 
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Grade 1 
               (Well differentiated) 
looks similar to normal ovarian tissue 
Grade 2  
               (Moderately differentiated) 
looks less like ovarian tissue 
Grade 3  
               (Poorly differentiated) 
does not look like ovarian tissue 
Table 1-3 Grading of ovarian cancer 
(Larma and Gardner, 2006) 
1.2.1.3 CA125 Biomarker 
CA125 is a serum tumour marker. Tumour markers are generally used for four main 
purposes, to screen for the disease, to diagnose the disease, to monitor the response to 
treatment, and to diagnose recurrence. 
As a tumour marker CA125 has a relatively high sensitivity but a poor specificity 
meaning that its role as a screening and diagnostic test has limitations (Hogdall et al., 
2008).  
Research (Seltzer, 1999) suggested that CA125 levels are elevated in 80% of women 
with epithelial ovarian cancer.  The normal level of CA125 is 30-35 U/mL (unit per 
millilitre)(Helzlsouer et al., 1993). Zurawski et al. (1988) described an increase of 
CA125 level prior to clinical detection of ovarian cancer.  
Although overall CA125 has a high sensitivity this is not the case for early stage disease 
where CA125 is often unhelpful (Helzlsouer et al., 1993). Another concern is that 
CA125 levels are often increased slightly as a result of other conditions including 
ovulation, menstruation, fibroids and endometriosis (Muyldermans et al, 1995), 
meaning that this test is really only applicable to postmenopausal women. On the other 
hand, most of the ovarian cancer cases are postmenopausal women (Cancer Research 
UK, 2008b).  As a result CA125 remains the most widely used biomarker in the 
management of ovarian cancer. 
Zurawski et al. (1990) and Skates et al. (1995) tried to improve the sensitivity of the 
marker by using the levels of CA125. They concluded many women with initially 
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elevated CA125 levels have stable CA125 levels over time, in comparison with ovarian 
cancer patients where CA125 levels were steeply rising during the study.  
There are other methods available for improving the sensitivity of CA125, including 
decreasing the standard level of CA125 to 20 U/mL (Bourne et al., 1994) or using 
CA125 along with other biomarkers (Zhang et al. 2004, Hogdall et al. 2008 and Su et al. 
2007).    
 
1.2.1.4 Tumour Histology 
The histology of the tumour affects the treatment of ovarian cancer (Farley and Birrer, 
2010). Among all ovarian cancer tumour histology, 50-60% is reported as serous. The 
less common histology subtypes include endometrioid (25%), mucinous (4%) and clear 
cell (4%) (Seidman and Kurman, 2003). Clear cell and mucinous subtypes tend to 
present at limited sites (one or both ovaries) (Kikkawa et al, 2006), on the other hand 
serous and endometrioid tend to present at advanced  stages of the cancer in many sites 
of the abdomen and pelvis (Seidman and Kurman, 2003).   
 
1.2.1.5 Radiography 
Imaging of the pelvic mass is regarded as one of the most important diagnostic tool for 
investigating ovarian cancer (Simon, 2005). There are many methods that are used to 
image ovarian cancer such as Computed tomography (CT) scan, Ultrasound and 
Magnetic Resonance Imaging (MRI). 
CT scan is widely used for the primary diagnosis of ovarian cancer (Williams et al., 
2010). CT utilises a series of x rays taken in a 360
o
 sweep, each of which estimates 
tissue density in a 1D plane. These estimates then undergo tomography using the Radon 
transformation to reconstruct a 2D or 3D image.  
CT gives a quick and accurate measurement of disease within the abdominal cavity and 
provides hard images which can be used to give serial measurements to assess treatment 
response by comparison with post treatment images, unlike ultrasound. 
The imaging of the pelvis and abdomen remains an important factor for staging and 
diagnosis of this cancer.  
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Table 1-4 summarizes the radiographic characteristics of Anexel masses (Simon, 2005). 
This table compares the size, consistency, septation and other characteristics of benign 
and malignant masses.  
 
 
 Benign Malignant 
Size <8 cm >8 cm 
Consistency Cystic Solid or cystic and solid 
Septation Unilocular Multilocular 
Bilateral/Unilateral Unilateral Bilateral 
Other Calcification 
(especially teeth) 
Ascites 
Table 1-4 Radiographic characteristics of Adnexel masses 
(Simon, 2005) 
 
 
 
 
 
 
1.2.1.6 Age 
Ovarian cancer is rare among girls and young women (under the age of 30); however it 
increases with age (Elmasry and Gayther, 2007).   
Figure 1-1 illustrates the association between age and incidence of ovarian cancer. The 
risk of ovarian cancer under the age of 30 is low. From the age of 30 to 50 the incidence 
increases slowly. Peak incidence is 60.5 per 100,000 at the age of 75 to 79.  
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Figure 1-1 Age associated incidence of ovarian cancer  
(Elmasry and Gayther, 2007) 
Ovarian cancer is rare for ages under 30. For the age group of 75 to 79 it reaches the 
maximum value of 60.5 per 100,000. 
 
 
 
 
 
 
 
1.2.1.7 Physical examination 
Ovarian cancer has been called ‘the silent killer’ as 70% of cases are diagnosed at an 
advanced stage of the cancer (Edmondson and Todd, 2008). Patients may present with 
weight loss or vague lower abdominal pain and abdominal enlargement (Simon 2005), 
therefore physical examination can play an important role in first line diagnosis of the 
disease. Patient will be tested for mobility, consistency, bilateral and cul-de-sac 
involvement of the pelvic mass. 
Table 1-5Error! Reference source not found. summarizes the characteristics of Pelvic 
ass on physical examination (Simon, 2005). This table compares these characteristics 
for benign and malignant masses.  
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 Benign Malignant 
Mobility Mobile Fixed 
Consistency Cystic Solid or firm 
Bilateral/Unilateral Unilateral Bilateral 
Cul-de-sac Smooth Nodular 
Table 1-5 Characteristics of Pelvic mass on physical examination  
(Simon, 2005) 
 
 
 
 
 
 
 
 
 
 
 
1.2.1.8 Surgery 
The detection of the pelvic mass as discussed in previous sections (1.2.5 and 1.2.7) is 
relatively easy, however characterization of that mass as benign or malignant has 
remained a challenge. Based on the author’s observation in the operating theatre and 
literature (Edmondson and Todd, 2008; Balega and Shepherd, 2007; Sood and 
Gershenson, 2005), surgery is the most important part of the detection and diagnosis 
process which leads to an appropriate multimodal treatment approach. According to 
Sood and Gershenson (2005) “Although surgery alone is curative in only a small 
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number of patients, it remains the most important modality of treatment in an individual 
with a suspicious pelvic mass found to be ovarian cancer”.  
The proper staging of the disease which was discussed in the previous section (1.2.1.) is 
performed at surgery. In many cases surgery results in upstaging the cancer as the 
tumour was more spread than the initial examination revealed (Sood and Gershenson, 
2005).  
The main goal of the surgery is to accurately define the stage of the disease and remove 
as much tumour as possible (Edmondson and Todd, 2008). However, as discussed 
previously (1.2.7) most patients present at  stages of the cancer and as a result tumour is 
spread to other sites. Therefore the complete removal (complete cytoreduction) is not 
achievable. Complete cytoreduction is achieved when there is no macroscopic residual 
tumour left during surgery. The other possible outcomes of  surgery are optimal 
cytoreduction (residual disease less than 1-2cm in diameter) and sub-optimal 
cytoreduction (residual disease more than 1-2cm in diameter) (Edmondson and Todd, 
2008).  
Table 1-6 summarizes the association between the residual disease and outcomes of the 
surgery. The role of the surgery will be discussed in more details in chapter five of this 
thesis. 
At this stage, it is important to distinguish between two key words that play an 
important role in this investigation: Prognostic and Predictive Factors. According to 
Cianfranco and Goldstein (2004) prognostic factors are any measurements available 
before surgery that determines the overall survival rate before any treatment or therapy. 
In contrast, any measurement that calculates the response to a therapy is called 
predictive factor. 
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Outcome of the surgery Residual disease  
Complete cytoreduction  no macroscopic residual tumour 
Optimal cytoreduction less than 1-2cm in diameter 
Sub-optimal cytoreduction more than 1-2cm in diameter 
Table 1-6 Outcomes of the surgery 
 
 
 
 
 
 
 
 
 
1.2.1.9 Other possible contributors  
There are other possible risk factors to be considered in investigations, diagnosis and 
determining the survival rate in ovarian cancer, such as: combination of biomarkers 
(Zhang et al., 2004, Hogdall et al., 2008; Su et al., 2007), race, diet, viral and familial 
factors (Chu and Rubin, 2005). These risk factors can be employed in the proposed 
model if appropriate.  
1.2.1.10 Standard management  
The first line management of ovarian cancer is surgery. Surgery as discussed previously 
is the main factor in determining the stage of the disease. According to Simon (2005), 
“patients with early stages of the cancer (stage one and two) with well or moderately 
differentiated tumours require no additional therapy after surgery”. Surgery is carried 
out to remove as much of the tumour as possible and may include removing one or both 
ovaries and if the disease is in its advance stages, removing fallopian tubes and uterus.  
In most advanced cases a second line surgery is required (Thackery, 2005).  
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After surgery, chemotherapy will be used to target cells that have spread to other 
organs. Chemotherapy is given usually in a day centre, one day every 21 days for six 
cycles. Blood tests are taken to ensure bone marrow recovery before each cycle (Le et 
al., 2006). Chemotherapy is usually employed after surgery when bowel function has 
recovered. There are no advantages in delaying chemotherapy because of wound 
healing (Rothenberg et al., 2003). Research (Rothenberg et al., 2003) also suggested 
that there are no further advantages in continuing the chemotherapy after six cycles. 
During the chemotherapy process, bone marrow function and the level of CA125 will 
be investigated.  
Vasey et al. (2004) suggested that chemotherapy should continue for a maximum of six 
cycles if the levels of CA125 continue to fall. Following surgery chemotherapy is the 
recommended treatment for ovarian cancer, however in research (Rodriguez, 1992) it is 
suggested that in some cases radiation therapy has been useful. 
 
1.2.1.11 Outcomes of the management  
There is a need to measure the success and failure of a treatment for a cancer patient. 
Maurizi et al. (1999) suggested the possible measurable outcomes of the disease 
management.  
Table 1-7 describes the possible outcomes of the management (Maurizi et al., 1999). 
Defining these outcomes is important as the success of a treatment is measured using 
these measurable end points.  
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Outcomes Description 
Tumour response rate The number of patients whose tumours responded to 
treatment. 
Death from disease Number of patients that died because of the disease. 
Disease free survival Period of time that no cancer was detected after specific 
treatment. 
Progression free survival Period of time that disease stopped spreading.  
Overall survival rate The patients who are alive for a certain period of time 
after treatment. 
Table 1-7 Outcomes of the management 
(Maurizi et al., 1999) 
 
 
 
 
 
 
 
 
1.2.2 Clinical decision making 
Thompson and Dowding (2002) defined clinical decision making as choosing between 
alternatives. There are different types of models available in the clinical decision 
making literature; The Information Processing Model (Joseph and Patel, 1990), The 
Intuitive-Humanist Model (Benner, 1982; Benner, 1984; Young, 1987) and O’Neill’s 
Clinical Decision-Making Model (O’Neill et al., 2005). The investigation of these 
techniques is out of the scope of this research, however the first model (The Information 
Processing Model) is used in this research as this method is the best fitted to the purpose 
of this research. This model is widely used for clinical decision making (Banning, 
2008). 
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 This model uses decision trees to numerically assess the potential outcome of each 
decision or situation. For each tree the potential outcome will be calculated and based 
on that the decision will be made. Decision making in cancer needs a specialist team to 
evaluate and suggest possible treatments for the disease, this team is called an MDT 
(multi-disciplinary team). MDT members may vary depending on the case, and may 
include surgeons, clinical and medical oncologists, Radiologists, Pathologists, Palliative 
care specialists and MDT coordinator and secretarial support (Blazeby et al., 2006).    
For ovarian cancer treatment, the similar MDT reviews the referral patients and based 
on the markers (that have been discussed previously) the possible treatment for the 
patient will be suggested (surgery, chemotherapy or no action). After surgery each case 
is also discussed at MDT meetings and possible further treatments are considered for 
each patient.  
1.2.3 Future paths 
In previous sections (1.2.1 and 1.2.2) the current understanding and standard 
management of ovarian cancer were discussed. This investigation highlights some 
possible issues in the field of ovarian cancer. Some of these issues are as follows:  
 As the number of markers, treatments and the sequences of treatments are rising 
(such as new chemotherapy agents), it is getting more complex for the human 
brain to perform clinical decision making. There is the potential need for an 
expert computer system (eg. Artificial Intelligence) capable of investigating the 
possible outcome for each marker, treatment and sequence of the treatment 
(Friedman, 2009). 
 The prediction of overall survival of an individual patient is a very difficult task. 
There may be some benefits in predicting the overall survival as this prediction 
may change the path of treatment as well as inform the patient about likely 
prognosis. Therefore a system that can predict the overall survival of a patient is 
required (Teramukai et al., 2007; Chi et al., 2008; Gerestein et al., 2009). 
 As discussed previously (section 1.2.1.8), there are three different outcomes of 
surgery. The goal of the surgery is to remove as much tumour as possible. 
Therefore there are many benefits mentioned or suggested for a system that can 
predict the outcome of the surgery (Allen (2010); Leitao and Barakat, 2009).  
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1.3 Computing approaches 
Current improvements in biological sciences research, especially in the related fields of 
genetics, genomics; transcriptomics and proteomics are  producing large amounts of 
data. Bioinformatics is the science of developing and applying computational systems 
and methods for investigating and analyzing this data (Baldi and Brunak, 2001) and also 
it can be defined as “The science of informatics as applied to biological research” 
(Bioinformatics, 2008).  
Artificial Intelligence (AI) introduces many powerful methods for solving important 
problems in bioinformatics. AI techniques can help researchers to achieve the goal of 
extracting useful information from the available data by building high performance and 
suitable models.  
According to Narayanan, et al. (2002), most bioinformatics problems are seeking better 
solutions than currently available rather than finding the absolutely best or correct 
solution. AI techniques provide the methods to fit the nature of bioinformatics problems 
and try to find better solutions.  
As discussed in previous sections, there is a need for an expert (AI) system to evaluate, 
analyse and suggest the outcome of each treatment path or the importance of each 
marker for predicting the outcome of the treatment path. Abbod, et al. (2007) compared 
traditional regression statistics to AI methods in the area of cancer research and 
suggested that AI methods are more accurate and explorative for analysing such data. 
They concluded that AI methods can allow researchers to individually predict disease 
behaviour. AI methods are already widely used for different aspects of cancer research: 
Radiotherapy (Cancer Research UK, 2007), control of cancer cells (Nicolini, et al., 
1989), Detection (Petricoin et al., 2002), Diagnosis(Setiono, 1996) and DNA microarray 
classification and analysis (Mukherjee et al., 1999, Greer and Khan, 2004). AI has also 
been used for different types of cancer: Oral cancer (Speight et al., 1995), Lung cancer 
(Zhou et al., 2002), Prostate cancer (Adam et al., 2002), Breast cancer (Pena-Reyes and 
Sipper, 2000) and Bladder cancer (Catto et al., 2003).  AI systems are also used for 
different aspects of ovarian cancer such as: Early detection and serum analysis 
(Petricoin et al. 2002, Wulfkuhle, et al., 2003), Diagnosis (Vlahou et al., 2003) and 
Screening (Lewis and Menon, 2003). 
AI systems differ from standard computer algorithms in that they incorporate Machine 
Learning. Machine learning can be defined as the following “A computer program is 
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said to learn from experience E with respect to some class of tasks T and performance 
measure P, if its performance at tasks in T, as measured by P, improves with experience 
E” (Alpaydin, 2004). Machine learning systems tend to learn from existing data and 
adjust themselves for new data entries; also it is possible for them to fix existing errors 
in their design to achieve the required outcome. As discussed in the first section, clinical 
decision making for ovarian cancer consists of learning from past cases together with 
possible new approaches to suggest the possible treatment plan for the patient. It is 
understandable that clinical decision making perfectly fits into the machine learning 
concept.   
1.3.1 Machine learning (ML) 
Machine learning methods are the computer programs that improve their performance 
according to experiences (Alpaydin, 2004). The strengths of machine learning are as 
follows (Alpaydin, 2004): 
 In some cases the only way to define a task is by example. It may be possible for 
researchers to provide the input and output but unable to define the relation 
between them. In such cases machine learning can help to explore the data and 
define the rules and relations. 
 In large datasets it is possible to miss an important relation or rule between the data. 
Machine learning approaches can analyse most of the relations and help to find the 
hidden rules.  
 It is impossible for human minds to analyse the vast amount of data generated in the 
current research environment. 
 Environments change over time. Machines that can adapt to a changing environment 
reduce the need for constant redesign (self-adaptive AI).  
 
In one view ML methods can be divided into two categories: Unsupervised Learning 
(e.g. clustering) and Supervised Learning (e.g. classification). We may be given a set of 
observations with the aim of establishing the existence of classes or clusters in the data 
(Unsupervised Learning) and in general this is called clustering. Or we may know for 
certain that there are so many classes, and the aim is to establish a rule so we can 
classify a new observation into one of the existing classes (Supervised Learning). In 
other words according to Coppin (2004), in supervised learning, the goal is to learn the 
route from input data to an output which is correctly provided (by a supervisor). On the 
other hand, in unsupervised learning, the only available data is input data and the aim is 
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to find rules in input data to generally find out what happens and what does not (i.e. find 
patterns and trends in the data). The definition of these two types of learning is essential 
at this point. In ovarian cancer decision making involves some markers that will lead to 
an outcome (supervised learning) and there is uncertainty involved in prediction of the 
outcome of new markers or treatment paths (unsupervised learning). 
There are two distinctive terms in Machine Learning: Deductive and Inductive systems. 
Munakata (1998) suggests that in deductive systems, experts will provide the rules and 
the outcome will be determined by applying those rules to the input data; in contrast, 
inductive systems are the systems where there is no need for any experts and rules will 
be discovered by the system itself. In other words in deductive systems general rules 
will be introduced, the system will be trained using some examples and the trained 
system will be put in practice. On the other hand, in inductive systems, by using 
examples systems discover the rules in data and the discovered rules will be put into 
practice. The following sections of this chapter investigate some of the well-known ML 
methods.  
1.3.1.1 Nearest Neighbour approach (Decision tree) 
This section, firstly, introduces the nearest neighbour as a classifier. Later on, using this 
approach, the decision tree method is discussed.  
The k-nearest neighbour (KNN) mechanism is very simple. An object (e.g. a patient) is 
classified by the majority vote of its neighbours, with the object being assigned to the 
class most common amongst its k nearest neighbours. Enas and Choi (1986) described 
KNN algorithm as the following: 
(1) Determine parameter k = number of nearest neighbours  
The choice of k is the most critical aspect of this method. A small number for this 
variable may increase the influence of the noise on the results. On the other hand, 
a  large value for k, increases the computation time and also violates the 
philosophy of this method (the close instances may belong to the same class) 
(Duda et al., 2000). 
(2) Calculate the distance between the query-instance and all the training samples. Sort 
the distance and determine nearest neighbours based on the k-th minimum distance  
(3)Gather the category of the nearest neighbours  
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(4)Use simple majority of the category of nearest neighbours as the prediction value of 
the query instance  
Selection of k as an odd number helps to find the majority of the category. In this 
research the prediction value can be the survival rate of the patient or the outcome 
of the surgery.  
KNN mechanism is very simple to perform and according to Efron (1983) it is effective 
for a large training set, however the determination of the number of nearest neighbours 
is hard (Enas and Choi, 1986). The computation cost is quite high as we need to 
compute the distance of each query instance to all training samples.  
Figure 1-2 illustrates a very simple example of KNN method on an artificial dataset.   
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Figure 1-2 KNN method example (artificial dataset) 
 
This example is trying to classify new data (triangle) into ‘big star’ or ‘small star’ 
classes. In the KNN mechanism, if we assume that the k=3 then new data will be 
classified as big star class (2 big stars and 1 small star as nearest neighbours) and if we 
consider k=7 then new data will be classified as small star class (3 big Stars and 4 
small stars as nearest neighbours). This simple artificial example highlights the 
importance of k selection in this method. 
 
 
 
 
The above approach introduces a simple KNN; however in clinical decision making 
there are many attributes to be considered. In order to use KNN for multiple features 
(attributes) in an efficient way, it is essential to introduce the term “decision trees”. In 
the past the decision tree approach was considered as the most successful machine 
learning technique in practical applications (Munakata, 1998). According to Alpaydin 
(2004), a decision tree is a classifier in the form of a tree, which has nodes and a root. 
Each node is either a leaf node (indicates the value of outcome) or decision node (which 
performs some tests to be carried out on a single attribute with a branch or sub-tree for 
each outcome). The process starts from the root node of the tree and moves through 
decision nodes and branches until reaching the leaf node (outcome). 
K=7
K=3
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Above algorithm uses “Entropy” and “Information Gain” to construct the tree (Rokach 
and Maimon, 2008). 
2
1
( ) log
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Equation 1-1 Entropy using the frequency table of one variable  
(Rokach and Maimon, 2008) 
S is the variable, c is the number of classes, p is the probability of the occurrence of the 
class number i 
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Equation 1-2 Entropy using frequency table of two variables  
(Rokach and Maimon, 2008) 
T is the target class, X variable, c value(s) of variable X, P(c) probability of the c, E(c) 
entropy of c 
 
( , ) ( ) ( , )G T X E T E T X   
Equation 1-3 Information Gain of variable X  
(Rokach and Maimon, 2008) 
T is the target class, E is the entropy 
 
To clarify the construction of the tree processes consider the following well known 
dataset (Quinlan, 1986) (Table 1-8). 
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Outlook Temp Humidity Windy Play Golf 
Rainy Hot High False No 
Rainy Hot High True No 
Overcast Hot High False Yes 
Sunny Mild High False Yes 
Sunny Cool Normal False Yes 
Sunny Cool Normal True No 
Overcast Cool Normal True Yes 
Rainy Mild High False No 
Rainy Cool Normal False Yes 
Sunny Mild Normal False Yes 
Rainy Mild Normal True Yes 
Overcast Mild High True Yes 
Overcast Hot Normal False Yes 
Sunny Mild High True No 
Table 1-8 Play Golf dataset 
(Quinlan, 1986) 
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In order to construct the tree following steps have to be performed: 
Step 1: Calculate the Entropy of target class (Play Golf). 
            E(Play Golf)= 0.94 
Step 2: Calculate Information Gain of each variable. 
G(Outlook)= 0.247, G(Temp)=0.029, G(Humidity)=0.152, G(Windy)=0.048 
Step 3: Use the variable with largest value of ‘Gain’ as root node. 
Outlook holds the largest value of ‘Gain’. 
Step 4: Split the branches: 
4a: A branch with ‘Entropy’ more than 0 needs more splitting 
4b: A branch with ‘Entropy’ 0 is a ‘Leaf’ node. 
Step 5: Continue splitting process on none-‘Leaf’ branches to classify all the data. 
Finally above steps leads us to the decision Tree (Figure 1-3). 
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Figure 1-3 Decision Tree example  
(Quinlan, 1986) 
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Decision trees and nearest neighbour are widely used in the field of cancer research 
(Adam et al.,2002; Mangasarian et al., 1995; Vlahou et al., 2003; Liu et al. , 2011).   
According to Munakata (1998) decision trees are able to introduce understandable rules 
and identify the most important fields for prediction. Meanwhile, this method is easily 
understandable for every user, the important variables can be easily identified and well 
fitted to clinical decision making process. However according to Alpaydin (2004) 
decision trees can be computationally expensive to train, they are less appropriate for 
predicting continuous variables and are very sensitive to errors for prediction process of 
small data sets. Therefore, it is essential to prepare as much data as possible for this 
research, and making sure the continuous variables are categorized prior to prediction.  
In summary, the KNN and decision trees are widely used in the field of cancer research. 
These methods of prediction are easy to understand for a non-professional user. This 
method is also well fitted to the clinical decision making process.  
 
 
1.3.1.2 Neural networks 
Neural networks (NN) are a very abstract computer representation of the human brain. 
In other words “NNs are parallel information processing structures that attempt to 
emulate certain performance characteristics of the biological neural system” (Naguib 
and Sherbet, 2001). The part of the brain considered to be the fundamental functional 
source of intelligence is called a neuron (Fausett, 1994), similarly neural networks 
consist of artificial neurons. Although the term neural network is widely used in 
literature of some other authors, to distinguish from the natural brain neural networks, 
researchers use the term Artificial Neural Networks (ANN).  
The biological neuron, as the basic part of the brain, consists of three components:  
dendrites, soma and axon (Fausett, 1994). Dendrites are responsible for receiving 
signals from other neurons via axon, soma receives the inputs and when enough inputs 
are received and the needed operation performed, produces an output which will be sent 
to other neurons via output axon. Figure 1-4 illustrates a biological neuron (Fausett, 
1994). 
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Similarly in the mathematical model, dendrites are represented by different input values
mxxx ,...,, 21 . Each input has a corresponding weight and the product ii
wx
 will be fed 
into the neuron (Figure 1-5).  
 
mxxx ,...,, 21 are inputs, y is output, w represents the weight, Σ the value of the net, T is 
the transfer function 
Then the neuron calculates the net by adding up all the products for i=1…m, so the net 
value can be calculated using Equation 1-4.  
mmwxwxnet  ...11  
Equation 1-4 The value of the net (artificial neuron) 
x is input, w is weight 
The calculation of the net is the same as the calculation of the scalar (dot) product of 
vectors x and w. Finally the output value ‘Out’ will be calculated (Equation 1-5).  
( )Out f net  
Equation 1-5 The output of the net 
 
This function is called a transfer (activation) function, that may be a threshold function 
(only passes the information), or it may be a continuous function of the combined input 
(Naguib and Sherbet, 2001). 
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Figure 1-4 Biological neuron 
(Fausett, 1994) 
Dendrites are responsible for receiving the signal, soma processes the signal and axon 
transfer the appropriate signal to other neurons 
 
 
Figure 1-5 Artificial model of a neuron 
(Fausett, 1994) 
∑ is the value of the net (Equation 1-5) and T is the threshold  of the neuron 
 
 
 
 
 
 
 
T Σ 
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This model of ANN is called a ‘Feed forward’ model as the process only moves in one 
direction from inputs to outputs. There are no connection between outputs and inputs 
(Lee, 2008).  It contains ‘Input Layer’, ‘Output Layer’. The model may contain none, 
one or more than one ‘Hidden Layer(s)’. The ‘Feed forward’ ANN is the simplest and 
most used model of ANN (Wang et al., 2010; Lee, 2008). There are other forms of 
ANN such as: Recurrent Neural Network (RNN). RNN forms a ‘directed cycle’ 
between the connections in the network (Lee, 2008). This research uses the Feed 
forward ANN based on its simplicity for implementation and popularity.  
Figure 1-6 illustrates a Feed forward ANN model. This model consists of one hidden 
layer.There are number of input neurons ( iN ), hidden neurons ( hN ) and output neurons 
( oN ) according to the problem in hand. Each input neuron is connected to all hidden 
neurons and respectively each hidden neurons are connected to all output neurons. All 
connections carry a weight that normally will be assigned as a random number in a 
specific range. After setting up the network is ready to learn (ready to be trained). This 
model of NN is a supervised learning process and according to Fausett (1994) “A neural 
network learns patterns by adjusting its weights.”  
‘Back Propagation’ is the best known and most often used, as the learning method of 
multi layered feed forward ANN (Sekino and Nitta, 2007; Adali and Haykin, 
2010).  The goal of the learning method is to adjust the weights of the network in such a 
way that it minimises the ‘Sum of Squared Error (SSE)’ (Adali and Haykin, 2010). The 
SEE can be calculated using Equation 1-6. 
2
1
( )
n
i i
i
SSE A P

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Equation 1-6 Sum of Squared Error (SSE) 
 (Adali and Haykin, 2010) 
n is the number of instances for training, A is the actual value, P is the predicted value. 
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Figure 1-6 Feed Forward ANN model 
(Fausett, 1994) 
This model moves only in one direction (from inputs x, to outputs y).  
 
 
 
 
The learning process of the network can be defined in the following steps (Adali and 
Haykin, 2010; Fausett, 1994):  
Step 1: Randomly initial the weights of the network 
Step 2: Calculate the output. Given a set of inputs (I), calculate the predicted value 
(P).  
Step 3: Calculate the ‘error’. The error for output neurons is calculated as A-P (The 
difference between actual value and predicted value). The error of hidden or input 
neuron can be calculated using. : 
1
n
i i
i
B b w

   
Equation 1-7 Calculating the error of the neuron 
(Adali and Haykin, 2010) 
n is the number of neuron(s) connected to a given neuron, b is the error of target 
neuron, w is the weight of connection between given and target neuron. 
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Step 4: Adjust the weights. The new weights can be calculated using Equation 1-8. 
 
, , ( )i j i j j j j iw w r b f I o      
Equation 1-8 Adjusting the weights 
,i jw is the weight of connection between neuron i, j. r is the learning rate (user defined 
value of how much the weights can be modified),  
jb is the error of neuron j, ( )j jf I is 
the value of activation function of neuron j for the input 
jI , io is the output of neuron I 
during the first step. 
 
 
 
To clarify the process, the following simple example, demonstrates the process of the 
above method. Consider the ‘AND’ function. This function gets two possible binary 
inputs (x and y) and generates an output based on the input values. Table 1-9 
summarizes the all possible inputs and outputs of AND function.  
The goal is to generate an ANN model to satisfy all the possible answers to AND 
function (Table 1-9). It is understandable that this network can be constructed using a 
neuron (Figure 1-7 a). After creating the network, network has to be trained to identify 
the values of w1 and w2 and also the threshold value of the function. There are 
infinitive possible answers to this problem; however one possible network is illustrated 
in Figure 1-7 b. 
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x y output 
0 0 0 
0 1 0 
1 0 0 
1 1 1 
Table 1-9 AND function truth table 
 
 
 
Figure 1-7 Neural network for AND function 
(a) the initial generated model, (b) trained and ready to use network 
 
 
 
Let’s say that x=1 and y=0 as input values. The output values have to be 0 as ‘1 AND 
0=0’. So we have  which is less than the 0.5 threshold value so the 
output is 0. For x=1 and y=2 the value 0.6 is greater than 0.5 so the output is 1. The 
network produces the correct outcome for all possible inputs so it is trained and ready to 
predict new values. 
 
 
ANN is widely used in different fields of cancer research and for many different 
cancers: Wilding et al. (1994), Fogel et al. (1995), Zhou et al. (1997), Maclin and 
a b
3.03.003.01 
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Dempsey (1991), Maclin and Dempsey (1992), Burke et al. (2001) Djavan et al. (2002), 
Kawakami et al. (2008), Stephan et al. (2008); Hoyt et al. (2010) and Ayer et al., 2010. 
Similar to all methods NN has its strengths and weaknesses. NN are robust and can 
work if the training data contain errors (Burke et al., 2001) and also in most cases, the 
prediction accuracy is high (Fausett, 1994). NN provides a great power to predict the 
outcome on an individual basis (Naguib and Sherbet, 2001). According to McLaren et 
al. (2009) NN can capture non-linear relationships in the dataset. 
On the other hand, NN training time can be considerably high (Burke et al., 2001) and 
there is no guarantee that the network is trainable (Fausett, 1994). According to Naguib 
and Sherbet (2001) in most cases it is hard to understand the weights used in the 
network.  
 
In summary, NN as a prediction model is widely used in the field of cancer research. 
The prediction accuracy of this model is high and also it can handle errors in the dataset. 
The generated model can be adopted in such a way that it can handle new treatments 
and biomarkers. Considering that the most important goal for this research is prediction 
accuracy, the training time is not an issue and there is not necessity for the user to 
understand the weights of the network.   
 
1.3.1.3 Bayesian Networks 
“A Bayesian network is a graphical model for probabilistic relationships among a set of 
variables” (Neapolitan, 2004). There is a massive improvement in all branches of 
science, however in many cases there are still some uncertainties (Baldi and Brunak, 
2001). For example in cancer research the researchers are uncertain about the outcome 
of the new treatment or influences of a new biomarker. Bayesian networks can be the 
solution to many of these problems for the following reasons: 
Bayesian networks can handle incomplete data (Neapolitan, 2004). Most of the 
modelling approaches can effectively model and investigate the input data if a complete 
dataset is provided, however if one of the main input objects is not provided those 
models can not sufficiently model the data. On the other hand, when using Bayesian 
network it is possible to solve the problem. This advantage is very important especially 
in medical research as the input or outcome of some variables may not be complete at 
the start of the research.   
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“Bayesian networks allow one to learn about causal relationships” (Jensen, 2001). 
Understanding the casual relation will help us to fully understand the problem domain 
as well as making predictions about the activities even if they didn’t perform yet.  
Bayesian networks provide facilities that make the modelling of the prior knowledge 
straightforward (Baldi and Brunak, 2001). The modelling of the current knowledge 
about the data is facilitated in this method. This makes it a very powerful method as the 
prior knowledge about the data in connection with the relations that will be discovered 
using this method can fully model, understand and analyse the data.  
 
Before describing the structure of the Bayesian network it is essential to describe 
Bayesian approach to probability. According to Leonard and Hsu (1999) “Bayesian 
probability of an event is the person’s degree of belief in that event”, in contrast the 
classical probability of an event which is the physical property of that event. For 
example, classical probability considers the probability that a coin will land heads and 
Bayesian probability is interested in the degree of our belief that the coin will land 
heads. In other words, in Bayesian probability, “a probability will always depend on the 
state of the knowledge of the person who provides the probability” (Gelman et al., 
1995). For example in a normal situation a person predicts that the probability of a coin 
showing heads on the next toss is 0.5, however if we convince that person that the coin 
is weighted in favour of heads, he would assign the a higher probability to the event.  
There are some criticisms and solutions to those problems of the Bayesian approach to 
probability which is outside the scope of this thesis.  
First we are going to introduce the Bayesian theory. According to Neapolitan (2004), 
for two events E and F (the probability of E and F are not equal to zero) Bayesian 
theory is the probability of F given E, multiply by the ‘prior’ probability of E, divided 
by the ‘prior’ probability of F (Equation 1-9). Prior probability of E means the 
probability that E happens regardless of any other event.  
)(
)()|(
)|(
FP
EPEFP
FEP   
Equation 1-9 Bayesian theory 
( | )P F E  the probability of F given E, P(E) and P(F) are prior probability of events E 
and F. 
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In general according to Neapolitan (2004) a Bayesian network for a set of variables 
},...,{ 1 nXXX    consists of a network structure S that interprets a set of conditions 
about variables in X and a set of P of probabilities associated with each variables. These 
sets together define the joint probability distribution of X.  Bolstad (2004) describes the 
joint probability distribution as: The function f(x,y) which gives the probability for a 
given probability of x and y within the range of values of x, y. In Bayesian networks 
variables are depicted as nodes, connections represent the probabilistic dependence 
between variables and conditional probabilities encode the strength of the dependencies. 
To construct a Bayesian Network we simply draw connections for a given set of 
variables from the cause variables to their effects and finally we determine the local 
probability distributions. In other words according to Neapolitan (2004) the algorithm is 
as following: 
• 1. Choose an ordering of variables X1, … ,Xn 
• 2. For i = 1 to n 
– add Xi to the network 
– select parents from X1, … ,Xi-1 such that  
 P (Xi | Parents(Xi)) = P (Xi | X1, ... Xi-1)  
It is possible to have three types of connections in the network (Koski and Noble, 
2009):  
 Linear connection: The two end variables are usually dependent on each other. 
The middle variable renders them independent (Figure 1-8 a). 
 Converging connection: The two end variables are usually independent on each 
other. The middle variable renders them dependent (Figure 1-8 b). 
 Divergent connection: The two end variables are usually dependent on each 
other. The middle variable renders them independent (Figure 1-8 c). 
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Figure 1-8 Connections in Bayesian network 
a: linear connection, b: converging connection, c: diverging connection 
 
In order to clarify the process consider a well know example of “Given a situation 
where it might rain today, and might rain tomorrow, what is the probability that it will 
rain on both days?” (Niedermayer, 1998).  
It is possible to assume that raining on two consecutive days are not independent as if it 
is raining today it is more likely that it will rain tomorrow. Let’s assume that P(rain 
today)=0.20 and P(rain tomorrow given that it rains today)=0.70. We are going to 
calculate all the joint probabilities using the Bayesian theory (Equation 1-9). Table 1-10 
summarizes these probabilities.   
Suppose that P(A) is the probability of raining today and P(!A) the probability of not 
raining today. Similarly P(B) is the probability of raining tomorrow and P(!B) the 
probability of not raining tomorrow. Therefore, a Bayesian network can be constructed.  
 
 
 
 
 
 
 
a
b
ab
ca
c
b
c
Linear
Converging Diverging
a b c
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 Raining 
tomorrow 
Not Raining 
Tomorrow 
Marginal 
(Rain today) 
Raining today 0.14 0.06 0.20 
Not Raining today 0.16 0.64 0.80 
Marginal(Rain Tomorrow) 0.30 0.70  
Table 1-10 Joint probability results using Bayesian theory 
 
 
 
 
 
Figure 1-9 Bayesian network of probability of raining today and tomorrow 
P(A) probability of raining today, P(!A) probability of not raining today 
P(B) probability of raining tomorrow, P(!B) probability of not raining tomorrow 
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As mentioned earlier, because of the nature of this approach, many cancer researchers 
used this method for different aspects of cancer research such as: Kahn et al. (1997), 
Bulashevska et al. (2004), Wang et al. (1999), Jansen et al. (2003), Lacave and Diez 
(2003),  Van der Gaag et al. (2002), Burnside , et al. (2004), Gevaert et al. (2006).  
At the start of the section the potential benefits of this method have been mentioned 
however the initial knowledge of the probabilities (prior probabilities) are very 
important in this method and in some cases it is not possible to completely predict such 
probabilities (Niedermayer, 1998). It is common to miss the probability of an important 
event. It is possible that an event which plays an important role unanticipated in the 
network (Neapolitan, 2004).  Also the potential computing cost is high (Neapolitan, 
2004). 
 
In summary Bayesian network provides a powerful realistic prediction method for 
predicting the outcome. Many researchers applied this method to cancer research 
studies. The other benefit that makes this method a powerful prediction method is that it 
can handle incomplete data. Therefore, based on the strong facilities that this method 
provides and the fact that number of researchers applied this method to cancer research, 
this method was selected to include in for this research.  
 
1.3.2 Feature Selection 
The following sections of the report investigate some of the well-known feature 
selection techniques in two categories: Multivariate and Univariate Techniques.  
The next sections of the chapter investigate two most common and powerful Univariate 
feature selection techniques: Principal Component Analysis (PCA) and Information 
Gain (IG). The reason that these two techniques have been selected is that they are the 
most effective methods for univariate feature selection (Kantardzic (2002), Beer et al. 
(2002), Yeung, et al. (2001), Gabrilovich and Markovitch (2004), Changjing and Shen 
(2005), Cho and Ryu (2002), Ben-Dor et al. (2000), Blum and Langley (1997), Brazma 
and Vilo (2000) and Jensen and Shen (2004). 
Later on this section investigates the multivariate techniques. Saeys et al. (2007) 
described multivariate techniques as: methods that consider subsets of variables 
(features) together and assess the dataset based on the subset of selected features. Two 
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techniques have been selected for investigation in this research: Targeted Projection 
Pursuit (TPP) and Genetic algorithm (GA). TPP is proven to be one of the most 
effective feature selection techniques (Enshaie and Faith, 2009) and literature review 
revealed that GA is one of the high performance feature selection techniques. For each 
technique the algorithm is discussed by using mathematical demonstrations of the 
technique and the process is clarified by using an example. The limitations of each 
technique have been discussed and applications to gene expression data have been 
identified.  
 
1.3.2.1 Principal Component Analysis (PCA) 
The most popular method for dimensionality reduction of a large dataset is Principal 
Component Analysis (PCA) (Kantardzic, 2002). The idea of PCA is to reduce the 
dimensionality of a data set which includes a large number of interrelated variables, 
while collecting as much variation as possible that is present in the data set. PCA 
transforms original datasets into a new set of variables called the principal components 
(PCs). These components are uncorrelated, and they are sorted so that the first few keep 
most of the variation present in all of the original variables (Jolliffe, 2002). In other 
words PCA explains the correlation structure of a set of interpreter variables using a 
smaller set of linear combinations of these variables. These linear combinations are 
called components (Larose, 2006). 
Figure 1-10 (Scholz, 2006) is the transformation of a gene expression dataset using 
PCA. This technique reduces a large number of variables to a lower number of new 
variables known as principal components (PCs). Three-dimensional gene expression 
samples are projected onto a two dimensional component space that maintains the 
largest variance in the data. These two-dimensional visualisations of the samples allow 
us to make qualitative conclusions about the separation of the classes in the dataset.  
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Figure 1-10 Transformation of dataset using PCA 
Scholz (2006) 
Chart on the left is a representation of a 3 dimensional gene expression dataset. Using 
PCA three dimensional dataset is transformed to a two dimensional dataset, which uses 
two principal component (PC1, PC2), to be plotted. 
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Process and example 
Jolliffe (2002) introduced an informal process for applying PCA on a dataset; this 
section follows these steps and applies them to an artificial dataset (Table 1-11). This 
dataset consists of only two dimensions which made it possible for the author to 
demonstrate and visualize each step.   
Step 1: Data 
As mentioned above the dataset that has been used in this section is an own-made 
dataset (Table 1-11) which contains two variables.  
 
 
X 2.5 0.5 2.2 1.9 3.1 2.3 2 1 1.5 1.1 
Y 2.4 0.7 2.9 2.2 3 2.7 1.6 1.1 1.6 0.9 
Table 1-11 Artificial dataset for explaining PCA process 
 
Step 2: Normalization 
For PCA to work properly, we have to normalize the dataset by subtracting the mean 
from each of the data dimensions. The mean subtracted is the average across each 
dimension, therefore all the x values have X  (the mean of the x values of all the data 
points) subtracted from them, and all the y values have Y  subtracted from them. This 
produces a data set that its mean is zero. This procedure is known as “zero mean” 
(Kantardzic, 2002). Table 1-12, demonstrates the original dataset (Table 1-11) after 
normalization. 
 
 
X .69 -1.31 .39 .09 1.29 .49 .19 -.81 -.31 -.71 
Y .49 -1.21 .99 .29 1.09 .79 -.31 -.81 -.31 -1.01 
Table 1-12 Normalized artificial dataset for explaining PCA process 
 
Step 3: Calculate the covariance matrix 
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Covariance provides a measure of the strength of the correlation between two or more 
sets of random variates (Spiegel, 1992). The covariance for two random variates X and 
Y, each with sample size N, is defined in Equation 1-10.   
 
1
( )( )
cov( , )
N
i i
i
x x y y
X Y
N
 
  
Equation 1-10 Covariance of X and Y 
N is the sample size of X and Y, x is the mean value of X, y  is the mean value of Y. 
 
If we have a data set with more than 2 dimensions, there is more than one covariance 
measurement that can be calculated. For example, from a 3 dimensional data set 
(dimensions x, y, z) we could calculate cov(x, y), cov(x, z) and cov(y, z). In fact, for an 
n -dimensional data set, you can calculate 
!
( 2)! 2
n
n  
 different covariance values 
(Spiegel, 1992). A useful way to get all the possible covariance values between all the 
different dimensions is to calculate them all and put them in a matrix (Spiegel, 1992) 
(Equation 1-11).  
,( cov( , ))
mxn
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C y x y y y z
z x z y z z
 
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 
 
Equation 1-11 Covariance matrix 
The equation on left represents a covariance matrix for the sample size m and equation 
on the right is a generated covariance matrix for sample size 3. 
 
Keeping these in mind (Equation 1-11) we calculate the covariance matrix for our 
dataset: 
cov= 
.61 .61
.61 .71
 
 
 
 
Step 4: Calculate the eigenvectors and eigenvalues of the covariance matrix 
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Let A be a n ×n matrix. The  is an eigenvalue of A if there exists a non-zero vector v 
such that Av = v. In this case, vector v is called an eigenvector of A corresponding to 
. For each eigenvalue , the set of all vectors v satisfying Av = v is called the 
eigenspace of A corresponding to  (Press et al., 1992) 
The method of calculating these values is described by Press et al. (1992) and after 
applying those calculations on our covariance matrix we have the following: 
eigenvalues= 
.49
1.28
 
 
 
 
eigenvectors= 
.73 .67
.67 .73
  
 
 
 
 
Step 5: Choosing components and select features 
In general, once eigenvectors are found from the covariance matrix, the next step is to 
order them by eigenvalue, highest to lowest. This gives us the components in order of 
significance (Jolliffe, 2002). At this stage we can decide to ignore the components of 
lesser significance. By doing this we may lose some information, but if the eigenvalues 
are small the lost information is not significant. If we leave out some components, the 
final data set will have fewer dimensions than the original. Later we can pick the largest 
component(s) as chosen features. 
PCA relies upon on some assumptions which result in some limitations for this 
powerful technique. These assumptions are: 
 Linearity assumption: In PCA we assumed the observed dataset to be linear 
combinations of certain basis (Jolliffe, 2002). Some new methods such as kernel-
PCA (Scholkopf et al., 1998) overcome this limitation by considering non-linearity 
of the data.  
 Importance of mean and covariance assumption: As suggested above, PCA is based 
on the importance of the means of the (or) a dataset and accordingly the covariance 
of the values, which in some recent situations may mislead the method (Jackson, 
2003).  
 Sotoca, et al. (2007) investigated PCA for classification and observed that 
limitations of PCA arises from the fact that, in general, a principal component (for 
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the whole sample set) does not have to provide a high deviation rate and so therefore 
a good classification ability. 
 Bishop (1996) also discussed some major limitations for PCA such as: PCA need a 
large number of samples to perform well. In PCA we have to determine how many 
factors to retain and in some cases it is possible to get negative values for reduced 
data by PCA which in some cases (such as chemical components) it cannot clearly 
be connected to the sources. 
 The main problem mentioned (Banks et al., 2004) is that PCA can detect the linear 
structures in the data; however it is difficult to detect non-linear structures with 
PCA.  
 
PCA as one of the most powerful feature selection techniques is widely used to analyse 
and process gene expression data. Bicciato, et al. (2002) applied PCA on gene 
expression data and their results demonstrate that the employed procedure allows the 
identification of specific phenotype markers and can classify previously unseen 
instances in the presence of multiple classes of cancer. Beer et al. (2002) used PCA to 
classify lung cancer data and they concluded that this technique successfully classifies 
the data. 
However Yeung, et al. (2001) used PCA for clustering the ovarian cancer patient’s data 
and they recommended against using PCA to reduce dimensionality of the data before 
applying clustering algorithms because they observed that the quality of clustering 
results on the data after PCA is not necessarily higher than that on of the original data, 
sometimes lower, unless external information is available. 
PCA is used by cancer researchers to analyse and investigate the data for different 
aspects of cancer research: Bicciato et al. (2002), Beer et al. (2002), Skala et al. (2007), 
Rodríguez-Piñeiro et al. (2007), Yao et al. (2008), Kamath and Mahato (2009) and Hsu 
et al. (2009) 
In summary, PCA is widely used by many researchers for solving dimensionality 
reduction problems and in most cases this technique is very successful. Most 
researchers indicate that this technique is one of the most effective techniques in feature 
selection. 
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1.3.2.2 Information Gain (IG) 
Information gain is one of the most efficient measures of feature ranking in feature 
selection (Gabrilovich and Markovitch, 2004). IG estimates feature weights (importance 
of the features) determining for each feature how much information it contributes to the 
knowledge of the classes of the training data items. 
Yang and Pedersen (1997) compared five different feature selection scores on two 
datasets and showed that Information Gain is amongst the two most effective. The 
method which we use to assign weights to the features is called Gain Ratio, a 
normalized variant of information gain (Daelemans, et al., 1999). 
 
Let P and N be two classes and S a dataset with p-elements and n-elements. The amount 
of information needed to decide if a given example data belongs to P or N can be 
defined using Equation 1-12 (Larose, 2006).  
2 2( , ) log log
p p n n
I p n
p n p n p n p n
  
   
 
Equation 1-12 Amount of information required to assign an object to class P or N 
(Larose, 2006) 
P and N are two classes of dataset S, with p-elements and n-elements 
 
Let sets {S1, S2 , …, Sv} form a partition of the set S, when using the attribute A and 
each Si contain pi examples of P and ni examples of N. The entropy (the expected 
information) needed to classify objects in all the subsets Si is defined by Equation 1-13 
(Larose, 2006). 
1
( ) ( , )
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p n
E A I p n
p n

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
  
Equation 1-13 the entropy needed to classify objects in Si subsets 
(Larose, 2006) 
v number of subsets, pi and ni the examples of p and n in Si  
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Therefore, the information that would be gained by dividing on attribute A can be 
calculated using Equation 1-14. 
( ) ( , ) ( )Gain A I p n E A   
Equation 1-14 Information gained by dividing on attribute A 
( , )I p n is calculated using Equation 1-12, E(A) is calculated using Equation 1-13 
 
Process and example 
To clarify the IG process, the example (Quinlan, 1993) that was previously used 
(section 1.3.1.1) will be discussed. The dataset (Table 1-8) consists of four variables and 
an outcome class.  
Using Equation 1-12, the amount of information required to assign objects to each class 
for variable ‘Outlook’ is calculated. Table 1-13, summarizes the results of this 
calculation. 
 
 
Outlook p i  n i  I(p i , n i ) 
Sunny 2 3 0.971 
Overcast 4 0 0 
Rain 3 2 0.971 
Table 1-13 The amount of information required to assign objects to each class for variable 
‘Outlook’ 
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Therefore, using Equation 1-13, Entropy of variable ‘Outlook’ can be calculated as the 
following: 
 
5 4 5
E outlook  (2,3) (4,0) (3,2) 0.694
14 14 14
I I I     
The information gain can be calculated as the following: (Equation 1-14)  
Gain(outlook)= I(9,5)- E(outlook)= 0.246 
 
Similarly: 
Gain (temperature) = 0.029 and Gain (humidity) = 0.151 and Gain (windy) =0.048 
According to the IG mechanism attribute ‘Outlook’ holds most of the information by 
itself and therefore after sorting attributes in order of importance we have: 
Attributes selection using IG: 1) Outlook 2) Humidity 3) Windy 4) Temperature 
 
The following two problems with IG’s will have a negative influence on the 
classification accuracy, in particular when there are many features available. 
In IG if features are dependent, this will generally not be reflected in their weights 
(Hintz, 1991). For example a feature that contains some information about the 
classification class on its own, but none when another more informative feature is 
present will receive a non-zero weight. Features which contain little information about 
the classification class will receive a small weight but a large number of them may still 
overrule more important features (Chang et al., 2005).  
 
IG is considered to be one of the most effective algorithms for feature selection on gene 
expression data. Changjing and Shen (2005) concluded that in general, IG attribute 
selection is beneficial for improving the performance of the common learning 
algorithms on gene expression data. Cho and Ryu (2002) used IG for feature section and 
classification of gene expression data of cancer and observed that IG is a powerful and 
successful method for these types of feature selections. Ben-Dor et al. (2000), Blum and 
Langley (1997), Brazma and Vilo (2000) and Jensen and Shen (2004) also investigated 
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IG mechanism in their research and observed that this method successfully selected the 
appropriate features.  
IG is also used by researchers’ (Andrew et al., 2006; Ashraf et al., 2010) to identify the 
most important factors for outcome prediction in cancer research.  
IG is widely used for feature selection and research indicates the high performance of 
this technique. In gene expression data analysis literature, IG is treated as one of the 
most effective approaches for feature selection. 
 
 
 
 
1.3.2.3 Targeted Projection Pursuit (TPP) 
One of the major problems with linear methods such as PCA is that they are not able to 
detect non-linear structures in data. To overcome this problem projection pursuit 
method has been introduced which is widely viewed as an effective method which can 
find interesting structures, both linear and non-linear, in complex data (Banks et al., 
2004). In projection pursuit, it is assumed that interesting structure is different from 
normal distribution (All normal distributions are symmetric and have bell-shaped 
density curves with a single peak (Gaten, 2000)). The reason that normal distribution is 
uninteresting is that for most multi-dimensional data sets, almost all low dimensional 
projections are normal (Diaconis and Freeman, 1984). However this assumption is not 
always valid as the purpose of the research determines the importance of the features 
(Banks et al., 2004). Sometimes we would like to find interesting features in a dataset as 
compared to another dataset, and it may be possible that our later dataset does not 
follow a normal distribution (Hyvarinen, 2001). 
Normal projection searches the space of all possible projections to find out which 
maximises an index that measures the quality of each resulting view (Lee et al, 2005). 
In other words according to Friedman and Tukey (1974) projection pursuit searches for 
projection vectors that maximize projection indices which highlight deviations from the 
normal distribution. 
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There are some alternative approaches developed for normal projection pursuit such as: 
Relative Projection Pursuit (RPP) (Hiro, et al., 2002) and Targeted Projection Pursuit 
(TPP) (Faith, et al., 2006). The investigation of RPP is out of scope of this research 
however TPP method is going to be investigated in this research. 
According to Faith, et al.  (2006) “Targeted projection pursuit proceeds by 
hypothesizing an ideal view of the data, then finding a projection that best approximates 
that view.” This approach could be very useful as analysing all possible views for high 
dimensional data is almost impossible. In this approach the appropriate target view of 
the data is defined as the view that clearly shows the separation between known classes 
in the dataset.  
Figure 1-11, describes the overall process of TPP in which p is the number of features in 
the dataset and k is the new dimension which has to follow the rule k<p: 
 
 
Figure 1-11 The TPP process 
(Faith, Mintram and Angelova, 2006) 
p is the number of variables in the original dataset 
Feature Selection using TPP is achieved by finding a view that separates the class in 
question from all other samples, and then inspecting the resulting projection to see 
which genes are most significant. 
Process and example 
Suppose we have a n × f matrix which demonstrates the dataset S (n number of samples 
and f number of features in the dataset) and a target view T, a n × 2 (n number of 
samples) matrix that describes a two dimensional view of the dataset. Therefore, a 
projection P (p × 2 matrix) that minimizes the difference between the resulting of the 
projection and the desired view is required (Equation 1-15). 
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min || ||T SP  
Equation 1-15 definition of projection p in TPP 
 (Faith, 2007) 
T the target view, P the projection and S dataset 
||  || denotes Euclidean norm (Equation 1-16) 
Suppose a ij is the thi row and thj  column of matrix A. Euclidean norm can be defined 
as Equation 1-16. 
2
ij
ij
EN a   
Equation 1-16 Euclidean norm 
(Barni et al., 2000) 
A solution to Equation 1-15 may be found by “training a single layer perception with p 
input units and two linear output units” (Faith, 2007). In other words, for each element 
in the dataset, compute the corresponding row in P. 
As mentioned above, TPP tends to find the views in the data. In the field of feature 
selection, the interesting view of the data is the view in that separation in classes in the 
data set is clear. By selecting this view of the dataset (view in which all classes are 
separated), TPP calculates and sorts the importance of each feature in the view. This 
process identifies the most important features and they can be used as selected features.  
The process starts by loading a dataset to TPP. Figure 1-12 illustrates the original 
visualization of SRBCT dataset (Khan et al, 2001) (This dataset contains micro-array 
data of four cancers) using TPP.  
After loading the dataset, by selecting the “Separate class” option, TPP introduces the 
view of the data in which classes in the dataset are separated. Figure 1-13 illustrates the 
secreted class view of SRBCT dataset using TPP. At this stage TPP calculates the 
significance of each feature in this view and highlights the most important features. By 
sorting this table, the most important features can be selected. Figure 1-14 illustrates the 
significance table provided by TPP. For each variable the significance of the variable 
was calculated. 
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Figure 1-12 original view of SRBCT dataset using TPP 
 
 
Figure 1-13 separated class view of SRBCT dataset using TPP 
 
 
Figure 1-14 Significant variables in SRBCT discovered using TPP 
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TPP provides a beneficial significance in case of feature selection, as this technique 
visualizes the dataset and makes it more understandable for researchers. Considering the 
benefits of visualization of the dataset, generating views for large datasets can be a very 
time consuming process. At this stage of the research there is no other research 
available to clarify the possible limitations of this technique.  
Faith, et al. (2006) investigated TPP performance on 3 datasets and they are as follows:  
 LEUK: This dataset is the result of a study of gene expression in two types of 
acute leukaemia: acute lymphoblastic leukaemia (ALL) and acute myeloid 
leukaemia (AML) (Golub et al, 1999) 
 SRBCT: This dataset comprises cDNA microarray analysis (Khan et al, 2001). 
 NCI: This dataset records the variation in gene expression among the 60 cell 
lines from the National Cancer Institute’s anticancer drug screen (Scherf et al, 
2000) 
Results of investigations on the above datasets indicate that TPP performed better than 
the investigated methods. 
Another research (Haddow et al., 2008) analysed the relationship between the primary 
structure of proteins, and their functional properties using TPP. Researchers concluded 
that in the case of the kinase proteins, TPP offers useful analytical results and more 
importantly TPP identified regions that are known to be important in differentiating 
functional classes.  
In summary TPP techniques demonstrate a successful new method in dimensionality 
reduction. The views of the dataset that generated using TPP, help researchers have a 
better understanding of the dataset in hand. The investigated ion on the three datasets 
concluded a high performance for this technique. However further investigation is 
required to compare the performance of this technique with some other dimensionality 
reduction techniques in particular for feature selection. 
 
 
1.3.2.4 Genetic algorithm (GA) 
Genetic Algoritm (GA) was first used by John Holland and his students in 1975. 
Usually Genetic Algorithms are used in optimization (finding the optimum of a 
function).  Traditional optimization techniques like gradient descent are local in scope 
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(Butz et al., 2005). This means that the optima they seek are the best in a neighbourhood 
of the current point. This causes problems, if the function has many local optima or, 
even worse, if the gradient is not computable. Enumerative search methods (e.g. the A*-
algorithm) on the other hand are only applicable, if the search space is discrete and not 
too large (Russel and Norvig, 1995). The advantages of Genetic Algorithms are that 
there is no need to have much information about the function to optimize and GA is 
applicable even if the search space is very large.  
Genetic Algorithms are using random choice as a tool to guide a highly exploitative 
search through a discrete coding of the search space. That means the transition from one 
state in search space to another is probabilistic, not deterministic. According to Dechter 
and Mateescu (2004), deterministic matching systems use a combination of algorithms 
and business rules to determine when two or more records match. On the other hand, 
Probabilistic matching uses likelihood ratio theory to assign comparison outcomes to 
the correct or more likely decision. Another characteristic of Genetic Algorithms is that 
they don’t search from a single point, but from a population of points at the same time. 
That means Genetic Algorithms are a global search procedure, because they explore the 
search space from many points in parallel. This way they can avoid local optima. 
However, it should be mentioned that Genetic Algorithms are not always the best 
choice. Depending on the problem in hand, a traditional gradient descent may actually 
be much faster than a computationally expensive Genetic Algorithm (Lin and He, 
2005). 
The first step in the implementation of genetic algorithms is to identify and model 
(generate) the initial population. In normal genetic algorithm each member of this 
population will be a binary string of length N and it will be referred to as a 
“chromosome” (Reeves and Rowe, 2003). The most common and easiest way to 
achieve this is a binary code. Consider we want to find the maximum of the objective 
function    K: }128,..,0{  2, x x .  
 
Each point }128,..,0{x can be coded as a 7 bit binary number. By putting these points 
together we get a population of chromosomes as:  
}1,0{),,...,( 71 ibbb  
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Then each chromosome is evaluated by using a fitness function, which measures the 
quality of its corresponding solution. According to Reeves and Rowe (2003) the fitness 
function maps the outputs of the evaluation function for the different individuals in the 
population to the fitness value of one single individual. That means the fitness is defined 
with respect to other members of the population. Fitness function should always 
produce a positive value for the fitness and is defined as the following (Reeves and 
Rowe, 2003):  
:f x   
In the normal Genetic Algorithm the fitness is defined as i


  , where i   is the 
evaluation associated with individual and    is the average evaluation of all individuals 
of the population (Reeves and Rowe, 2003).The fitness value can also be assigned based 
on the ranking of the individuals (Goldberg, 1989). 
At each generation (step) the fittest (the best) chromosome will be kept, and as the 
process continues only the fittest chromosomes will remain (the best solution for the 
problem after last generation). For creating this new generation GA uses crossover and 
mutation operators (they are exchanging parts of their genetic information).  In GA 
roulette wheel parent selection is used to pick parents for the new population, where 
each individual is represented on the wheel by a space that is proportional to its fitness. 
The roulette wheel is rotated and an individual is chosen until the intermediate 
population is filled up.  
In broader usage of the term, a genetic algorithm is any population based model that 
uses selection and recombination operators to generate new sample points in the search 
space (Reeves and Rowe, 2003). 
In order to clarify the GA algorithm we are going to explain the crossover and mutation 
operators.  
Crossover: After selecting the parents we need to combine them to create new 
generation, this process is known as crossover. In other words crossover is a matter of 
replacing some of the properties in one parent by properties of the corresponding genes 
of the other (Reeves and Rowe, 2003). According to Reeves and Rowe (2003) there are 
different kinds of crossover operators used in GA such as: one point crossover, m point 
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crossover, non-linear crossover and generalized n point crossover. Imagine we have two 
strings of  
1 2 3 4 5( , , , , )b b a a a  And 1 2 3 4 5( , , , , )b b b b b  
one point crossover randomly selects crossover point (in this case between 1… 5) and 
new solution produced by combining the pieces of the original parents as follows 
(crossover point=2): 
1 2 3 4 5( , , , , )a a b b b  And 1 2 3 4 5( , , , , )b b a a a  
Mutation: The purpose of mutation in GA is preventing the population of 
chromosomes from becoming too similar to each other, thus slowing or even stopping 
evolution (Reeves and Rowe, 2003). Mutation simply means complementing the chosen 
bit(s). For example, the string 10001011 with mutation applied at genes 3 and 5, 
becomes 10100011. 
The following is a simple GA algorithm (Jones, 1998): 
1. A population of m random individuals is initialized. 
2. Fitness scores are assigned to each individual. 
3. Using roulette wheel parent selection m/2 pairs of parents are chosen from the 
current population to form a new population. 
4. With probability Pc, children are formed by performing crossover on the m/2 
pairs of parents. The children replace the parents in the new population. 
5. With probability Pm, mutation is performed on the new population. 
6. The new population becomes the current population. 
7. If the termination conditions are satisfied exit, otherwise go to step 3. 
Figure 1-15, illustrates the simple GA algorithm.  
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Figure 1-15 GA process 
(Mitchell, 1998) 
 
To clarify the process, consider the following artificial example (Table 1-14). The 
fitness values are generated based on an artificial scenario. 
 
 
ID  Chromosome Fitness 
1 11000 0.80 
2 00111 0.20 
3 10101 0.60 
4 11011 0.70 
Table 1-14 Artificial dataset as an example for GA process 
  
 
 
At this point GA will select the fittest chromosomes according to their fitness values. In 
this case chromosomes number one (f(1)=0.80) , chromosomes number four (f(4)=0.70) 
and chromosomes number three (f(3)=0.60) will be selected. 
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After selection chromosomes crossover and mutate. The first chromosome gets last bit 
mutated and second and third chromosome crossover to produce two new ones. After 
these transformations population at time 1nt   is 11001, 10001, and 10111. 
Figure 1-16 illustrates the process of the above example. 
 
 
Figure 1-16 GA process example 
 
 
Although genetic algorithms have proven to be an efficient and powerful problem-
solving strategy, on the other hand GA has certain limitations. However, it will be 
shown that all of these can be overcome and none of them “bear on the validity of 
biological evolution” (Mitchell, 1998). 
 Lack a convergence proof: It means that GA may not know when it is done (Jackson 
and Norgard, 2008). One possible solution to this problem is to examine some 
possible generations and if no improvement is observed, terminate the process. 
 Premature convergence: If a chromosome that is fitter than most of its competitors 
emerges early in the process of the algorithm, it may drives down the population's 
diversity too soon, leading the algorithm to unite on the local optimum that the 
individual represents rather than finding the global optimum (Forrest 1993, Mitchell 
1996). In other words according to Jackson and Norgard (2008) GA has the problem 
of “climbing local hills in the solution space”. One possible solution to this problem 
is to control the strength of the selection (Mitchell, 1998). 
 Time and computational effort: several researchers (Holland 1992; Forrest 1993; 
Haupt and Haupt 2004) advise against using genetic algorithms on analytically 
solvable problems. This doesn’t mean that GA cannot find the optimum solution for 
11000  00111 10101
11011  ……...  …….
11000  11011  10101
…….    …… …….
11001  10001  10111
……..   …….    …….
Tim: Tn Tim: Tn+1
Selection
Mutation
Crossover
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the problem, but the traditional analytic methods take much less time and 
computational effort than GA.  
 Suitable fitness function and operators: as mentioned in the previous section GA 
needs a high performance fitness function and suitable crossover and mutation 
operators to perform well. Failing to design and implement such properties for GA 
will lead algorithm to failure.  
 
As mentioned previously (section 1.3.2) feature selection is a search problem and on 
large datasets such as gene expression datasets, this search is proven to be more 
difficult. As described in this section GA is a high performance search process which is 
widely applied on gene expression data sets. Chakraborty and Maka (2005) investigated 
GA on gene expression data and compared some other methods (such as chi squared) 
and concluded that GA outperformed other algorithms. Karzynski et al. (2003) claims 
that GA is a 100% successful method in context of diagnostic applications of DNA 
micro-arrays. Many other researchers(Weinberg et al. 2001, Zhu et al. 2007, Hruschka 
et al. 2004, Liu et al. 2004, Gesu et al. 2005, Gesu et al. 2005 and Ma et al. 2003  ) 
employed GA for feature selection or clustering the gene expression datasets and 
claimed that this technique is very powerful and accurate compared to other methods.  
Considering efficiency and accuracy of GA, many researchers used GA on gene 
expression data and concluded that this technique is very effective and powerful. 
Although GA has some limitations, they can be resolved if they are carefully addressed 
during the implementation.  
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1.4 Research outline 
The following section demonstrates the outline of the present research. The statement of 
the problem is introduced and the research questions are introduced. Later on, the 
structure of the thesis is clarified.  
1.4.1 Statement of the problem 
Previously (Section 1.2) the current understanding of ovarian cancer was discussed. The 
standard management of ovarian cancer highlights some problems and possible 
improvement for management of ovarian cancer. The following sections address these 
problems. 
1.4.1.1 Complexity of the ovarian cancer management 
The number of markers, treatments and the sequences of treatments are rising. 
Therefore it is getting more complex for human brain to perform clinical decision 
making. There is a need for an expert computer system (e.g. Artificial Intelligence) 
which is capable of investigating the possible outcome for each marker, treatment and 
sequence of the treatment (Friedman, 2009).  
These expert systems provide a tool that may help clinicians to analyze and predict 
different treatment pathways. These models can act as a tool for predicting the outcome 
of each treatment pathway.  
The other possible benefits of using such systems are that they can learn from 
experience and improve their prediction accuracy.  
1.4.1.2 Prediction of survival 
The prediction of the overall survival of a patient is a very difficult task. There may be 
some benefits in predicting the overall survival as this prediction may change the path 
of treatment. The prediction of survival may change the method of recruitment in 
randomised studies. Understanding the possible survival duration of the patient may 
also be beneficial for the patient.   
Recently there were some attempts in predicting the overall survival (Gerstein et al., 
2009). Although the introduced models could predict the overall survival, the accuracy 
of the prediction is not high (c statistic of 0.67). The introduced system is a static model 
that cannot improve its prediction accuracy as the number of new cases emerges.  
Therefore a system that can predict the overall survival of the patient is needed 
(Teramukai et al., 2007; Chi et al., 2008; Gerestein et al., 2009). 
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1.4.1.3 Surgical prediction 
As discussed previously (section 1.2.1.8), there are three different outcomes of surgery. 
The current management of ovarian cancer is the surgery after discovering abnormality 
during the physical examination, rises in CA125 biomarker and abnormality on CT 
scans. Only in small number of cases, due to health issues, the patient is referred for 
other treatment pathways rather than surgery. As discussed (section 1.2.1.8) the goal of 
the surgery is to remove as much tumour as possible. Based on the author’s observation 
in theatre room and ovarian cancer literature, in some cases it is impossible to remove 
the entire tumour during surgery. Such patients (that complete cytoreduction surgery is 
not achievable) could be referred to another treatment pathway rather than primary 
surgery.  
In the past (Bristow et al., 2000; Funt et al, 2004) there were some attempts to predict 
the outcome of the surgery based on CT scan results. None of these attempts could 
successfully introduce a reliable model. At present there is an essential need for such 
system that can predict the outcome of the surgery (Allen, 2010). 
Therefore there are many benefits mentioned for a system that can predict the outcome 
of the surgery (Allen (2010); Leitao and Barakat, 2009). 
 
1.4.2 Research questions 
The research questions are derived from the problems identified in existing literature. 
Thus, two of this research’s questions are as follows: 
1. Can Artificial intelligence and Machine learning methods accurately predict the 
survival rate of ovarian cancer patients?  
Accuracy in this question refers to better prediction results compared to the 
current available models.  
2. Can Artificial intelligence and Machine learning methods predict the outcome of 
the surgery using the variables available for clinicians prior to surgery? 
 
1.4.3 Structure of the thesis 
The thesis consists of seven chapters.Chapter 1: This chapter investigates the current 
understanding of ovarian cancer. The current management of ovarian cancer and clinical 
decision making regarding ovarian cancer is investigated in this chapter. The Artificial 
intelligence, Machine learning methods and feature selection techniques are introduced 
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in this chapter. Based on the identified problems in current management of ovarian 
cancer and the potential benefits of computational methods the research questions are 
identified.  
Chapter 2: Introduces the dataset that will be used in this research. This chapter 
investigates the data pre-processing processes.  
Chapter 3: Investigates the process definition of this research. This chapter also 
introduces the estimates of prediction performance and prediction performance 
measurements.  In this chapter, the possible problems during the process are identified 
and addressed.  
Chapter 4: Investigates the possibility of prediction of survival rates. The most 
important variables for this prediction are identified. The results of the present model 
are compared against the previously developed model and conventional statistical 
models. 
Chapter 5: Investigates the prediction of the outcome of the surgery. The most 
important factors for this prediction are identified. The results of the prediction are also 
compared against the results of prediction using statistical models.  
Chapter 6: In this chapter, using feature selection and Artificial inelegance models, a 
gene analysis for discovering most important genes for prediction of chemotherapy 
response is introduced.  
Chapter 7: Finally this chapter summarizes the thesis and introduces the possible future 
work that can be completed.   
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Chapter 2 Data and Data handling 
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2.1 Introduction 
This chapter of the thesis introduces the datasets that will be used in this research. Each 
dataset is briefly described and the characteristics of each dataset are presented. These 
characteristics include the number of data and the percentage of the data which is 
available for all the variables. The number of data for the complete dataset (the dataset 
with no missing values) and the entire collected data is made available.   
Each dataset needed to be pre-processed prior to any analysis; therefore the pre-
processing phase including the normalization of the data, handling missing values, 
identifying outliers and coding the input values are briefly described. 
After the pre-processing phase, the datasets were merged and the initial comparison of 
the two datasets is described.  
2.2 Datasets 
To discover the hidden relations between the data, the appropriate datasets are required. 
The machine learning section in chapter one (section 1.3.1) describes the need for 
datasets to train and evaluate the created models. This section introduces the datasets 
that will be used to extract information from the data to build, train and evaluate the 
models. 
2.2.1 Newcastle ovarian cancer tissue micro array 2000 (OV_TMA_2000) 
The Newcastle ovarian cancer tissue micro array (OV_TMA_2000) (Wilkinson et al., 
2008) is used as a primary dataset. Briefly, the OV_TMA_2000 comprises 167 cases of 
epithelial ovarian cancer. All tissue samples were taken from sequential patients who 
underwent primary surgery between 1995 and 2000 at the Northern Gynaecological 
Oncology Centre, Gateshead, UK, with appropriate ethical approval.  All patients 
underwent maximal effort primary cytoreductive surgery followed by platinum based 
chemotherapy either with or without paclitaxel. For each tumour sample all histology 
reports, H&E stained slides and formalin fixed paraffin embedded blocks were retrieved 
and the diagnosis of epithelial ovarian cancer confirmed. 1mm cores were then taken 
from these areas and added to the OV_TMA_2000. Data were simultaneously extracted 
from the patient record to include age, FIGO stage, grade, histological subtype, 
preoperative CA125 and outcome of surgery. These data are available to a clinician 
immediately after staging surgery. The overall survival was also recorded. 
41/167 cases had more than two data items missing and were therefore excluded from 
further analysis giving a total of 126 cases within the dataset, summarised in table 2.1.  
63 
 All 
available 
cases 
Complete 
data 
1 or 2 
missing 
values 
Useable 
data 
Unusable 
data 
Number 
of cases 
167 70 56 126 41 
Table 2-1 OV_TMA_2000 
The available data in OV_TMA_2000 dataset 
 
 Age: The age of the patient in years or missing. (Table 2-2) 
 FIGO stage: The value is recorded as one of the following: 1a, 1b, 1c, 2a, 2b, 2c, 
3a, 3b, 3c, 4 or missing. (Table 2-3) 
 Grade: The possible values are: poorly differentiated, moderately differentiated, 
well differentiated or missing. (Table 2-4) 
 Histological subtype: The possible subtypes (section 1.2.1.4) are: serous, 
papillary serous, mucinous, clear cell, endometrioid or missing. (Table 2-5) 
 CA125: Continuous data greater than one. (Table 2-6) 
 Outcome of the surgery (section 1.2.1.8): complete cytoreduction, optimal 
cytoreduction, sub-optimal cytoreduction or missing. (Table 2-7)  
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 Number of available cases (#) Percentage of the data (%) 
Age All data Complete data All data Complete data 
20-30 2 1 1.20 1.43 
30-40 3 1 1.80 1.43 
40-50 12 6 7.19 8.57 
50-60 36 13 21.56 18.57 
60-70 54 27 32.34 38.57 
70-80 39 16 23.35 22.86 
80-90 12 5 7.19 7.14 
90-100 1 0 0.60 0 
100+ 2 1 1.20 1.43 
Missing 6 0 3.59 0 
Total 167 70 100% 100% 
Table 2-2 OV_TMA_2000 Age 
Breakdown of available data for Age 
 Number of available cases (#) Percentage of the data (%) 
FIGO stage All data Complete data All data Complete data 
1a 15 4 8.98 5.71 
1b 1 1 0.60 1.43 
1c 11 5 6.59 7.14 
2a 1 1 0.60 1.43 
2b 3 1 1.80 1.43 
2c 10 4 5.99 5.71 
3a 6 5 3.59 7.14 
3b 9 2 5.35 2.86 
3c 76 40 45.51 57.14 
4 18 7 10.78 10.00 
Missing 17 0 10.18 0 
Total 167 70 100% 100% 
Table 2-3 OV_TMA_2000 FIGO stage 
Breakdown of available data for FIGO stage 
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 Number of available cases (#) Percentage of the data (%) 
Grade All data Complete data All data Complete data 
Poorly 
differentiated 
80 39 47.90 55.71 
Moderately 
differentiated 
45 21 26.95 30.00 
Well 
differentiated 
42 10 25.15 14.29 
Missing 0 0 0 0 
Total 167 70 100% 100% 
Table 2-4 OV_TMA_2000 Grade 
Breakdown of available data for Grade 
 
 
 Number of available cases (#) Percentage of the data (%) 
Histological 
subtype 
All data Complete data All data Complete data 
Serous 38 15 22.75 21.43 
Papillary 
serous 
41 18 24.55 25.71 
Mucinous 18 5 10.78 7.14 
Clear cell 16 4 9.58 5.71 
Endometrioid 54 28 32.34 40.00 
Missing 0 0 0 0 
Total 167 70 100% 100% 
Table 2-5 OV_TMA_2000 Histological subtype 
Breakdown of available data for Histological subtype 
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 Number of available cases (#) Percentage of the data (%) 
CA125 All data Complete data All data Complete data 
1-35 9 1 5.39 1.43 
35-100 15 8 8.98 11.43 
100-500 46 28 27.54 40.00 
500-1000 25 12 14.97 17.14 
1000-3000 26 12 15.57 17.14 
3000+ 19 9 11.38 12.86 
Missing 27 0 16.17 0 
Total 167 70 100% 100% 
Table 2-6 OV_TMA_2000 CA125 
Breakdown of available data for CA125 
 
 Number of available cases (#) Percentage of the data (%) 
Outcome of 
the surgery 
All data Complete data All data Complete data 
Complete 
cytoreduction 
54 22 32.34 31.43 
Optimal 
cytoreduction 
30 18 17.96 25.71 
Sub-optimal 
cytoreduction 
64 30 38.32 42.86 
Missing 19 0 11.38 0 
Total 167 70 100% 100% 
Table 2-7 OV_TMA_2000 Outcome of the surgery 
Breakdown of available data for Outcome of the surgery 
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2.2.2 Newcastle ovarian cancer tissue micro array 2005 (OV_TMA_2005) 
The original dataset (OV_TMA_2000) was discussed in the previous section (section 
2.2.1). However according to Marzban (2009) and Lee (2010) availability of more data 
can significantly improve the performance of the models. Therefore in order to improve 
the models, a further dataset was required. Subsequently, with appropriate ethical 
approval, the patient’s files which were admitted to the Northern Gynaecological 
Oncology Centre, Gateshead, UK, between 2000 and 2005 were analysed and 
appropriately recorded. The number of patient files that are available for analysis in the 
period of 2000-2005 is 1057. In order to capture all required data for each patient, it was 
essential to read and record the following for each patient: 
 MDT meeting reports.  
 Operation notes. 
 The letters sent to each patient. 
 
The following table (Table 2-8) summarizes the number of MDT meeting reports, 
operation notes and the letters sent to each patient during the 2000-2005 period that 
were analyzed and recorded during the collection of OV_TMA_2005 dataset. Most of 
this information was paper based, therefore making the analysis and the recording 
process very difficult and time consuming.    
 
 
Number of 
patients 
MDT 
reports 
Patients’ 
letters 
Operation 
notes 
1057 3300 28300 4310 
Table 2-8 Analysed data for collection of OV_TMA_2005 dataset 
The amount of analysed patient files for collection of the OV_TMA_2005 dataset 
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The data was divided into similar categories as the previous section.  
 All 
available 
cases 
Complete 
data 
1 or 2 
missing 
values 
Useable 
data 
Unusable 
data 
Number 
of cases 
501 248 34 282 219 
Table 2-9 OV_TMA_2005 
The available data in OV_TMA_2005 dataset 
 
 
 
Similar to the OV_TMA_2000 dataset, each variable can hold different possible values: 
 Age: (Table 2-10) 
 FIGO stage: (Table 2-11) 
 Grade: (Table 2-12) 
 Histological subtype: (Table 2-13) 
 CA125: (Table 2-14) 
 Outcome of the surgery: (Table 2-15) 
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 Number of available cases (#) Percentage of the data (%) 
Age All data Complete data All data Complete data 
20-30 2 0 0.40 0.00 
30-40 10 3 2.00 1.21 
40-50 48 20 9.58 8.06 
50-60 98 42 19.56 16.94 
60-70 153 79 30.54 31.85 
70-80 116 54 23.15 21.77 
80-90 69 46 13.77 18.55 
90-100 5 4 1.00 1.61 
100+ 0 0 0.00 0.00 
Missing 0 0 0.00 0 
Total 501 248 100% 100% 
Table 2-10 OV_TMA_2005 Age 
Breakdown of available data for Age 
 Number of available cases (#) Percentage of the data (%) 
FIGO stage All data Complete data All data Complete data 
1a 68 33 13.57 13.31 
1b 5 2 1.00 0.81 
1c 70 31 13.97 12.50 
2a 3 1 0.60 0.40 
2b 2 1 0.40 0.40 
2c 20 10 3.99 4.03 
3a 14 9 2.79 3.63 
3b 19 11 3.79 4.44 
3c 230 128 45.91 51.61 
4 46 22 9.18 8.87 
Missing 24 0 4.79 0 
Total 501 248 100% 100% 
Table 2-11 OV_TMA_2005 FIGO stage 
Breakdown of available data for FIGO stage 
70 
 Number of available cases (#) Percentage of the data (%) 
Grade All data Complete data All data Complete data 
Poorly 
differentiated 
225 172 47.90 44.91 
Moderately 
differentiated 
49 29 26.95 9.78 
Well 
differentiated 
63 47 25.15 12.57 
Missing 164 0 0 32.73 
Total 501 248 100% 100% 
Table 2-12 OV_TMA_2005 Grade 
Breakdown of available data for Grade 
 
 Number of available cases (#) Percentage of the data (%) 
Histological 
subtype 
All data Complete data All data Complete data 
Serous 19 19 3.79 7.66 
Papillary 
serous 100 64 19.96 25.81 
Mucinous 44 30 8.78 12.10 
Clear cell 30 14 5.99 5.65 
Endometrioid 206 121 41.12 48.79 
Missing 102 0 20.36 0 
Total 501 248 100% 100% 
Table 2-13 OV_TMA_2005 Histological subtype 
Breakdown of available data for Histological subtype 
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 Number of available cases (#) Percentage of the data (%) 
CA125 All data Complete data All data Complete data 
0-35 22 14 4.39 5.65 
35-100 62 34 12.38 13.71 
100-500 131 88 26.15 35.48 
500-1000 56 31 11.18 12.50 
1000-3000 71 43 14.17 17.34 
3000+ 46 38 9.18 15.32 
Missing 113 0 22.55 0 
Total 501 248 100% 100% 
Table 2-14 OV_TMA_2005 CA125 
Breakdown of available data for CA125 
 
 
 Number of available cases (#) Percentage of the data (%) 
Outcome of 
the surgery 
All data Complete data All data Complete data 
Complete 
cytoreduction 207 120 41.32 48.39 
Optimal 
cytoreduction 134 80 26.75 32.26 
Sub-optimal 
cytoreduction 72 48 14.37 19.35 
Missing 88 0 17.56 0 
Total 501 248 100% 100% 
Table 2-15 OV_TMA_2005 Outcome of the surgery 
Breakdown of available data for Outcome of the surgery 
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2.3 Data pre-processing  
The quality of a machine learning model or a classifier is highly dependent on many 
factors. Probably the most important factor is the quality and representation of the 
available data (Kotsiantis et al., 2006; Asyali et al., 2006). This is an important part of 
the research as the models such as ANN are very sensitive to the quality of the data and 
consequently, the predictive results can be highly affected. Therefore, the identification 
of undesirable data in the dataset and the removal of such data can ensure the better 
performance of the models. This section investigates the essential parts of data pre-
processing. 
 
2.3.1 Handling missing values 
It is common for real world datasets to contain missing values (Kotsiantis et al., 2006). 
On some occasions due to technical issues it is impossible to calculate the value of a 
feature for a given instance or occasionally the data is lost based on how the data is 
recorded. There are many methods suggested for handling the missing values in the 
dataset. One of the most common methods is to remove the instances that have missing 
value(s) (Engelbrecht, 2007). Removal of the instances in case of missing value may 
resolve the problem of missing values. However as the number of cases is limited in 
most real world datasets, the available data for analysis will be reduced. Also by 
removing such cases , vital information about the data may be lost (Engelbrecht, 2007). 
The other method is to replace the missing value with the average value of the 
remaining available cases in case of continues data, or replacing the missing value with 
the most occurring value in case of nominal data (Kotsiantis et al., 2006). 
It is also possible to estimate the missing value using KNN method (section 1.3.1.1). As 
discussed previously, KNN can estimate the missing value based on the likelihood of its 
similar data in the dataset. Research (Kim et al., 2005; Dudoit et al., 2002; Troyanskaya 
et al., 2001) suggested that KNN may be the most reliable method for estimation of the 
missing value.  
2.3.2 Outliers 
In statistical terms, outliers are defined as the data that significantly differs from other 
data in the dataset (Barnett and Lewis, 1994). Engelbrecht (2007) highlighted the issues 
of outliers in the data and suggested as the values of outliers are significantly different 
to the rest of data, it affects the function (or model) that fits to the data and they tend to 
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pull the resulted function (or model) towards themselves (Figure 2-1). As a result they 
play an important role in reducing the accuracy of the model.  
The problem of outliers can be addressed using different methods. The most common 
and straightforward approach is to completely remove such data from the data set. It is 
argued (Engelbrecht, 2007) that removing the outliers from dataset resolves the issues 
surrounding outliers in the dataset; however it is possible to lose vital information about 
the data. There are many approaches developed based on removing the outliers. Gedeon 
et al. (1995) and Slade and Gedeon (1993), developed the approach of removing the 
outliers during training the model based on the distribution of the data.  
Some other researchers (Huber, 1981), suggest that it is possible to build the robust 
model or function that is not influenced by outliers.  
Outliers were included but data were always cross checked between paper and 
electronic formats and cases with discrepancies discarded. In this research, the removal 
approach for handling the outliers will be employed. This is because of the nature of the 
present data for this research, as many of the outliers may have been caused by human 
error during the entering and recording of the data into paper based files.  
 
 
Figure 2-1The issue of outliers in the dataset 
(Engelbrecht, 2007) 
Outliers tend to distance the desired function (or model) to be closer to them and as a 
result significantly affect the accuracy of the model. 
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2.3.3 Coding the input values 
Some classifiers and machine learning models such as ANN, can only handle numeric 
values. Therefore, it is essential to convert nominal values into numeric values before 
analysis. The solution for the variables that only hold two nominal values such as ‘Sex’ 
is straightforward, one of the values for example male can be coded to ‘1’ and the other 
(female) to ‘0’. It is possible to apply the same approach for other variables and map 
each nominal value to a unique numeric value, however as Engelbrecht (2007) argues, 
the model may assume that this set of numbers represents a continuous dataset which 
will cause the model to lose the original characteristic of such data. The possible 
solution is to use binary labelling for converting the nominal data (Huang and Ng, 
2003). The nominal data with n different values can be coded into n different variables 
where the corresponding variable’s value is set to ‘1’ and the rest of variables are set to 
‘0’ (Engelbrecht, 2007). In the other words, the n entry values for a nominal variable 
will be converted to n different variables that each variable is set to one of the entry 
values. For each case the new converted variable is set to ‘1’ if and only if it 
corresponds to the entered value for the nominal variable. 
 
2.3.4. Normalization and scaling 
Data normalization and scaling is a common practice which is used for most of the 
research that involves some sort of data and modelling (Cheng and Li, 2008). It is 
essential to note that in this thesis, normalization refers to the process of scaling down 
the values to a specific range, rather than scaling it up. Most of the classifiers and 
models normalize data before processing. Normalization may ensure higher 
performance for models and classifiers as this technique preserves the relation between 
features in the dataset and it simplifies the computing process (Han et al., 2006). It has 
been argued that the normalization process is an essential part of data pre-processing as 
it prevents the feature with a large range dominating the other features in the dataset 
with relatively smaller ranges (Han et al., 2006; Engelbrecht, 2007; Kotsiantis et al., 
2006). 
There are many methods developed for normalizing the data. One of the most 
commonly used techniques is to consider the mean and the standard deviation of a 
feature and normalizing each value of the feature. This method is commonly known as 
zero-mean normalization. According to Han et al. (2006), consider v is one of the values 
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of feature X and the standard deviation of X is calculated as X  and the mean value of X 
is X . Therefore the nv  normalized value of v can be calculated as: 
n
X
v X
v


  
Equation 2-1 zero-mean normalization 
Where V is one of the values of feature X and X is the standard deviation of X and X
is the mean value of X. 
Max-min normalization is another method that is widely used. Assume max X and min X  
are the maximum and minimum values of feature X and v one of the values of feature X. 
nv the normalized value of v can be calculated as (Han et al., 2006):  
min
max min
x
n
x x
v
v



 
Equation 2-2 max-min normalization 
Where v is a value of X, max X and min X  are the maximum and minimum values of 
feature X and nv the normalized value of v 
 
There are many other methods developed for data normalization. However the 
differences between methods are not very noticeable (Han et al., 2006) and due to the 
simplicity of the zero-mean method, this method is selected for this research.  
Although the data normalization is common practice in most research and datasets 
(Cheng and Li, 2008), we have to keep in mind that in some cases it is essential to 
consider that some data may show some domination in the data by their nature (such as 
gene analysis data). Consequently, scaling down the gene expression data may equalise 
the expression of genes. Therefore, it is essential to consider the data and type of 
analysis in hand before performing the data normalization. 
2.4 Comparison of datasets 
In section 2.2 datasets OV_TMA_2000 and OV_TMA_2005 were discussed. Prior to 
merging the two datasets, they were compared to ensure no significant differences 
existed between the two. In order to achieve this, a paired sample T test using 
Wilcoxon, Sign, McNemar and Marginal Homogenity is performed. These tests are 
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used to compare groups that are related in some way. The results of these tests indicate 
the similarity or differences between the values of the features in each dataset 
(Riffenburgh, 2005). 
There is no statistical difference between Age, FIGO, Histology, CA125 and Grade 
variables in the two datasets. However there was a statistical difference between 
outcome of the surgery and survival rates.  
The comparison of survival and outcome of surgery (Figure 2-2 and Figure 2-3), 
indicates an increase in the number of complete cytoreduction from 2000-2005 
(OV_TMA_2005) compared to 1995-2000 (OV_TMA_2000). Also it shows a decrease 
in the number of sub-optimal cytoreduction from 1995-2000 compared to 2000-2005. 
Meanwhile the survival rates increased from 1995-2000 compared to 2000-2005.  
In the absence of significant differences between other variables in the datasets, this 
analysis suggests, a strong correlation between the outcome of surgery and the survival 
rates of the patients. This may draw a significant conclusion that the attempts to remove 
as much tumour as possible from the patients significantly increase their survival rate. 
On the other hand it may be that these days the only patients that considered for surgery 
are better patients (patients with good physical and mental conditions). 
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Figure 2-2 Two datasets comparison 
The statistical comparison of OV_TMA_2000 and OV_TMA_2005 concluded that there 
is a statistical significant difference between the outcome of surgery (p value of .006) 
and survival (p value of .006) in the two datasets. 
 
 
Figure 2-3 Survival vs. Outcome of surgery 2000-2005 
Correlation between outcome of surgery and survival rates from 2000-2005. 
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2.5 Summary of chapter  
This chapter of the thesis introduced the datasets that will be used in this research. Each 
dataset was briefly described and the process of collection was highlighted. 
Furthermore, the process of pre-processing of the datasets including the data 
normalization, handling the missing values and identifying the outliers was described. 
Following the validation process, the initial comparisons of the two available datasets 
were presented. This initial comparison highlighted an important conclusion, which is 
the strong relation between the outcome of the surgery and the survival rate of the 
patients.  
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Chapter 3 Experimental methodology 
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3.1 Introduction 
This chapter introduces the methods and metrics used for measuring the performance of 
the models, which will enable comparison and selection of the best model. There are 
many estimates and metrics available; however the most popular methods were selected 
and are briefly described in this chapter. This chapter also introduces the design of 
algorithms which demonstrates the analysis part of this research. Finally, the tools that 
were used in this research will be introduced and briefly described.  
3.2 Estimates of prediction performance 
Machine learning and some of its techniques were discussed previously (section 1.3).  
Briefly, a typical task in data mining, machine learning or statistics is to train a model 
using available data, the training data, and then apply the trained model to new data, 
referred to as evaluation data. As discussed previously (section 1.3) , there are many 
different algorithms available in this field. Ideally the true risk (performance of all 
related data) of the model would select the better algorithm. Unfortunately, in real 
applications only a finite number of data are available, therefore, estimates have to be 
made (Chapelle et al., 2002). In order to assess the performance of the model, it is 
essential that the model is not assessed using the data with which it was trained. The 
model should make appropriate predictions of the evaluation data, (Fujikoshi et al., 
2010). The following approaches were proposed to overcome the above issue. 
3.2.1 Resubstitution Validation  
This approach uses all available data for training the model and evaluates the model 
using the same data (Braga-Neto et al., 2004). In other words, in this approach data has 
been used twice, once for training the model and then for evaluation.   
The Resubstitution Validation, uses the same data for training and evaluation, and will 
therefore underestimate the true error rate (Dubitzky et al., 2006). This validation 
process is widely used in statistics where the number of data instances is relatively 
larger than the number of parameters (factors) in the dataset, because of its simplicity 
(Dubitzky et al., 2006). On the other hand, where the number of parameters (factors) in 
the dataset is large, this estimate tends to be insignificant and misleading (Dubitzky et 
al., 2006). Simon et al. (2003) argue that to measure the prediction ability of a model 
the data for training and evaluation should be separate.  Figure 3-1 demonstrates the 
amount of data that is used for training and evaluation of the model. 
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Figure 3-1 Resubstitution Validation 
This method uses the entire dataset for training and evaluation. 
 
 
3.2.2 Hold-out validation  
To overcome the problem of the Resubstitution validation method Hold-out validation 
was introduced. This approach of validation randomly splits the data in to two separate 
sections, one for training the model and one for evaluation (Lee, 2010). Typically less 
than one third of the data is selected as the evaluation set (Lee, 2010). In other words 
the evaluation set part of the dataset is held out and not used during the training process 
(Figure 3-2). Hold out validation, uses separate data for training and validation, 
therefore this approach leads us to a more accurate estimate for prediction performance 
of the model (Lee, 2010).   
In this approach, the results of training and validation are highly dependent on the split 
in the data set (Marzban, 2009). Since this method uses a single training and evaluation 
over the data set, it may result in an easy or hard section of the data for training and 
validation and leads to “unfortunate” splits (Marzban, 2009). These problems can be 
partially addressed by repeating the process multiple times and using the average 
performance as the final prediction performance. However, as there is no system 
defined for this process, some of the data may be included in the training set multiple 
times, while the others are not included at all. It is also possible that some data may 
always fall into the training set and never have a chance to take part in the evaluation set 
(Marzban, 2009). 
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Figure 3-2 Hold-out Validation 
Hold-out validation splits the data set into two separate sets for training and validation. 
 
3.2.3 K-Fold Cross-Validation 
This method partitions the data into k equally (or nearly equal) sized partition or folds 
(Figure 3-3). For each of k experiment, the ‘k-1’ folds will be used for training the 
model and the remaining one for testing (Lee, 2010). In order to make sure that each 
fold is a good representative of the whole data set, at the start of the process data is 
“stratified” (Dziuda, 2010). The main disadvantage of this technique is that the training 
and evaluation have to be repeated k times; therefore it takes k times longer than the two 
previously described methods. However the training and validation sets are always 
separate to each other and the whole dataset is covered. 
Therefore the true error is estimated as an average error rate on the test sets. Equation 
3-1, illustrates the calculation of the true error rate, where k is the number of folds, and 
iE  is the error rate for each test.  
1
1 k
i
i
E E
k 
   
Equation 3-1 True error rate of k-fold cross-validation 
Where k is the number of folds, and iE is the error test for each test. 
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Figure 3-3  4-fold Cross-Validation 
4-fold cross-validation splits the dataset into training and evaluation sets. Each time 
3(4-1) folds will be used for training and the remaining for evaluation. This process will 
be repeated 4 (k) times. 
 
 
 
Most researchers tend to use k=10 for cross-validation (Dziuda, 2010). Lee (2010) 
argues that the number of folds may depend on the size of the available data set. A 
larger number of folds increase the accuracy of the estimator, on the other hand the 
variance of the estimator will be large and the computational time will be high due to 
many experiments. The small number of folds reduces the computational time and the 
variance of the estimator will be small, however the estimator will be less accurate (Lee, 
2010).  
3.2.4 Leave-One-Out Cross-Validation (LOOCV) 
LOOCV is a special case of k-fold cross-validation, where k is equal to the number of 
data items in the dataset (Dubitzky et al., 2006). In other words, for a dataset with k 
number of data, k tests will be performed, where k-1 examples will be used for training 
the model and the remaining 1 example will be used for evaluation (Figure 3-4). 
LOOCV is widely used especially where the number of available data is very small 
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(Dziuda, 2010).The running time in this method is higher than k-fold cross-validation 
due to increase in number of folds. 
The true error rate in this case is calculated similarly to the k-fold cross validation 
(Equation 3-1).  
 
 
Figure 3-4 Leave-One-Out Cross-Validation 
Each time N-1 number of data will be used for training and the remaining data for 
evaluation. 
 
3.2.5 Repeated k-fold Cross-Validation 
This method has a similar concept to k-fold cross-validation (Section 3.2.3), and it 
repeats the process multiple times (Lee, 2010). At the start of each round data is 
reshuffled. 
This method increases the computational time, however Dziuda (2010) argues as the 
number of estimators’ increases it may lead to a higher accuracy.  
3.2.6 Evaluation of the estimates 
Previously (section 3.2.1-3.2.5) some of the different prediction performance estimators 
were discussed. There have been many attempts in the past to understand the advantages 
and drawbacks of each method and conclude which method performances are the best. 
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Although this conclusion is very dependent to the available data set, it is possible to 
select one of these methods for estimation of the prediction performance in this 
research. Kohavi (1995), Salzberg (1997) and Dietterich (1998) compared several 
methods to estimate accuracy and concluded that 10-fold cross-validation is the best 
selection method. More recently, Molinaro et al. (2005) compared several methods of 
estimation on very wide range of datasets and concluded that 10-fold cross-validation 
performs the best compared to the other methods. 
Furthermore many researchers such as Patnaik et al. (2010), Boutros et al. (2009), 
Hartmann et al. (2009), Dragonieri et al. (2009), Barnett et al. (2010) and Crijns et al. 
(2009) used one type of cross-validation for their research.  
Therefore the 10-fold cross-validation has been selected to estimate the prediction 
performance in this research. 
3.3 Prediction performance measurements 
The criteria for evaluating the performance of a model or a classifier are an important 
part of its design and the research. Using defined criteria allows estimates of the actions 
of a model or a classifier on unseen data to be calculated and also it can be used to 
compare the performance of generated models or classifiers. This will help to decide if 
the model or classifier is good enough for the purpose or to enable the researcher to 
improve it or replace it with another procedure. Several criteria have been used to 
evaluate the performance of classifiers or models. This section, introduces some of these 
criteria. 
3.3.1 Possible outcomes of a model 
There is a need for measurements to identify which of the used models or classifiers 
performed better. In order to introduce such measurements, it is essential to define the 
types of outcomes that a model can produce. Consider a dataset with two classes 1 
(“yes”) and 0 (“no”). The following are four possible outcomes of the prediction: 
False positive (FP): the outcome incorrectly classified “yes” (or 1 or positive) when the 
actual class is “no” (or 0 or negative). 
False negative (FN): the outcome incorrectly classified as “no”, when the actual class is 
“yes”. 
True positive (TP): the outcome correctly classified as “yes”, when the actual class is 
“yes”’ 
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True negative (TN): the outcome correctly classified as “no”, when the actual value is 
“no”. 
Figure 3-5 summarizes the above predictions: 
 
 
Figure 3-5 The possible outcomes of prediction 
 
The true negative rate is the proportion of class 1 (“yes”) items which are correctly 
classified as class 1 (“yes”) and it is denoted as tn (Krzanowski and Hand, 2009).  
1tn FP   
Equation 3-2 True Negative Rate 
 
The false negative rate is the proportion of class 0 (“no”) items, which are incorrectly 
classified as class 1 (“yes”) and is denoted as fn (Krzanowski and Hand, 2009).  
1fn TP   
Equation 3-3 False Negative Rate 
 
3.3.2 Accuracy 
It is possible to measure the performance of a model by counting the correctly classified 
instances and incorrectly classified instances. Furthermore Dobbin et al. (2008) 
considered the accuracy of a model as number of correctly classified instances in the 
dataset (Equation 3-4). 
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number of correctly classifed instance
number of instances
TP TN
Accuracy
TP TN FP FN

 
  
 
Equation 3-4 Accuracy 
Where TP: true positive, TN: true negative, FP: false positive, FN: false negative  
 
However accuracy on its own will not provide the complete information about the 
performance of a model. Olson and Delen (2008) suggested that the domination of a 
category (class) in a dataset affects the value of accuracy and also accuracy returns 
small information about the performance of the model (for example is 90% accuracy 
good or bad?). Furthermore Provost et al. (1998) argues that accuracy assumes the equal 
costs of false positive and false negative; regardless of the fact that in the real world one 
type of error can be more costly than the other.  Therefore Olson and Delen (2008) 
suggested the following metrics to measure the ‘effectiveness’ of a model or a classifier. 
 
3.3.3 Recall 
One of the metrics that is widely used is recall. Recall is the percentage of the correctly 
identified instances among all instances in the dataset that actually belongs to the given 
class (Olson and Delen, 2008). Recall is also known as sensitivity or true positive rate 
of a model. Recall of a given class ‘a’, can be measured as the number of correctly 
classified instances of that given class over number of instances in that class (a). 
 
tan ( )
( )
tan ( )
number of correctly classified ins ces of a givenclass s TP
recall a
number of ins ces inclass a TP FN
 

 
Equation 3-5 Recall of given class a 
Where ‘a’ is the given class, TP: true positive, FN: false negative 
 
3.3.4 Precision 
This metric is the percentage of the correctly identified instances among instances that 
the model considered to belong to that class (Olson and Delen, 2008). This can be 
measured as number of correctly classified instances of given class ‘a’ over number of 
instances model classified as class ‘a’. 
88 
 
number of correctly classified instances of a given class (a)
( )= 
number of instances model classified as class (a)
TP
precision a
TP FP


 
Equation 3-6 Precision of given class a 
Where ‘a’ is the given class, TP: true positive, FP: false positive 
 
When comparing the models, the model with higher value of precision is the better 
model. 
3.3.5 Mean Absolute Error (MAE) 
In data mining, mean absolute error, is a metric that shows how the prediction of the 
model is close to the actual values. Mean absolute error “is the average of the 
differences between predicted and actual value in all test cases” (Patil et al. , 2010).  
Patil et al. (2010) introduces MAE as shown below (Equation 3-7): 
| | ... | |i i n np a p aMAE
n
   
  
Equation 3-7 Mean Absolute Error 
Where ‘p’ is the predicted value by the model, ‘a’ the actual value, n is the total number 
of instances. 
MAE is an error rate; therefore the model with the lower value of MAE is the better 
model. 
3.3.6 Root Mean Squared Error (RMSE) 
RMSE is one of the most widely used metrics to calculate the performance of a model 
(Caipeng et al., 2010). RMSE, like MAE, measures the performance of the model by 
calculating the difference from the predicted value and the actual value. However as the 
name suggests the errors are squared, therefore it gives a higher value to large errors. 
This metric is very useful where large errors are undesirable. According to Patil et al. 
(2010), RMSE can be measured as below (Equation 3-8): 
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2 2( ) ... ( )i i n np a p aRMSE
n
   
  
Equation 3-8 Root Mean Squared Error 
Where ‘p’ is the predicted value by the model, ‘a’ the actual value, ‘n’ is the total 
number of instances. 
Similar to MAE, RMSE is an error rate; therefore the model with the lower value of 
RMSE is the better model. 
3.3.7 Receiver Operating Characteristic (ROC) 
This method was developed in the 1940s to evaluate the performance of signal detection 
systems (Zaknich, 2003). More recently the ROC has also been used to analyse the 
performance of models and classifiers. Previous sections have described the metrics that 
can be used to measure the performance of the model, and one can use the metric which 
is suited for the condition. However it is difficult to identify a metric that works in all 
circumstances and can be used in similar situations in the future.  Therefore it is useful 
to have a method to display and summarise the performance over a wide range of 
situations. The ROC curve exactly does that (Krzanowski and Hand, 2009). 
ROC graph is a plot with true positive rate on the Y axis and false positive rate on the X 
axis as the classification threshold t varies (Krzanowski and Hand, 2009) (Figure 3-6).  
 
Figure 3-6 Receiver operating characteristic (ROC) 
ROC curve plots the true positive rate against the false positive rate and is widely used 
for the performance analysis of a given model. 
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In most classifiers or models there is a parameter that can be adjusted to increase the 
true positive at the cost of a decrease in the false positive or vice versa, this parameter is 
called the classification threshold or ‘t’. Each value of t provides a (FP, TP) pair that can 
be plotted on the graph.  Justifiably the point (0, 1) represents the perfect model or 
classifier as it shows that the false positive rate is 0 (or none) and the true positive rate 
is 1 (or all). The point (0, 0) on the graph represents the model (or classifier) that 
predicts all instances to be negative, while point (1, 1) corresponds to the model (or 
classifier) that predicts every instance to be positive.  
The areas under the ROC curve which is commonly denoted as AUC is the most widely 
used summary index (Krzanowski and Hand, 2009). 
1
0
( )AUC y x dx   
Equation 3-9 Area under ROC curve (AUC) 
 
Accordingly the AUC value of 1 represents the perfect test and the value of 0.5 a 
worthless test. Table 3-1 summarizes the interpretation of AUC values (Krzanowski and 
Hand, 2009). 
AUC Results 
0.90-1.00 Excellent 
0.80-0.90 Very Good 
0.70-0.80 Good 
0.60-0.70 Fair 
0.50-0.60 Poor 
Table 3-1 AUC results interpretation 
(Krzanowski and Hand, 2009) 
3.4 Over fitting 
Over fitting which is also known as poor generalisation, is a major problem for learning 
methods and can reduce the accuracy of the algorithm by 10-25% (Mitra and Acharya, 
2003).  In most cases over fitting occurs where the training data does not adequately 
represent the entire dataset or there is noise in the dataset (Coppin, 2004). The problem 
of over fitting may also occur when the number of available data is not enough for a 
complex model to learn from the data. The number of training data along with the 
amount of training process is an important factor for a learning model so it can cope 
with the unseen data. However as Marsland (2009) claims there should be a balance for 
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the training process, if the model is trained for too long we may over fit the data, as the 
model should learn about noise in the data and this makes the model more complex. If 
the model is trained for a short time it may lose its accuracy for predicting the unseen 
data.   
In most situations, an over fitted model will perform well on the training data, but the 
performance decreases on evaluation data. In other words model T is over fitted where 
there is another model M that gives a higher error on the training data, while giving less 
error on evaluation data (Mitra and Acharya, 2003).  
However over fitting can be used as a tool to discover when the training process has to 
end. The most obvious option is to set the N number of repetitions and stop the training 
when the number N is reached. However in this case the model may not learn 
sufficiently from the data or conversely the model has already become over fitted by 
then. The other solution is to continue the training until the model reaches a threshold 
error rate. This solution also has its draw backs as the model may never reach the 
defined error rate or over fits. 
The possible solution is to somehow combine the two above approaches together.  
Marsland (2009) suggested that the error rate during the training phase along with the 
validation error rate during the validation phase may provide us with such a tool.  
If we plot the error rates during the training phase (which will be reduced over the 
training period until it reaches a local minimum) along with the validation performance 
it gives us an indication on when to stop training. Validation error decreases, until a 
point when it escalates again (Figure 3-7). This point is the over fitting point, as the 
model starts to include noise in the model.  
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Figure 3-7 Stop training time 
Marsland (2009) 
The plot of error rate during the training phase and the error rate during the validation 
phase provides us with a stopping point for training. 
 
 
 
3.5 Process definition 
A defined process definition is needed for assessing the discussed machine learning 
(section 1.3.1) and datasets (section 2.2) to discover the highest performance method for 
constructing the final model. The following diagram (Figure 3-8) explains the process 
of assessing the models which is generated during this research: 
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Figure 3-8 Process definition 
 At the start of the process the dataset is randomized. The initial training and 
evaluation of the model starts with 190 cases randomly selected from the dataset 
(a). Each time 18 new cases are added to the dataset (k) until all 352 available 
cases are added to the dataset (j). This process will also enables investigation of 
the model’s performance by increasing the number of data and will help us 
discover when to stop training the model (as discussed in section 3.4).  
 To discover the best suited machine learning method for this research, different 
methods will be assessed (b).  
 In order to predict survival models improved to categorize the survival rate for 
different categories (c). The highest survival rate in the mentioned dataset was 
116 months. At the start the system calculates the median point for the survival 
in the particular dataset and predicts the survival rate as less/more than median 
(variable C). Then each category will be divided into half and the prediction 
performance calculated and recorded (g) and the process will be continued until 
the survival rate is divided in 64 categories (f).  
 In order to find the best feature set which maximises the performance of the 
classifiers, all possible combinations and permutations of the features were 
investigated (d). The process starts by creating the datasets that only contain 
one feature (variable N) and it continues to create all permutations of the 
features (e). Each time a new feature will be added to the dataset (i), until all 6 
available features were assessed (h). It is possible to predict this feature set 
using algorithms that was discussed in chapter 1 ( section 1.3.2 ), however as 
the size of the dataset is relatively small and the computing power is available, 
this assessment may provide us with a bench mark for comparing the 
performance of feature selection techniques.  
 Each interval of the process contains a training (m) and evaluation (l) process. 
The 10-fold cross validation (as discussed in section 3.2.3) is used to estimate 
the performance prediction (n). 
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3.6 Summary of the chapter  
This chapter introduced the estimates of the prediction performance of a model. These 
estimates are an essential part of the research as each one introduces a view point for 
building a frame work for measuring the performance of the model. Based on the 
evidence discussed, it was decided to use the k-fold cross validation. 
This chapter also introduced the prediction performance measurements. These are the 
metrics that made possible a comparison of the models and selection of the best possible 
one. All the metrics that were briefly discussed in this chapter will be used to measure 
the performance of the models. Although ROC analysis is one of the most popular and 
powerful methods, all of the other metrics also provide us with essential information. 
The design and a brief description of the analysis process for this research are included 
in this chapter. 
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Chapter 4 Prognostic Data 
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4.1 Introduction 
This chapter investigates the possibility of predicting the survival rate of an ovarian 
cancer patient. The most important features in the dataset will be introduced and the 
optimum feature set size will be discovered. The survival rates will be divided into 
many categories and the prediction performance for each survival category will be 
analysed. The effects of increasing the number of data items on prediction performance 
will be discussed and analysed. Furthermore the best possible model for this research 
will be discovered. The prediction results of the best model will be compared to the 
prediction results of a conventional statistical model. Finally, previously developed 
methods will be briefly described and the prediction performance of such models will 
be compared to the best developed model in this research.   
4.2 Finding the best feature set 
The process of finding the best feature set has been discussed previously ( section 3.5). 
Briefly, this process enabled the model to investigate all the possible combinations and 
permutations of the features. This analysis highlights the most important feature and 
feature sets amongst all other feature and feature sets. As standard practice, to perform 
this analysis, feature selection techniques are used. However, the relatively small dataset 
and the available computer power for this research provided us with the possibility to 
establish a bench mark for comparison of the feature selection techniques ability. A total 
number of 7,668 analyses were performed. This investigation may answer two 
important questions. Firstly, what is the optimum size (less than six) feature set that can 
be used? Secondly, what are the most important features in the dataset?    
4.2.1 The optimum feature set size 
As discussed previously, all possible permutations of the features were analysed.  
Figure 4-1 illustrates the percentage that each feature set achieved the highest accuracy 
(based on all the perfumed analysis). The combination of two features in most cases 
(33.93% of all analyses) achieved the highest accuracy.  The combination of three 
features is in second place (29.46% of all analyses), and in third place is the one feature 
sets (20.09% of all analyses).  
Figure 4-2 illustrates the percentage of total number of analysis that each feature set 
achieved the lowest value of MAE. The combination of three features in most cases 
(31.74% of all analyses) achieved the lowest value of MAE. The combination of four 
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features in second place (25.22% of all analyses) and in third place the combination of 
two features (22.94% of all analyses) achieved the lowest value of MAE. 
Figure 4-3 illustrates the percentage of total number of analysis that each feature set 
achieved the lowest value of RMSE. The combination of three features achieved the 
lowest value of RMSE (37.94% of all analyses). The combination of two features in 
second place (36.05% of all analyses) and in third place one feature sets (18.32% of all 
analyses) achieved the lowest value of RMSE. 
 The combination of two features achieved the highest number of accuracy among all 
analyses (33.93% of cases) (Figure 4-1). However the results of MAE (22.94% of total 
analyses) and RMSE (36.05% of all analyses) put the combination of two features in 
second place (Figure 4-2 and Figure 4-3), while the combination of three features was in 
second place in terms of accuracy (29.46% of all analyses) and the best results of MAE 
(31.74% of all analyses) and RMSE (37.94% of all analyses). 
Considering the results of accuracy (Figure 4-1) and the results of MAE (Figure 4-2) 
and RMSE (Figure 4-3), it can be concluded that the optimum feature set size is the 
combination of three features, in this dataset. 
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Figure 4-1 the optimum feature set size (Accuracy) 
The percentage of total number of analysis that each feature set achieved the highest 
accuracy. 
 
Figure 4-2 the optimum feature set size (MAE) 
The percentage of total number of analysis that each feature set achieved the lowest 
value of MAE. 
 
Figure 4-3 the optimum feature set size (RMSE) 
The percentage of total number of analysis that each feature set achieved the lowest 
value of RMSE. 
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4.2.2 The most important features in the dataset 
In order to discover the most important features in the dataset, all features set sizes were 
investigated. The combination of features that in most number of analyses acheived the 
highest value of accuracy and lowest values of MAE and RMSE were recorded. In some 
analysis more than one feature set achieved the same highest performance results (or 
lower values of MAE and RMSE). Therefore, it was essential to present the values in 
terms of numbers to address this situation.  
Based on the number of times a feature set achieved the highest values of prediction 
performance and lowest values of MAE and RMSE the best feature set is selected. 
The results of these investigations are as follows: 
4.2.2.1 One feature sets  
Figure 4-4 a: In most number of cases Age and Histology achieved the highest 
performance (129 times). In third place the outcome of the surgery (123 times) and in 
fourth place FIGO (107 times).  
Figure 4-4 b: Grade achieved the lowest MAE in most cases (134 times). In second 
place outcome of the surgery (126 times) and in third place CA125 (101 times). 
Figure 4-4 c: Grade in most number of cases achieved the lowest RMSE (130 times). In 
second place outcome of the surgery (124 times) and in third place CA125, Age and 
FIGO (96 times).  
Age in most number of analyses ranked number one in terms of accuracy. However Age 
achieved the lowest number of times that MAE is the lowest and fourth place in terms 
of lowest values of RMSE. Meanwhile Outcome of the surgery was second place in 
terms of accuracy, MAE and RMSE.  
Based on the results it can be concluded that the Outcome of the surgery is the most 
important feature if a single feature dataset was selected. 
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Figure 4-4 one feature sets performance results 
a: Accuracy, b: MAE, c: RMSE 
A: Age, F: FIGO, G: Grade, H: Histology, O: Outcome of surgery and C: CA125 
Y Axes: The number of times each set achieved the highest values of accuracy or lowest 
values of MAE or RMSE. 
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4.4.2.2 Two features sets 
Figure 4-5 a: The combination of Outcome of the surgery and CA125 achieved the 
highest accuracy in most number of cases (196 times). The combination of Grade and 
Histology in second place (182 times) and in third place the combination of Histology 
and Outcome of the surgery (154 times). 
Figure 4-5 b: The combination of Grade and Outcome of the surgery in most number of 
cases (130 times) achieved the lowest values of MAE. In second place the combination 
of Outcome of the surgery and CA125 (126 times) and in third place the combination of 
Age and Grade (122 times). 
Figure 4-5 c: The combination of Grade and CA125 as well as Grade and Outcome of 
the surgery in most number of cases (131 times) achieved the lowest values of MAE. In 
second place the combination of Outcome of the surgery and CA125 (127 times) and in 
third place the combination of Age and Grade (118 times).  
The combination of Outcome of the surgery and CA125 performed the best in terms of 
accuracy. This combination was also in second place in terms of the lowest values of 
MAE and RMSE. The combination of Grade and Histology performed reasonable in 
terms of accuracy; however this combination did not achieve good scores in terms of 
MAE and RMSE. 
Based on the results it can be concluded that the combination of Outcome of the surgery 
and CA125 is the most important feature set, if a two features dataset was selected. 
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Figure 4-5 two features sets performance results 
a: Accuracy, b: MAE, c: RMSE 
A: Age, F: FIGO, G: Grade, H: Histology, O: Outcome of surgery and C: CA125 
Y Axes: The number of times each set achieved the highest values of accuracy or lowest 
values of MAE or RMSE. 
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4.4.2.3 Three features sets 
Figure 4-6 a: The combination of FIGO, Outcome of the surgery and CA125 in most 
number of cases (193 times) achieved the highest values of accuracy. In second place 
the combination of Grade, Outcome of the surgery and CA125 (176 times) as well as 
the combination of Grade, Histology and CA125 (176 times). In third place the 
combination of Histology, Outcome of the surgery and CA125 (140 times). 
Figure 4-6 b: The combination of FIGO, Outcome of the surgery and CA125 in most 
number of cases (130 times) achieved the lowest values of MAE. In second place the 
combination of Grade, Outcome of the surgery and CA125 (126 times).  
Figure 4-6 c: The combination of Grade, Outcome of the surgery and CA125 in most 
number of cases (140 times) achieved the lowest values of RMSE. In second place the 
combination of FIGO, Outcome of the surgery and CA125 (123 times) and in third 
place the combination of Age, Grade and CA125 (119 times). 
The combination of FIGO, Outcome of the surgery and CA125 achieved the best results 
in terms of the accuracy and MAE values. This combination scored second in terms of 
RMSE values. The combination of Grade, Outcome of the surgery and CA125 was 
closely behind and scored second place overlay. 
Based on the results it can be concluded that the combination of FIGO, Outcome of the 
surgery and CA125 is the most important feature set, if a three features dataset was 
selected. 
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Figure 4-6 three features sets performance results 
a: Accuracy, b: MAE, c: RMSE 
A: Age, F: FIGO, G: Grade, H: Histology, O: Outcome of surgery and C: CA125 
Y Axes: The number of times each set achieved the highest values of accuracy or lowest 
values of MAE or RMSE. 
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4.4.2.4 Four features sets 
Figure 4-7 a: The combination of Age, Grade, Histology and CA125 in most number of 
cases (336 times) achieved the highest results of accuracy. In second place the 
combination of FIGO, Grade, Histology and CA125 (240 times) and the combination of 
Age, Grade, Outcome of the surgery and CA125 (240 times). 
Figure 4-7 b: The combination of Age, Grade, Histology and Outcome of the surgery in 
most number of cases (197 times) and the combination of FIGO, Histology, Outcome of 
the surgery and CA125 achieved the lowest values of MAE. In second place the 
combination of Age, Grade, Outcome of the surgery and CA125 (190 times).  
Figure 4-7 c: The combination of FIGO, Grade, Outcome of the surgery and CA125 in 
most number of cases (306 times) achieved the lowest values of RMSE. In second place 
the combination of Age, Grade, Outcome of the surgery and CA125 (293 times). 
The combination of Age, Grade, Outcome of the surgery and CA125 is in second place 
in terms of the values of accuracy, MAE and RMSE. All the other combinations failed 
to achieve the high values of accuracy and low values of MAE and RMSE.  
Based on the results it can be concluded that the combination of Age, Grade, Outcome 
of the surgery and CA125 is the most important feature set, if a four features dataset 
was selected. 
 
 
106 
 
Figure 4-7 four features sets performance results 
a: Accuracy, b: MAE, c: RMSE 
A: Age, F: FIGO, G: Grade, H: Histology, O: Outcome of surgery and C: CA125 
Y Axes: The number of times each set achieved the highest values of accuracy or lowest 
values of MAE or RMSE. 
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4.4.2.5 Five features sets  
Figure 4-8 a: The combination of Age, FIGO, Grade, Histology and CA125 in most 
number of cases (202 times) achieved the highest accuracy. In second place the 
combination of Age, Grade, Histology, Outcome of the surgery and CA125 (187 times) 
and in third place the combination of FIGO, Grade, Histology, Outcome of the surgery 
and CA125 (101 times). 
Figure 4-8 b: The combination of Age, Grade, Histology, Outcome of the surgery and 
CA125 in most cases (118 times) achieved the lowest values of MAE. In second place 
the combination of Age, FIGO, Grade, Histology and outcome of the surgery (114 
times) and in third place the combination of Age, FIGO, Histology, Outcome of the 
surgery and CA125 (109 times). 
Figure 4-8 c: The combination of Age, FIGO, Histology, Outcome of the surgery and 
CA125 in most number of cases (123 times) achieved the lowest values of RMSE. In 
second place the combination of Age, FIGI, Grade, Outcome of the surgery and CA125 
(119 times) and the combination of Age, Grade, Histology, Outcome of the surgery and 
CA125 (119 times). 
The combination of Age, Grade, Histology, Outcome of the surgery and CA125 was in 
second place in terms of accuracy, number one in terms of MAE and number two in 
terms of RMSE. The combination of Age, FIGO, Grade, Histology and CA125 
achieved the highest score of accuracy and third place in terms of MAE and RMSE 
values.  
Based on the results it can be concluded that the combination of Age, Grade, Histology, 
Outcome of the surgery and CA125 is the most important feature set, if a five features 
dataset was selected. 
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Figure 4-8 five features sets performance results 
a: Accuracy, b: MAE, c: RMSE 
A: Age, F: FIGO, G: Grade, H: Histology, O: Outcome of surgery and C: CA125 
Y Axes: The number of times each set achieved the highest values of accuracy or lowest 
values of MAE or RMSE. 
  
0
50
100
150
200
Accuracy 202 187 101 58 58 43
A,F,G,H,C A,G,H,O,C F,G,H,O,C A,F,H,O,C A,F,G,O,C A,F,G,H,O
0
50
100
150
200
MAE 118 114 109 109 109 88
A,G,H,O,C A,F,G,H,O A,F,H,O,C A,F,G,H,C F,G,H,O,C A,F,G,O,C
0
50
100
150
200
RMSE 123 119 119 110 110 68
A,F,H,O,C A,F,G,O,C A,G,H,O,C F,G,H,O,C A,F,G,H,C A,F,G,H,O
a b
c
109 
4.4.3 Discovering best features using feature selection techniques 
The feature selection techniques were discussed previously (section 1.3.2). Briefly, the 
role of these techniques is to identify the most important features (factors) in the dataset. 
The most important factors were discovered and discussed previously. These results can 
be compared against the results of feature selection techniques. This comparison can 
identify the best feature selection technique among the discussed techniques.  
Table 4-1 summarizes the results of using feature selection techniques for identification 
of the most important features. TPP identified Age, FIGO and Outcome of the surgery 
as the most important features. IG discovered Grade, FIGO and Age as the most 
important features. Grade, Histology and CA125 selected by PCA and GA highlighted 
the importance of FIGO, Age and Outcome of the surgery.  
Earlier in this section the most important features were identified as FIGO, Outcome of 
the surgery and CA125. Based on the results of using feature selection techniques 
(Table 4-1), none of the techniques completely discovered the best possible feature set. 
However TPP and GA generated the same results.  
All of the techniques failed to discover the optimum feature set; however GA and TPP 
performed better compared to two other techniques.  
 
 
 
 
Technique Selected feature 
TPP Age, FIGO, Outcome of surgery 
IG Grade, FIGO, Age 
PCA Grade, Histology, CA125 
GA FIGO, Age, Outcome of surgery 
Table 4-1 Important features using feature selection techniques 
TPP: Targeted projection pursuit, IG: Information Gain, PCA: Principal Components 
Analysis, GA: Genetic Search 
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4.3 Prediction of survival for many categories 
Later on (section 4.4), the potential problems and benefits of categorization of 
continuous data are discussed. However in real world applications it may be beneficial 
to compromise accuracy to achieve better response. In this research, it is more 
convenient for a clinician to predict the survival of patients in categories instead of the 
actual survival value. This will enable the relevant person to predict the domain (or 
category) of the survival. 
In all analyses, the tolerable level is the accuracy level as close as possible to 100% and 
also the AUC more than 0.70. The error rate also has to be no more than 0.25. 
4.3.1 Analysis of 64 survival categories 
In order to predict survival of each case, models were generated to categorize the 
survival data in categories. The highest survival rate in months in the mentioned dataset 
was 116 months. The system at the start calculates the median point for the survival 
numbers in the particular dataset and predicts the survival rate as less/more than median. 
Then each category will be divided in half and the prediction performance calculated 
and the process will be continued until the survival rate is divided in 64 categories. 
Based on the survival categories model the prediction categories are as following: 
2 categories: 1- 58 months and 58 to 116 months. 
4 categories: 1-29 months, 29-58 months, 58-87 months and 87-116 months. 
8 categories: 1-14.5 months, 14.5-29 months … 87-101.5 months and 101.5- 116 
months. 
16 categories: 1-7 months, 7-14.5 months … 101.5-109 months and 109-116 months. 
32 categories: 1-3.5 months, 3.5-7 months … 109-112.5 months and 112.5-116 months. 
64 categories: 1-2 months, 2-4 months … 112-114 months and 114-116 months. 
Figure 4-9 demonstrates the prediction performance results for 64 survival categories. 
Figure 4-9 a, illustrates the prediction accuracy for 64 survival categories. According to 
these results the prediction accuracy for two survival categories (less or more than 
median) was around 90%. As expected, as the number of categories increased, the 
accuracy decreased. These results also demonstrated that the prediction accuracy for 64 
survival categories was around 10%. Figure 4-9 b, illustrates the MAE results. The 
MAE value for two survival categories was around 0.18 and for 64 survival categories 
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was around 0.03. The MAE value decreased as the number of categories increased in 
most cases (the only exception was for four categories). Figure 4-9 c, illustrates the 
results of RMSE. The RMSE value for two survival categories was around 0.31 and for 
64 survival categories was around 0.12. The RMSE value decreased as the number of 
categories increased in most cases (the only exception was for four categories). 
Table 4-2 summarizes the prediction performance accuracy for 64 survival categories. 
These results were collected and recorded for all the analyses that performed on the 
dataset. According to these results, model could predict the survival categories of less or 
more than median with 93.64% of accuracy. As expected the accuracy decreased as the 
number of categories increased. As a result the prediction accuracy for 64 survival 
categories recorded as 9.21%. 
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Figure 4-9 Prediction performance results for 64 categories of survival 
(a): Accuracy,(b): MAE and (c): RMSE 
X axes: number of survival categories 
 
 
Number of 
categories 
2 4 8 16 32 64 
Minimum 87.09 45.99 30.20 16.83 9.84 3.65 
Median 88.34 48.39 35.39 17.77 11.30 6.54 
Maximum 93.64 52.37 42.55 21.21 19.95 9.21 
Table 4-2 Prediction performance results for 64 survival categories (Accuracy) 
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Figure 4-10 illustrates the ROC curves for the best model when the number of 
categories was two. Figure 4-10 a, is the ROC curve for survival prediction less than the 
median value. The AUC for this curve was 0.72. Figure 4-10 b, is the ROC curve for 
survival prediction more than the median value. The AUC for this curve was 0.72. 
Figure 4-11 illustrates the ROC curves for the best model when the number of 
categories was four. Figure 4-11 a, is the ROC curve for the survival prediction when 
the survival was between 0 and 29 months. The AUC for this curve was 0.63. Figure 4-
11 b, is the ROC curve for the survival prediction when the survival was between 29 
and 58 months. The AUC for this curve was 0.60. Figure 4-11 c, is the ROC curve for 
survival prediction when the survival was between 59 and 87 months. The AUC for this 
curve was 0.60. Figure 4-11 d, is the ROC curve for survival prediction when the 
survival was between 87 and 116 months. The AUC for this curve was 0.61.  
The model could predict the survival rates for many survival categories. The accuracy 
of prediction for two survival categories (less or more than median) was around 90%. 
The final model predicted the survival categories by 93.64% accuracy where the 
prediction was based on less or more than the median value. These perditions recorded 
relatively small MAE and RMSE values. As expected the accuracy of the model 
decreased as the number of categories increased. As the result the accuracy of the 
prediction recorded as 9.21% for 64 survival categories.  
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Figure 4-10 ROC curves: 2 survival categories 
(a): survival is less than the median value. (b): survival is more than the median value 
 
Figure 4-11 ROC curves: 4 survival categories 
(a): survival between 0 and 29 months; (b): survival between 29 and 58 months; 
(c): survival between 58 and 87 months ;(d): survival between 87 and 116 months. 
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4.3.2 Analysis of Overall Survival (OS)  
Previous section (section 4.3.1) analysed and discussed the prediction of survival for 64 
categories. As mentioned the highest survival in months in dataset was 116 months. The 
first analysis divided dataset into two categories: survival less or more than 58 (median 
value).  However, as standard practice most researchers are interested about Overall 
Survival (OS) of five years (or 60 months). Therefore to perform the survival prediction 
in a standard manner and also to make comparison with other methods easier, the model 
was also adjusted to predict the five year survival.  
Table 4-3 summarizes the results of OS prediction performance for the best model. The 
accuracy of the prediction is 92.7 %. The error rate values are relatively small: MAE: 
0.16 and RMSE: 0.30. The recall values for both categories (less/more than 5 years) are 
0.25 and 0.30 respectively. The precision values for both categories are high, 0.89 for 
less than 5 years and 0.82 for more than five years. The area under the ROC curve 
(AUC) indicated that the model performed very good. The AUC values for less/more 
than 5 years were 0.74.    
Figure 4-12 illustrates the ROC curves for OS prediction. Figure 4-12 a, is the ROC 
curve for less than five years category. The AUC for this curve was 0.74. Figure 4-12 b, 
is the ROC curve for more than five years category. The AUC for this curve was 0.74. 
The produced model can predict the OS by 92.07% accuracy. The error rates of this 
model were small and the AUC results were 0.74 for both categories.  
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Measurement Result 
 
Accuracy 92.07% 
Mean absolute error 0.16 
Root mean squared error 0.30 
Outcome Recall Precision AUC 
Less than 5 years 0.25 0.89 0.74 
More than 5 years 0.30 0.82 0.74 
Table 4-3 OS prediction performance 
 
 
 
Figure 4-12 OS prediction performance: ROC curves 
a: less than five years; b: more than five years 
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4.4 Categorization of the continues data 
There are some benefits considered for the categorization of continues data (Liu et al, 
2002; Krzysztof et al., 2007). Some of the data mining methods can only handle 
categorized data. Furthermore if the number of continuous values of variables (features) 
is large, it is hard or inefficient to build a model for such data (Krzysztof et al., 2007). 
On the other hand, it has been argued that categorization leads the model to loss of 
power, precision and accuracy (Royston et al., 2006; Fedorov et al., 2009). Therefore, in 
order to assess the optimal method for analysing continuous data, the two parameters 
with continuous data were chosen: CA125 level and Age. Based on author’s supervisor 
experience and suggestions, CA125 parameter was then categorised into five categories: 
Less than 35, Between 35 and 200, Between 200 and 600, Between 600 and 1200 and 
More than 1200. Age parameter was categorized into four categories based upon its 
quartiles.  The dataset was then analysed twice, firstly using all categorised data, 
secondly using all four parameters as continuous data. Table 4-4 summarizes the 
prediction performance for categorized and continuous data for six different survival 
categories. 
The prediction performance results for both models are similar. However, accuracy of 
the model when using continuous data is higher than the model that uses categorized 
data (Table 4-4). The MAE and RMSE values for the model that uses continuous data is 
lower compared to the model that uses categorized data (table 4-4).  
The possible problems and benefits of categorizing continuous data were discussed at 
the start of this section. On the other hand, all the models that were used in this research 
can handle continuous data and the values of continuous variables (age and CA125) are 
relatively small. Furthermore, the accuracy and the power of the models are the most 
important factors for this research. The prediction performance results for the model 
that uses continuous data are better, compared to the model that uses categorized data. 
Keeping these in mind, the performance of the models were optimal with all two 
parameters analysed as continuous data.  
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 Categorized data Continuous data 
Number of survival 
categories 
Accuracy MAE RMSE Accuracy MAE RMSE 
2 91.03 0.21 0.32 93.64 0.18 0.24 
4 50.16 0.28 0.41 52.37 0.22 0.31 
8 40.15 0.18 0.33 42.55 0.13 0.27 
16 19.94 0.1 0.26 21.21 0.05 0.26 
32 14.32 0.05 0.19 19.95 0.05 0.19 
64 4.98 0.03 0.13 9.21 0.03 0.13 
Table 4-4 Prediction performance: Categorized data versus Continuous data 
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4.5 Model analysis by increasing the number of data 
The process of data analysis in this research was discussed previously (section3.5). 
Briefly at the start of the process 190 cases were randomly selected and initial analyses 
were performed. In each interval 18 new cases were added to the dataset and the 
prediction performances were recorded. These processes were continued until all cases 
were added and analyzed. According to Marzban (2009) and Lee (2010), the increase in 
number of data can improve the performance of the models. Therefore the increases in 
the performance of the models were expected.  
Figure 4-13 illustrates the effects of increasing the number of cases on the accuracy of 
the model for all survival categories. As discussed, at the start of the process 190 cases 
were randomly selected. At each interval 18 new cases were added to the dataset and the 
performance of the model was analyzed and recorded. As expected for all survival 
categories the accuracy of the model slightly improved as the number of cases 
increased. The only exception was when the number of cases reached 280. At this point 
the accuracy of the model was slightly reduced compared to the previous dataset (262 
cases). This reduction in accuracy may cause by completely new values that the latest 
number of cases were held.   
As expected the performance of the model improved as the number of cases increased. 
The performance of the model continued to increase until all available cases were added 
to the dataset. Therefore it is impossible to discover the training stop point (as discussed 
in section 3.4). As a result, adding new cases to the dataset may improve the 
performance of the models. 
 
120 
 
Figure 4-13 Effects of increasing number of cases on accuracy of the model 
190 cases randomly selected at the start of the process. At each interval 18 new cases 
were added to the dataset and the performance of the model was analysed and 
recorded. 
 
4.6 The best model 
Previously (section 1.3.1) three different methods were introduced for creating models. 
These models are Artificial Neural Network (ANN), Bayesian Network (BN) and 
Decision Tree (DT). These three models were assessed to discover the best method for 
this research.  
Figure 4-14 illustrates the comparison results of ANN, NB and DT methods. Figure 4-
14 a, demonstrates the accuracy of predictions of the above methods. ANN in 78% of 
all analyses achieved the higher accuracy compared to two other methods. DT gained 
better accuracy results of 13% compared to BN of 9%. Figure 4-14 b, demonstrates the 
MAE results for the above models. In 96% of all analyses ANN achieved the lower 
values of MAE. DT placed in second (3%) and BN in last place (1%). Figure 4-14 c, 
demonstrates the RMSE results. In 87% of all analyses, ANN achieved lower RMSE 
results. DT was in second place (8%) and BN came last (5%). These results demonstrate 
that ANN is the optimum prediction method which is well suited to the dataset available 
for this research. 
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In order to achieve better comparison, the ROC curve for all the above were produced 
(for survival less/more than median value). Figure 4-15 illustrates the ROC curves for 
ANN, DT and BN where the number of survival categories was two. Figure 4-15 a, was 
produced using the ROC analysis for survival less than the median value. This analysis 
indicated that ANN (0.72) performed better than the other two methods (DT: 0.57; BN: 
0.51).The area under ROC curve produced by ANN was more than the areas produced 
by the other two methods. Figure 4-15 b, demonstrates the results of ROC analysis 
when the survival rate was more than the median value. The area under ROC curve for 
ANN results (0.72) was more than the areas produced by the other two methods (DT: 
0.60; BN: 0.55). 
In most cases ANN achieved the highest accuracy results (78% of all analyses). ANN 
also in most number of cases (96% of all analyses) gained the lower value of MAE. In 
87% of all analyses ANN scored the lower values of RMSE. The results of ROC 
analysis (when the number of survival categories was two), indicated that the area under 
ROC curve that produced by ANN was more than the areas produced by other two 
methods. 
Based on the results of accuracy, of MAE and RMSE (Figure 4-14), it can be concluded 
that the best was ANN. 
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Figure 4-14 Prediction performance comparison (ANN, DT and BN) 
a: Accuracy, b: MAE and c: RMSE 
 
 
Figure 4-15 Model comparison using ROC curve 
(a): survival is less than median value. (b): survival is more than median value 
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4.7 Comparison with conventional statistics 
In order to have a complete comparison between models, Logistic Regression models as 
standard conventional statistical prediction models were developed. The results of 
Logistic Regression Models were then compared against the ANN results.  
Figure 4-16 compares the prediction performance results of ANN and Logistic 
Regression. Figure 4-16 a, indicate that in 75% of all analysis ANN achieved higher 
accuracy results compared to Logistic Regression (25%). Figure 4-16 b, demonstrate the 
results of MAE for ANN and Logistic Regression. In 98% of all analyses, ANN 
produced lower values of MAE compared to Logistic Regression (2%). Figure 4-16 c, 
demonstrate the results of RMSE for ANN and Logistic Regression. In 92% of all 
analyses ANN scored lower values of RMSE compared to Logistic Regression (8%). 
Figure 4-17 compares the results of ROC analysis of ANN and LR when the number of 
survival categories was two. Figure 4-17 a, represents the results of ROC analysis when 
the survival was less than the median. These results indicated that the area under the 
ROC curve for ANN (0.72) was more than the area under the ROC curve for LR (0.62). 
Figure 4-17 b, represents the results of ROC analysis when the survival was more than 
the median. These results indicated that the area under the ROC curve for ANN (0.72) 
was more than the area under the ROC curve for LR (0.62). 
Based on total of analyses performed, in 75% of the cases ANN achieved higher results 
of accuracy. Meanwhile, ANN in most number of analyses (98%) achieved the lower 
values of MAE and in 92% of all analyses scored lower values of RMSE. Also the area 
under the ROC curve when the number of survival categories was two, for ANN was 
0.72 and for LR was 0.62.  
Based on the results of Accuracy, MAE and RMSE, it can be concluded that ANN 
outperforms Logistic Regression.  
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Figure 4-16 ANN vs. Logistic Regression 
a: Accuracy, b: MAE and c: RMSE 
 
 
 
Figure 4-17 ANN vs. Logistic Regression (ROC curves) 
(a): survival is less than the median value. (b): survival is more than the median value 
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4.8 Comparison with pervious work 
Recently there were some attempts to predict the overall survival of an ovarian cancer 
patient (Teramukai et al., 2007; Chi et al., 2008; Gerestein et al., 2009). Gerestein et al. 
(2009) developed a ‘Nomogram’ which predicts five year survival rates of patient based 
on five parameters. This Nomogram calculates the five year survival rate to a 
percentage probability. This research had c statistic of 0.67. 
As discussed previously (Section 3.3.2) using ANN, a model was developed to predict 
the five year survival of an ovarian cancer patient. ANN produced a good prediction 
model with an accuracy of 92.7%. The MAE of this model was 0.16 and RMSE was 
0.30. The AUC for this model was 0.74. Based on the AUC (which is same as c 
statistic), it can be concluded that the model that developed using ANN, outperformed 
the previously developed model. The prediction range of the present model (2, 4, 8, 16, 
32 and 64 categories) is much wider than the previously developed model (2 
categories). 
The other possible advantage of the current model is that as discussed previously 
(Section 4.5), the prediction results can be improved by increasing the number of 
available data.  
It also can be argued the present model is more user friendly. The user only needs to 
enter available variables and the system would show the prediction results.  
4.9 Summary of the chapter 
The analyses were performed to discover the optimum size of the feature set that 
maximizes the prediction accuracy. Based on the results of accuracy, of MAE and 
RMSE, it can be concluded that the combination of three features was the optimum 
feature set. Later on, all possible permutations and combinations of the features were 
discussed and for all possible feature set sizes the best possible combination(s) was 
analyzed. Briefly, Outcome of the surgery is the most important feature if a single 
feature dataset was selected. The combination of Outcome of the surgery and CA125 is 
the most important feature set, if a two features dataset was selected. The combination 
of FIGO, Outcome of the surgery and CA125 is the most important feature set, if a three 
features dataset was selected. The combination of Age, Grade, Outcome of the surgery 
and CA125 is the most important feature set, if a four features dataset was selected. The 
combination of Age, Grade, Histology, Outcome of the surgery and CA125 is the most 
important feature set, if a five features dataset was selected. The above results were also 
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compared against the results of the most important features that were identified using 
feature selection techniques. All of the techniques failed to discover the optimum 
feature set; however GA and TPP performed better compared to two other techniques. 
The survival was divided into 64 categories based on the median value available in the 
dataset. The prediction performance for all categories were recorded and analyzed. In 
summary the prediction performance of the model decreased as the number of 
categories increased. The prediction accuracy when the number of categories was two 
(less or more than median) was around 90%. The best model for this number of 
categories produced 93.64% of prediction accuracy. The prediction recorded as 9.21% 
for 64 survival categories. The AUC for the prediction of two survival categories was 
0.72. The AUC for prediction of four survival categories was around 0.61. 
The potential advantages and disadvantages of categorization of continuous data were 
discussed. The Age and CA125 as two continuous features were categorized and the 
prediction performance results were compared to the prediction performance results of 
uncategorized features. Based on the results of accuracy, of MAE, RMSE and ROC 
values, this research concluded that analysis using continuous data was superior to 
categorical data. The five year survival rate (OS) of the patients was also analysed in 
this chapter. In summary ANN produced a good prediction model by accuracy of 
92.7%. The MAE of this model was 0.16 and RMSE was 0.30. The AUC for this model 
was 0.74.  
The effects of increasing number of cases were also analysed and discussed. In 
summary, by increasing the number of cases the prediction performance of the models 
were improved.  
Considering all the performed analyses, this research concluded that ANN was the best 
analysed model. In summary, these results were based on number of times ANN 
achieved the higher values of Accuracy and lower values of MAE and RMSE. ANN in 
78% of all analyses achieved the higher values of accuracy. ANN also in 96% of all 
analyses achieved the lower values of MAE. ANN in 87% of all analyses produced the 
lower values of RMSE. The AUC produced by ANN for two survival categories was 
0.72 compared to DT of 0.60 and BN of 0.55.  
The prediction performance results of ANN as the best analysed model was compared 
to the prediction performance results of Linear Regression. This research concluded that 
ANN outperformed Linear Regression. In summary in 75% of all analyses ANN 
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achieved higher accuracy results. ANN also in 98% of all analyses scored lower values 
of MAE. Furthermore, ANN in 92% of all analyses scored lower values of RMSE. The 
AUC produced by ANN for two survival categories was 0.72 compared to LR of 0.62.  
The previous survival prediction models that had been produced by other researchers 
were briefly discussed. The results of other methods were discussed and compared to 
the present model. In summary, the present model performed better in comparison to the 
previously developed models, it may be easier to use and the prediction results can be 
improved as the number of cases increases.  
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Chapter 5 Surgical Prediction 
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5.1 Introduction 
This chapter investigates the potential benefits of predicting the outcome of surgery. 
The possibility of developing models for such a prediction was investigated and 
analysed. Artificial intelligence and statistical models were developed for this 
investigation. The complete comparison of these two techniques is made available in 
this chapter. This chapter also investigates and introduces the most important variables 
(factors) in the dataset for predicting the outcome of the surgery.  
5.2 Statement of the problem 
The benefits of primary surgery for ovarian cancer patients were discussed previously 
(section 1.2.1.8). Despite aggressive attempts at optimal cytoreduction, many patients 
are left with sub-optimal disease after surgery. As discussed previously (section 
1.2.1.10), the current treatment of ovarian cancer is chemotherapy after surgery, 
however research (Vergote et al., 2005) indicates that the outcome for patients left with 
sub-optimal disease after surgery is worse than that of optimally debulked patients. In 
fact a consistent finding is that residual bulk of disease following surgery is the greatest 
prognostic factor in ovarian cancer (Edmondson et al., 2008). Indeed it has now been 
suggested (Stack and Fishman, 2009) that the aim of surgery should be to remove the 
entire cancer from the patient. A pre-operative assessment tool, capable of predicting 
surgical outcome is therefore needed to identify cases where complete cytoreduction is 
achievable or cases with early stages of cancer.  
In recent years a new possible treatment is recommended for cases where complete or 
optimal cytoreduction appears unlikely. The recommended treatment is chemotherapy 
prior to surgery (Neoadjuvant chemotherapy).  Neoadjuvant chemotherapy seems to be 
the best solution for some patients as it may reduce the size of the tumour and boost the 
possibility of the complete/optimal cytoreduction during surgery (Stack and Fishman, 
2009). Neoadjuvant chemotherapy appears to be beneficial in the following situations 
(Stack and Fishman, 2009):  
 Where complete or optimal cytoreduction appears unlikely due to the position of 
the tumour.  
 Where the patient is too weak for surgery. These types of patients may benefit 
from chemotherapy as the size of the tumour will reduce with relief of 
symptoms after few cycles of chemotherapy.  
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 Where the patient suffers from poor nutritional status. Neoadjuvant 
chemotherapy may reduce the symptoms of cancer and allow the patient to 
improve their nutritional status. Poor nutritional intake is related to poor 
outcome after surgery including delayed wound healing (Windsor et al., 1998),  
 Where the patient suffers from depression. A study on cervical cancer patients 
(Plante et al., 2006), considered depression as one of the factors causing more 
difficulty for patients to be mobile and more active. Neoadjuvant chemotherapy 
may reduce the effects of the disease on patients, improve their mood and help 
them to recover faster.  
 Where the patient lives in a country where the surgery admission process takes a 
long time. The long waiting lists for surgery may decrease the chances of 
survival for patients, as most cases of ovarian cancer present in the late stages of 
the cancer (section 1.2.1.1).  
The other possible benefit of neoadjuvant chemotherapy is that it gives an early 
indication of tumour response to chemotherapy (Stack and Fishman, 2009). If the 
tumour did not respond to neoadjuvant chemotherapy, the chemotherapy can be 
changed for further treatment.   
At present, there is no strong evidence to support the role of neoadjuvant chemotherapy 
(Stack and Fishman, 2009). However, research (Vergote et al., 2005) suggests higher 
rates of optimal cytoreduction after neoadjuvant chemotherapy. On the other hand, the 
same study concluded similar outcomes for patients with primary surgery and 
neoadjuvant chemotherapy. Other research (Bristow and Chi, 2006) suggested that the 
overall survival rates of patients did not improve using the neoadjuvant approach; on the 
other hand this method was recommended for patients with difficulties as discussed 
previously. More recently, research (Vergote et al., 2010) did not conclude the 
replacement of Neoadjuvant treatment by primary surgery. The complete results of two 
large randomised studies, the Chemotherapy or Upfront Surgery (CHORUS) and 
European Organization for Research and Treatment of Cancer (EORTC) 55971, are not 
published yet. These two large studies may resolve the issues surrounding the 
neoadjuvant treatment.  
As discussed, the prediction of the outcome of the surgery may be very beneficial to the 
patients. This prediction may help clinicians to suggest Neoadjuvant treatment for 
patients with possible outcome of sub-optimal cytoreduction after surgery. Allen (2010) 
argues that a clinical model that can predict which patients will undergo optimal 
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cytoreduction would be very useful and he emphasizes that “at present, no such model 
exists”. In the past, Bristow et al. (2000) and Funt et al. (2004) developed the models 
for predicting outcome of the surgery using the findings on CT scans. These models 
were either very complex to assess or they did not conclude any significant results.  
5.3 Residual prediction 
As there is no model available to assist clinicians with such predictions we considered 
the potential of Machine learning and artificial intelligence models (section 1.3.1). This 
section investigates the opportunities of employing such models for predicting the 
outcome of surgery. The factors in the datasets available for this investigation (section 
2.2), can all be collected prior to surgery. Therefore using the available datasets (section 
2.2), and employing machine learning and artificial intelligence model, this section 
investigates the performance of prediction of such models. 
Prior to this investigation it is essential to make some adjustments in the dataset as 
stated below: 
 The prediction goal (class) has to be changed from the survival rates to outcome 
of the surgery. In the main datasets, the survival rates of the patients are set as 
the prediction goal of the models, as we are going to predict the outcome of the 
surgery the prediction goal has to be changed to outcome of the surgery.  
 The survival rate has to be omitted from the dataset. Prior to the surgery the 
survival rates of the patients are not known, therefore it cannot be used as a 
prediction factor.  
 The CA125 is a continuous data (section 2.2), categorization of these values will 
be performed to investigate the categorization of the performance of the models. 
Then the results will be compared with the performance of the models using 
actual values of CA125. The categorization criteria are as stated below: 
1. CA125 greater than 0 and less than 35. 
2. CA125 greater than 35 and less than 200. 
3. CA125 greater than 200 and less than 600. 
4. CA125 greater than 600 and less than 1200. 
5. CA125 greater than 1200. 
 The possible outcomes of the prediction are: complete, optimal and sub-optimal 
cytoreduction (section 1.2.1.8). However as discussed previously (section 5.2) it 
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would be beneficial to distinguish between the following categories in 
cytoreduction outcome:  
1. The possibility of complete cytoreduction versus optimal and sub-optimal 
cytoreduction. 
2. The possibility of complete and optimal cytoreduction versus sub-optimal 
cytoreduction. 
3. The possibility of complete cytoreduction versus optimal cytoreduction 
versus sub-optimal cytoreduction. 
 
In order to make a comparison with conventional statistical methods, regression models 
were built using SPSS and the prediction performances of these models are made 
available.  
5.3.1 Residual prediction: Complete/Optimal/Sub-optimal cytoreduction  
Using ANN (section 1.3.1.2) the possibility of predicting the outcome of surgery for all 
possible outputs will be investigated. First the model was trained and evaluated using 
the actual values of CA125, then CA125 is categorized to the mentioned categories and 
the model was trained and evaluated. The evaluation process is similar to the process 
that defined previously (section 3.5) and 10 fold cross validation (section 3.2.3) is 
employed. 
Table 5-1 summarizes the results of the prediction performance for actual values (no 
categorization) of CA125 for the best model produced using ANN. The accuracy of the 
model was 59.75% and the MAE value was 0.34 and RMSE value was 0.42. The AUC 
for complete cytoreduction curve was 0.75. The AUC for optimal cytoreduction was 
0.66 and the AUC for suboptimal cytoreduction was 0.71. 
Table 5-2 summarizes the results of the prediction performance for actual values (no 
categorization) of CA125 for the best model produced using Logistic Regression. The 
MAE value for this model was 0.61 and RMSE value was 0.75. The AUC for complete 
cytoreduction was 0.24. The AUC for optimal cytoreduction was 0.70 and for sub-
optimal was 0.60.  
Figure 5-1 illustrates the ROC curves for actual values (no categorization) of CA125 
for the best model produced using ANN (complete cytoreduction: 0.75. optimal 
cytoreduction: 0.66 and suboptimal cytoreduction: 0.71). 
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Figure 5-2 illustrates the ROC curves for actual values (no categorization) of CA125 
for the best model produced using Logistic Regression (complete cytoreduction: 0.24. 
optimal cytoreduction: 0.70 and sub-optimal: 0.60). 
ANN produced two good models based on the curve analysis (Figure 5-1) for complete 
cytoreduction (0.7587) and suboptimal cytoreduction (0.7123), however the results for 
optimal cytoreduction (0.6609) prediction is fair. These results are much higher than the 
prediction performance produced by logistic regression (Figure 5-2). The error rates of 
prediction using ANN (Table 5-1) are much lower than logistic regression (Table 5-2).  
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Measurement Result 
 
Accuracy 59.75% 
Mean absolute error 0.34 
Root mean squared error 0.42 
Outcome Recall Precision AUC 
Complete 0.636 0.8 0.7587 
Optimal 0.691 0.428 0.6609 
Sub-optimal 0.28 0.477 0.7123 
Table 5-1 Prediction performance of results for complete/optimal/sub-optimal cytoreduction when 
CA125 is not categorized using ANN 
 
 
 
Measurement Result 
Mean absolute error 0.61 
Root mean squared error 0.75 
Outcome AUC 
Complete 0.2440 
Optimal 0.7060 
Suboptimal 0.6000 
Table 5-2 Prediction performance results for complete/optimal/suboptimal cytoreduction when 
CA125 is not categorized using Logistic Regression 
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Figure 5-1 ROC curve (ANN): Complete / Optimal /Sub-optimal cytoreduction (CA125 not 
categorized) 
(a) complete cytoreduction(0.75);(b) optimal cytoreduction(0.66); (c) sub-optimal 
cytoreduction(0.71) 
 
 
 
 
Figure 5-2 ROC Curve (Logistic Regression): Complete / Optimal /Suboptimal cytoreduction 
(CA125 not categorized) 
(a) complete cytoreduction(0.24);(b) optimal cytoreduction(0.70); (c) suboptimal 
cytoreduction(0.60) 
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Table 5-3 summarizes the results of the prediction performance for categorized values 
of CA125 for the best model produced using ANN. The accuracy of this model was 
53.15%. The MAE value was 0.35 and the RMSE value was 0.43. The AUC for 
complete cytoreduction was 0.7253. The AUC for optimal cytoreduction was 0.6416 
and AUC for sub-optimal cytoreduction was 0.7174.  
Table 5-4 summarizes the results of the prediction performance for categorized values 
of CA125 for the best model produced using Logistic Regression. The MAE value for 
this model was 0.61 and RMSE value was 0.75. The AUC for complete cytoreduction 
was 0.23. The AUC for optimal cytoreduction was 0.72 and AUC for sub-optimal 
cytoreduction was 0.59. 
Figure 5-3 illustrates the ROC curves for categorized values of CA125 for the best 
model produced using ANN (complete cytoreduction: 0.7253. optimal cytoreduction: 
0.6416 sub-optimal cytoreduction: 0.7174). 
Figure 5-4 illustrates the ROC curves for categorized values of CA125 for the best 
model produced using Logistic Regression (complete cytoreduction: 0.23. optimal 
cytoreduction: 0.72 sub-optimal cytoreduction: 0.59). 
ANN produced two good models based on the curve analysis (Figure 5-3) for complete 
cytoreduction (0.7253) and suboptimal cytoreduction (0.7174), however the results for 
optimal cytoreduction (0.6416) prediction is fair. These results are much higher than the 
prediction performance produced by logistic regression (Figure 5-4). The error rates of 
prediction using ANN (Table 5-3) are much lower than logistic regression (Table 5-4).   
Discussion: ANN produced the same accuracy and error rates for actual values of 
CA125 compared to categorized values of CA125.  Also there are no noticeable 
differences in recall, precision and AUC values. Logistic regression also produced the 
same results when using actual values of CA125 compared to categorized values of 
CA125.  
 Conclusion: Considering the prediction performance results produced by ANN (Table 
5-1 and Table 5-3) and the prediction performance results of Logistic Regression (Table 
5-2 and Table 5-4), it can be concluded that ANN outperforms Logistic Regression.  
Also it can be concluded that the categorization of CA125 did not improve the 
prediction performance results.   
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Measurement Result 
 
Accuracy 53.15% 
Mean absolute error 0.35 
Root mean squared error 0.43 
Outcome Recall Precision AUC 
Complete 0.659 0.784 0.7253 
Optimal 0.681 0.438 0.6416 
Sub-optimal 0.253 0.432 0.7174 
Table 5-3 Prediction performance results for complete/optimal/sub-optimal cytoreduction when 
CA125 is categorized using ANN 
 
 
Measurement Result 
Mean absolute error 0.61 
Root mean squared error 0.75 
Outcome AUC 
Complete 0.2320 
Optimal 0.7220 
Sub-optimal 0.5980 
Table 5-4 Prediction performance results for complete/optimal/sub-optimal cytoreduction when 
CA125 is categorized using Logistic Regression 
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Figure 5-3 ROC curve (ANN): Complete / Optimal /Suboptimal cytoreduction (CA125 categorized) 
(a) complete cytoreduction(0.72);(b) optimal cytoreduction(0.64); (c) suboptimal 
cytoreduction(0.71) 
 
 
 
 
Figure 5-4 ROC Curve (Logistic Regression): Complete / Optimal /Suboptimal cytoreduction 
(CA125 categorized) 
 
(a) complete cytoreduction(0.23);(b) optimal cytoreduction(0.72); (c) suboptimal 
cytoreduction(0.59) 
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5.3.2 Residual prediction: Complete and Optimal versus Suboptimal cytoreduction 
At the start of this process, the dataset was redefined, so the outcome of the surgery is 
changed to either ‘complete or optimal’ or ‘suboptimal’. Similar to previous analysis 
(Section 5.3.1), first the model is trained and evaluated using categorized values of 
CA125, then the investigation is repeated using the actual values of CA125. Similar to 
the process of previous section, the 10 fold cross validation is used for the evaluation 
process.   
Table 5-5 summarizes the results of the prediction performance for actual values (no 
categorization) of CA125 for the best model produced using ANN. The accuracy of this 
model was 77.75%. The MAE value was 0.29 and the RMSE value was 0.38. The AUC 
for complete or optimal cytoreduction was 0.7310 and the AUC for sub-optimal 
cytoreduction was 0.7310. 
Table 5.6 summarizes the results of the prediction performance for actual values (no 
categorization) of CA125 for the best model produced using Logistic Regression. The 
MAE for this model was 0.37 and the RMSE was 0.43. The AUC for the complete or 
optimal cytoreduction was 0.3970 and AUC for sub-optimal cytoreduction was 0.6330. 
Figure 5-5 illustrates the ROC curves for actual values (no categorization) of CA125 
for the best model produced using ANN (complete or optimal cytoreduction: 0.73, sub-
optimal cytoreduction: 0.73) 
Figure 5-6 illustrates the ROC curves for actual values (no categorization) of CA125 
for the best model produced using Logistic Regression (complete or optimal 
cytoreduction: 0.39, sub-optimal cytoreduction: 0.63) 
ANN produced two good models based on the AUC values (Table 5-5). The AUC 
results for complete or optimal cytoreduction (0.7310) and for suboptimal cytoreduction 
(0.7310) indicate a very good prediction performance. The error rates are relatively 
small and the accuracy (77.40 %) is good. On the other hand the AUC results of 
Logistic Regression model are 0.3970 for complete or optimal cytoreduction and 0.6330 
for suboptimal cytoreduction (Table 5-6).  The error rates produced by Logistic 
Regression are higher compared to ANN.  
 
 
140 
 
 
Measurement Result 
 
Accuracy 77.75 % 
Mean absolute error 0.29 
Root mean squared error 0.38 
Outcome Recall Precision AUC 
Complete or 
Optimal 
0.359 0.775 0.7310 
Sub-optimal 0.147 0.647 0.7310 
Table 5-5 Prediction performance results for (complete or optimal) cytoreduction versus sub-
optimal cytoreduction when CA125 is not categorized using ANN 
 
 
 
 
 
Measurement Result 
Mean absolute error 0.37 
Root mean squared error 0.43 
Outcome AUC 
Complete or Optimal 0.3970 
Sub-optimal 0.6030 
Table 5-6 Prediction performance results for (complete or optimal) cytoreduction versus sub-
optimal cytoreduction when CA125 is not categorized using Logistic Regression 
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Figure 5-5 ROC curve (ANN): (Complete or Optimal) cytoreduction versus Sub-optimal 
cytoreduction (CA125 not categorized) 
(a) complete or optimal cytoreduction(0.73);(b) sub-optimal cytoreduction(0.73); 
 
 
 
 
 
 
Figure 5-6 ROC curve (Logistic Regression): (Complete or Optimal) cytoreduction versus Sub-
optimal cytoreduction (CA125 not categorized) 
 
(a) complete or optimal cytoreduction(0.39);(b) sub-optimal cytoreduction(0.60); 
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Table 5-7 summarizes the results of the prediction performance for categorized values 
of CA125 for the best model produced using ANN. The accuracy of this model was 
75.75%. The MAE value was 0.34 and the RMSE value was 0.31. The AUC for 
complete or optimal cytoreduction was 0.6290 and the AUC for sub-optimal 
cytoreduction was 0.6290. 
Table 5-8 summarizes the results of the prediction performance for categorized values 
of CA125 for the best model produced using Logistic Regression. The MAE value for 
this model was 0.37 and RMSE value was 0.43. The AUC for complete or optimal 
cytoreduction was 0.39. The AUC for sub-optimal cytoreduction was 0.60. 
Figure 5-7 illustrates the ROC curves for categorized values of CA125 for the best 
model produced using ANN (complete or optimal cytoreduction: 0.62, optimal 
cytoreduction: 0.62). 
Figure 5-8 illustrates the ROC curves for categorized values of CA125 for the best 
model produced using Logistic Regression (complete or optimal cytoreduction: 0.39, 
sub-optimal cytoreduction: 0.60). 
Based on the prediction performance results of ANN (Table 5-7) two good prediction 
models were developed. The error rates are small and the accuracy is high (75.75 %). 
On the other hand the prediction performance results of Logistic Regression are very 
poor (Table 5-8) and the error rates are higher than ANN. 
 
Discussion: The prediction performance results that were produced using ANN (Table 
5-7and Figure 5-7) and Logistic Regression (Table 5-8 and Figure 5-8) for actual values 
of CA125 are similar to the results that were produced using categorized values of 
CA125. 
 Conclusion: ANN managed to create two good prediction models for the prediction of 
complete or optimal cytoreduction versus suboptimal cytoreduction. ANN by far 
outperforms Logistic Regression in this analysis. Also there are no noticeable 
differences of the results when CA125 is categorized.  
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Measurement Result 
 
Accuracy 75.75 % 
Mean absolute error 0.34 
Root mean squared error 0.31 
Outcome Recall Precision AUC 
Complete or 
Optimal 
0.773 0.751 0.6290 
Sub-optimal 0.027 0.250 0.6290 
Table 5-7 Prediction performance results for (complete or optimal) cytoreduction versus sub-
optimal cytoreduction when CA125 is categorized using ANN 
 
 
 
 
Measurement Result 
Mean absolute error 0.37 
Root mean squared error 0.43 
Outcome AUC 
Complete or Optimal 0.3970 
Sub-optimal 0.6020 
Table 5-8 Prediction performance results for (complete or optimal) cytoreduction versus 
suboptimal cytoreduction when CA125 is categorized using Logistic Regression 
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Figure 5-7 ROC curve (ANN): (Complete or Optimal) cytoreduction versus Sub-optimal 
cytoreduction (CA125 categorized) 
 
(a) complete or optimal cytoreduction(0.62);(b) suboptimal cytoreduction(0.62); 
 
 
 
 
 
Figure 5-8 ROC curve (Logistic Regression): (Complete or Optimal) cytoreduction versus Sub-
optimal cytoreduction (CA125 not categorized) 
(a) complete or optimal cytoreduction(0.39);(b) sub-optimal cytoreduction(0.60); 
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5.3.3 Residual prediction: Complete versus Optimal or Sub-optimal cytoreduction 
For this analysis the dataset was redefined in such a way that the outcome of the surgery 
is either ‘complete cytoreduction’ or ‘optimal or sub-optimal cytoreduction’. The 
analysis is similar to the previous sections (Section 5.3.1 and Section 5.3.2). 
Table 5-9 summarizes the results of the prediction performance for actual values (no 
categorization) of CA125 for the best model produced using ANN. The accuracy of this 
model was 77.74%. The MAE value was 0.32 and the RMSE value was 0.42. The AUC 
for complete cytoreduction was 0.79 and the AUC for optimal or sub-optimal 
cytoreduction was 0.80. 
Table 5-10 summarizes the results of the prediction performance for categorized values 
of CA125 for the best model produced using Logistic Regression. The MAE value for 
this model was 0.39 and RMSE value was 0.44. The AUC for complete cytoreduction 
was 0.24 and the AUC for optimal or sub-optimal cytoreduction was 0.69. 
Figure 5-9 illustrates the ROC curves for actual values (no categorization) of CA125 
for the best model produced using ANN (complete cytoreduction: 0.79, optimal or sub-
optimal cytoreduction: 0.80). 
Figure 5-10 illustrates the ROC curves for actual values of CA125 for the best model 
produced using Logistic Regression (complete cytoreduction: 0.24, optimal or sub-
optimal cytoreduction: 0.69). 
ANN managed to produce a very good (AUC: 0.80) and a good (AUC: 0.79) prediction 
models based on the AUC results (Table 5-9). The Logistic Regression did not manage 
to produce any worthy models (Table 5-10).  Based on the results ANN outperformed 
Logistic Regression.  
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Measurement Result 
 
Accuracy 77.74 % 
Mean absolute error 0.32 
Root mean squared error 0.42 
Outcome Recall Precision AUC 
Complete 0.621 0.75 0.79 
Optimal or Sub-
optimal 
0.213 0.76 0.80 
Table 5-9 Prediction performance results for complete cytoreduction versus (optimal or sub-
optimal) cytoreduction when CA125 is not categorized using ANN 
 
 
 
 
 
 
Measurement Result 
Mean absolute error 0.39 
Root mean squared error 0.44 
 
Outcome AUC 
Complete  0.2490 
Optimal or Sub-optimal 0.6910 
Table 5-10 Prediction performance results for complete cytoreduction versus (optimal or sub-
optimal) cytoreduction when CA125 is not categorized using Logistic Regression 
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Figure 5-9 ROC curve (ANN): Complete cytoreduction versus (Optimal or Sub-optimal) 
cytoreduction (CA125 not categorized) 
(a) complete cytoreduction(0.79);(b) optimal or sub-optimal cytoreduction(0.80); 
 
 
 
 
 
Figure 5-10 ROC curve (Logistic Regression): Complete cytoreduction versus (Optimal or Sub-
optimal) cytoreduction (CA125 not categorized) 
(a) complete cytoreduction(0.24);(b) optimal or suboptimal cytoreduction(0.69); 
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Table 5-11 summarizes the results of the prediction performance for categorized values 
of CA125 for the best model produced using ANN. The accuracy of this model was 
73.75%. The MAE value was 0.34 and the RMSE value was 0.42. The AUC for 
complete cytoreduction was 0.7710 and the AUC for sub-optimal cytoreduction was 
0.7710. 
Table 5-12 summarizes the results of the prediction performance for categorized values 
of CA125 for the best model produced using Logistic Regression. The MAE value for 
this model was 0.39 and RMSE value was 0.44. The AUC for complete cytoreduction 
was 0.24. The AUC for optimal or sub-optimal cytoreduction was 0.76. 
Figure 5-11 illustrates the ROC curves for categorized values of CA125 for the best 
model produced using ANN (complete cytoreduction: 0.77, optimal or sub-optimal 
cytoreduction: 0.77). 
Figure 5-12 illustrates the ROC curves for categorized values of CA125 for the best 
model produced using Logistic Regression (complete cytoreduction: 0.24, optimal or 
sub-optimal cytoreduction: 0.75). 
The prediction performance results of ANN (Table 5-11) indicate two average 
predictors. However ANN did not manage to produce a worthy model. Similarly 
Logistic regression only managed to produce one worthy predictor (Table 5-12). The 
error rates are similar, however on average ANN outperforms Logistic Regression 
(based on AUC values). 
 
Discussion: Based on the performance prediction results produced by ANN (Table 5-11 
and Figure 5-11) and the performance prediction results by Logistic Regression (Table 
5-12 and Figure 5-12), categorization of CA125 did not improve the prediction results.  
Conclusion: ANN performed better than Logistic Regression. On average, ANN 
performed better than Logistic Regression. It also can be concluded that categorization 
of CA125 did not improve the prediction results.  
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 Measurement Result  
Accuracy 73.75 % 
Mean absolute error 0.34 
Root mean squared error 0.42 
Outcome Recall Precision ROC 
Complete  0.644 0.794 0.7710 
Optimal or Sub-
optimal 
0.57 0.758 0.7710 
Table 5-11 Prediction performance results for complete cytoreduction versus (optimal or sub-
optimal) cytoreduction when CA125 is categorized using ANN 
 
 
 
Measurement Result 
Mean absolute error 0.39 
Root mean squared error 0.44 
Outcome AUC 
Complete 0.2420 
Optimal or Sub-optimal 0.7580 
Table 5-12 Prediction performance results for complete cytoreduction versus (optimal or sub-
optimal) cytoreduction when CA125 is categorized using Logistic Regression 
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Figure 5-11 ROC curve (ANN): Complete cytoreduction versus (Optimal or Sub-optimal) 
cytoreduction (CA125 categorized) 
(a) complete cytoreduction(0.77);(b) optimal or suboptimal cytoreduction(0.77); 
 
 
 
 
 
 
Figure 5-12  ROC curve (Logistic Regression): Complete cytoreduction versus (Optimal or Sub-
optimal) cytoreduction (CA125 categorized) 
(a) complete cytoreduction(0.24);(b) optimal or sub-optimal cytoreduction(0.75); 
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5.4 Discovering important factors 
The available dataset was discussed previously. The dataset includes five variables: 
CA125, Age, Histology type, Grade and FIGO stage and the target variable is the 
outcome of the surgery. In order to identify the most important factors (variables) the 
methods of feature selection (section 1.3.2) are deployed. The following table (Table 5-
13) summarizes the results of this investigation. 
 
All three 
outcomes 
Complete vs. Optimal 
or suboptimal 
Complete or Optimal vs. 
Suboptimal 
TPP G, H, F F, G F, H, G 
IG F, G F, G, H F, G 
GA F F, G F 
PCA F, H, G F, G F, G 
Table 5-13 The most important variable identified using feature selection methods 
(G): Grade, (H): Histology type, (F): FIGO stage 
Discussion: The results of using feature selection techniques indicated that the most 
important factor in the dataset for predicting the outcome of surgery is FIGO stage. 
Grade of the tumour and Histology are other important factors.  
 
5.5 Summary of the chapter  
The benefits of predicting the outcome of the surgery were investigated in this chapter. 
As discussed, currently there is no such system for predicting the outcome of the 
surgery. Prediction of the outcome of the surgery has many potential benefits for the 
patients. Clinicians may offer new treatment pathways (e.g. neoadjuvant chemotherapy) 
for a patient with high chance of suboptimal cytoreduction. The potential benefits of 
neoadjuvant chemotherapy were also investigated in this chapter. ANN and Logistic 
Regression predicting models were developed to predict the outcome of the surgery. 
Three major investigations were deployed: the prediction of all outcomes (complete or 
optimal or suboptimal), the prediction of complete or optimal cytoreduction versus 
suboptimal cytoreduction and finally the prediction of complete cytoreduction versus 
optimal or suboptimal cytoreduction. CA125 as the only continuous variable in the 
dataset was categorized. The models that can distinguish between complete or optimal 
cytoreduction versus suboptimal cytoreduction had the best performance compared to 
the other two categories. The most important variables (factors) for predicting the 
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outcome of the surgery were identified. These important variables are: FIGO stage, 
Grade and Histology. 
Based on the results, it can be concluded that ANN outperforms Logistic Regression. 
Furthermore, categorization of CA125 did not improve the prediction results. 
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Chapter 6 Gene analysis for classification of 
Homologous recombination  
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6.1 Introduction  
An increasing understanding of the biology of cancer coupled with the availability of 
high throughput techniques provides new challenges in cancer research. These 
techniques allow the generation of large datasets. These datasets may comprise data 
describing DNA (mutations or epigenetic information), RNA or protein. The 
interrogation of these datasets is challenging, in part because of the size of the datasets 
but also because of the signal to noise problems. This chapter introduces the concept of 
a new treatment for ovarian cancer, the PARP inhibitors, and a DNA repair pathway, 
homologous recombination (HR) which may be used to stratify therapy. Following this 
is a description of a dataset generated to investigate this area followed by experiments 
using the model to investigate the role of artificial intelligence in developing predictive 
biomarkers. This analysis combined with the models that developed in previous 
chapters, may introduce the suitable treatment pathway for the management of the 
patients.  
6.2 statement of the problem  
DNA is damaged many times during each cell cycle, and this damaged DNA has to be 
repaired (Karp, 2009). This damage is repaired by DNA repair pathways. One of the 
DNA repair pathways is homologous recombination (HR) and two of the important 
proteins in this pathway are BRCA1 and BRCA2 (Yap et al., 2010).There is strong 
evidence that patients with germline mutations in BRCA1 and BRCA2 have a high risk 
of ovarian cancer (Woosetr and Weber, 2003). Poly (ADP-ribose) polymerase (PARP) 
is an important protein in another DNA repair pathway, called base excision repair. 
Inhibiting PARP results in deficient base excision repair and if this occurs in a cell 
which already has defective HR, as a result of a BRCA mutation, then the combination 
of the two effects is lethal to the cell (Yap et al., 2010). PARPi are thus effective in 
cancers with mutated BRCA1 and BRCA2 genes (Audeh et al., 2010; Ledermann et al., 
2011). This is a process known as synthetic lethality: the drugs block one DNA repair 
pathway whilst the BRCA mutation has already silenced another pathway (Dedes et al., 
2011). A cell can survive with one pathway blocked but when both are affected the cell 
dies as there are many genes involved in this process. 
Drugs may also be useful in other ovarian cancer patients, essentially those with 
tumours which are HR defective by other mechanisms. Recent work by our group 
(Mukhopadhyay et al., 2010) has suggested that up to 50% of ovarian cancers could be 
deficient in HR. 
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A simple test that would identify tumours with defective HR would therefore identify a 
group of patients who would likely respond to a PARP inhibitor. 
 
Figure 6-1 Selective cytotoxity of PARP inhibitors 
One pathway is silenced by using PARPi drug (top pathway). If a BRCA mutation or 
other genetic event silences the other pathway (bottom pathway) the cell dies. 
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6.3 Dataset 
The dataset available for this analysis (Table 6-1) was developed by Gynaecological 
Oncology team at Queen Elizabeth hospital in Gateshead and NICR based in Newcastle 
University (Mukhopadhyay et al., 2010). 
To collect the above dataset, ascities was collected at surgery from patients undergoing 
primary surgery for ovarian cancer. Primary cultures were generated to investigate the 
sensitivity to PARPi and collect DNA, mRNA and Protein.  A functional assay was 
developed to measure HR (Mukhopadhyay et al., 2010) although this process works 
perfectly, it is very time consuming. Therefore it was decided that an investigation of 
the expression of relevant genes in this process may provide a simpler test, more 
suitable for clinical practice.  
cDNA analysis became a widely used tool to study gene expression patterns in human 
cancer. In ovarian cancer this tool has been employed extensively to understand the 
different aspects of this cancer (Resnick et al., 2009; Gunawardana et al., 2009; 
Kulasingam et al., 2010). 
For this study, eight primary cultures were selected for analysis. These had already been 
classified as HR competent (n=4) and HR deficient (n=4), using the functional assay 
described above. mRNA was extracted from unstimulated cells, converted into cDNA 
and analysed using the SA Biosciences DNA repair microarray chip which contains 
probes for 84 DNA repair genes. Data were normalised to housekeeping genes 
contained within the chip.  
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 AVG ΔCt 
Gene  HR+ HR+ HR+ HR+ HR- HR- HR- HR- 
 PCO 
44 
PCO9
5 
PCO9
6 
PCO8
1 
PCO9
0 
PCO100 PC
O93 
PCO 
106 
APEX1 2.61 2.72 2.93 2.35 2.97 3.28 1.99 3.88 
APEX2 8.1 8.85 8.43 8.33 9.53 8.74 8.18 10.05 
ATM 8.8 8.45 8.55 8.69 9.18 7.62 7.35 8.63 
ATR 6.98 6.83 6.81 7.38 7.42 7.25 6.03 8.02 
ATXN3 7.3 8.38 7.77 7.29 8.28 7.24 6.89 8.05 
BRCA1 7.86 6.46 8.44 8.77 7.74 8.92 11.9
5 
8.53 
BRCA2 9.67 6.64 9.12 9.67 9.59 12.76 9.9 9.43 
BRIP1 6.17 6.68 7.38 7.33 6.27 6.98 6.85 7.99 
CCNH 5.23 4.78 4.07 4.67 4.71 4.52 3.08 5.05 
CCNO 10.1
7 
10.74 11.13 10.84 10.84 11.34 8.54 11.64 
CDK7 4.59 5.89 4.68 4.96 5.05 5.08 3.9 5.37 
DDB1 3.31 3.4 2.84 2.82 3.95 2.4 2.16 4.29 
DDB2 4.74 5.09 5.04 5.67 5.01 5.04 4.59 6.13 
DMC1 11.0
5 
11.87 11.18 12.36 11.68 14.48 13.6
3 
12.91 
ERCC1 5.86 5.76 5.09 5.55 7.94 5.78 5.07 6.52 
ERCC2 5 5.09 4.1 5.12 5.6 3.93 4.09 5.46 
ERCC3 6.52 6.52 6.09 6.47 6.84 5.96 5.35 7.59 
ERCC4 7.33 7.26 6.8 6.29 7.32 6 5.33 8.38 
ERCC5 4.08 4.72 3.96 4.49 4.04 4.04 3.35 4.84 
ERCC6 8.19 8.27 7.84 8.25 8.36 7.09 6.31 8.62 
ERCC8 7.78 7.72 7.04 7.25 7.49 6.62 6.56 7.52 
EXO1 6.82 7.14 7.24 8.01 7.48 9.64 9.98 8.6 
FEN1 4.97 5.07 4.73 5.51 6.47 6.36 5.23 7.3 
LIG1 6.97 6.92 6.91 7.81 8.28 9.32 8.34 8.93 
LIG3 6.65 7.33 6.28 6.26 7.69 5.74 5.87 7.95 
LIG4 9.2 8.03 8.08 10.07 8.38 7.94 8.03 8.29 
MGMT 4.19 4.71 3.55 3.81 4.5 4.05 3.59 4.09 
MLH1 5.25 5.63 5.25 7.08 5.34 6.2 5.61 5.72 
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MLH3 7.23 7.45 6.94 7.28 7.72 6.9 5.79 6.83 
MMS19 5.03 5.38 5.11 4.85 5.16 4.63 4.34 5.31 
MPG 3.81 3.95 4.17 3.21 3.85 4.34 2.98 4.48 
MRE11
A 
10.2
4 
9.92 9.41 10.23 10.26 10.43 9.23 11.3 
MSH2 5.25 5.37 5.56 6.59 5.68 7.45 6.17 6.7 
MSH3 6.54 6.95 6.26 6.37 6.94 6.74 5.86 7.39 
MSH4 12.6
8 
15.36 14.09 15.88 14.25 13.74 14.6
2 
13.37 
MSH5 8.46 9.29 8.25 8.8 10.05 8.9 7.84 9.74 
MSH6 4.52 4.8 4.51 5.12 4.94 4.63 4.6 5.13 
MUTYH 7.98 8.68 8.7 8.47 9.9 8.94 8.22 9.65 
NEIL1 9 10.65 9.23 10.45 11.18 9.26 8.75 10.1 
NEIL2 7.84 7.75 6.6 7.52 8.47 7.01 6.6 8.72 
NEIL3 9.55 9.06 9.39 11.65 8.64 11.67 12.5
7 
10.38 
NTHL1 6.99 7.87 6.71 7.18 7.3 7.55 6.33 7.84 
OGG1 7.16 7.06 6.75 6.83 7.51 6.59 6.29 7.7 
PARP1 4.35 4.86 5.6 4.81 5.17 5.61 5.36 7.48 
PARP2 5.47 6.45 6.04 6.36 6.16 7.13 5.59 6.66 
PARP3 5.49 6.07 5.6 5.67 6.58 6 5.48 6.33 
PMS1 6.5 7.27 6.74 7.1 7.27 6.8 6.16 7.48 
PMS2 5.87 6.28 6.11 5.56 6.98 5.53 5.2 6.66 
PNKP 6.21 6.37 5.55 6.13 7.56 5.73 4.99 7.55 
POLB 5.96 6.09 5.85 6.4 5.88 6.28 5.15 6.35 
POLD3 6.62 6.99 7.2 7.19 7.64 7.44 7.58 7.55 
POLL 6.95 7.83 7.43 7.27 7.42 6.52 6.22 6.82 
PRKDC 4.27 4.11 3.82 3.44 4.46 3.81 3.38 5.12 
RAD18 6.11 6.74 5.63 6.33 6.11 6.52 5.28 7.14 
RAD21 2.75 3.73 3.61 3.43 3.39 3.05 3.31 4.4 
RAD23
A 
4.33 4.87 4.26 4.07 4.98 3.7 3.44 4.77 
RAD23
B 
2.37 2.74 2.37 2.12 2.8 2.08 1.83 3.47 
RAD50 6.99 7.61 7.09 8.03 8.28 7.19 6.84 8.32 
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RAD51 10.5
5 
10.94 11.7 11.59 11.6 13.09 14.2
6 
11.83 
RAD51
C 
6.56 8.06 6.98 7.78 7.25 8.06 7.09 8.48 
RAD51
L1 
8.05 8.32 7.94 8.03 8.67 7.99 7.1 8.82 
RAD51
L3 
9.13 8.44 8.29 9.43 9.37 8.78 9.36 9.52 
RAD52 8.83 9.22 8.82 9.41 9.29 9.03 7.85 9.4 
RAD54
L 
7.37 7.99 8.34 9.69 8.2 10.06 9.26 8.63 
RFC1 5.71 6.38 6.01 6.77 5.64 5.78 5.84 6.26 
RPA1 4.04 3.85 3.75 3.77 4.24 4.06 3.35 4.88 
RPA3 4.57 5.45 4.85 5.24 5.25 5.75 5.47 5.68 
SLK 3.78 4.12 4.71 3.67 3.62 3.25 2.93 5.42 
SMUG1 6.52 7.04 6.38 7.06 6.84 6.79 6.28 7.57 
TDG 5.63 5.71 5.81 6.18 5.7 5.99 5.47 6.39 
TOP3A 7.7 7.85 8.02 7.84 8.94 8.31 7.16 8.95 
TOP3B 6.96 7.77 6.78 7.27 8.63 6.74 5.53 8.86 
TREX1 6.15 6.67 7.18 7.08 7.72 7.1 6.81 6.88 
UNG 4.82 5.85 5.07 5.55 5 5.36 4.81 5.73 
XAB2 4.85 5.75 5.07 5.31 5.33 4.97 4.14 5.34 
XPA 6.47 6.59 6.53 7.07 6.14 6.7 6.21 6.49 
XPC 4.61 5.43 4.99 5.67 4.75 4.91 4.84 5 
XRCC1 5.3 5.58 5.39 6 5.95 5.93 5.38 5.97 
XRCC2 9.76 8.6 9.23 10.68 9.45 11.32 11.0
9 
10.17 
XRCC3 11.0
2 
11.67 9.84 11.64 13.75 10.55 9.59 13.28 
XRCC4 6.55 6.6 5.75 6.42 6.25 3.74 4 6.56 
XRCC5 2.12 2.15 1.88 1.89 1.9 1.75 1.3 2.97 
XRCC6 3.02 3.82 2.99 3.36 3.07 3.67 2.93 3.94 
XRCC6
BP1 
7.56 8.4 8.27 7.83 7.87 7.97 7.73 7.76 
Table 6-1 Gene analysis dataset 
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6.4 Most important Genes  
Previously it has been explained that the prediction of HR can play an important role in 
future treatment path of ovarian cancer. Using feature selection techniques (section 
1.3.2), the analysis was performed to identify the most important genes for this 
prediction.  
TPP (section 1.3.2.3)was used to analyse the dataset to compare the gene expression 
between HR competent and HR deficient tumours. This showed a clear separation 
between the two sets, Figure 6-2 illustrates the first view of the dataset produced using 
TPP. At first glance there is a separation between HR and HR  cases. HR cases 
clustered together in the middle of the dataset and HR  cases produced two separated 
clusters at the top and left of HR  cases. In order to discover the most important genes, 
TPP was further employed to generate the separated class view of the data.  
Figure 6-3 illustrates the separated class view of the dataset using TPP. The HR and 
HR  cases are clearly separated from each other. HR  cases clustered together at the 
top of the figure and HR  cases clustered together at the bottom of the figure. 
In parallel with above analysis other feature selection techniques such as IG and GA 
(section 1.3.2) were employed for identification of the most important genes. The 
algorithms were used to identify the top 12 differentially regulated genes between the 4 
HR competent and the 4 HR deficient tumours (Table 6-1). All three methods (TPP, GA 
and IG) identified LIG1 and POLD3 as the most important genes.  
 
Discussion: Based on the TPP analysis there is a clear separation between HR+ and 
HR- cases. All three techniques identified LIG1 and POLD3 as the most important 
genes. The other genes that identified by all three techniques were FEN1 and EX01. The 
results of TPP and GA have more similarities (10 of 12 important genes) compared to 
the results of IG.  
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Figure 6-2 First view of dataset using TPP 
 The dots are displayed as a 2D projection of the 84 dimension analysis. HR

cases 
clustered in the middle whilst two HR

cases clustered  at the top and other two HR

 at 
the bottom left. 
 
Figure 6-3 Separated class view of the dataset using TPP 
This separated class’s view of the dataset was produced using TPP and demonstrates 
that HR

and HR

are clearly separated.  
 
 
Method Identified Genes 
TPP 
LIG1, POLD3, XPA, FEN1, EX01, XRCC4, LIG4, PARP3, 
RFC1, RPA3, POLL, RAD51 
GA 
LIG1, POLD3, XPA, EX01, PARP3, POLL, RFC1, FEN1, 
RPA3, RAD51, ERCC1, DMC1 
IG 
LIG1, POLD3, MLH3, MLH1, MMS19, MPG, FEN1, EX01, 
MGMT, LIG3, LIG4, MUTYH 
Table 6-2 12 most differentially regulated genes identified between 4 HR competent and 4 HR 
deficient tumours using three methods 
 
HR
HR
HR
HR
HR
162 
6.5 HR prediction models 
The models used in previous sections (ANN, DT and BN) were then employed to 
develop prediction models of HR.  
Table 6-2 summarizes the ANN results of prediction performance of HR. The accuracy 
of this model was 75%. The MAE value was 0.27 and RMSE value was 0.42. ANN 
managed to produce a very good model (AUC: 0.8750). 
Figure 6-4 illustrates the ROC curves produces by ANN for prediction of HR. The AUC 
for both of the curves was 0.8750.  
 
 
 
 
Measurement Result 
 
Accuracy 75.00% 
Mean absolute error 0.27 
Root mean squared error 0.42 
Outcome Recall Precision AUC 
HR+ 1.00 0.667 0.8750 
HR- 0.750 1.00 0.8750 
Table 6-3 ANN prediction performance results (HR) 
 
 
Figure 6-4 HR prediction ROC curves using ANN 
a: HR+ and b: HR- 
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Table 6-3 summarizes the BN results of prediction performance of HR. The accuracy of 
this model was 62.50%. The MAE value was 0.46 and RMSE value 0.63. BN did not 
manage to produce any worthy model (AUC: 0.3750). 
Figure 6-5 illustrates the ROC curves produced by BN for the prediction of HR. BN 
failed to produce any worthy model (AUC: 0.3750) 
 
 
 
Measurement Result 
 
Accuracy 62.50% 
Mean absolute error 0.46 
Root mean squared error 0.63 
Outcome Recall Precision AUC 
HR+ 0.750 0.600 0.3750 
HR- 0.500 0.633 0.3750 
Table 6-4 BN prediction performance results (HR) 
 
 
Figure 6-5 HR prediction ROC curves using BN 
a: HR+ and b: HR- 
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Table 6-4 summarizes the DT results of prediction performance of HR. The accuracy of 
this model was 62.50%. The MAE value was 0.37 and RMSE value 0.61. DT managed 
to produce an average model (AUC: 0.6250). 
Figure 6-6 illustrates the ROC curves produced by DT for the prediction of HR. DT 
managed to produce an average model (AUC: 0.6250). 
 
 
 
 
Measurement Result 
 
Accuracy 62.50% 
Mean absolute error 0.37 
Root mean squared error 0.61 
Outcome Recall Precision AUC 
HR+ 0.750 0.600 0.6250 
HR- 0.625 0.633 0.6250 
Table 6-5 DT prediction performance results (HR) 
 
 
 
Figure 6-6 HR prediction ROC curves using DT 
a: HR+ and b: HR- 
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Discussion: Based on the results ANN managed to develop a very good model (AUC: 
0.8750).  The accuracy of this model was 75%. The MAE value was 0.27 and RMSE 
value was 0.42. ANN managed to produce a very good model. The other models failed 
to introduce any good results. However DT performed better than BN. 
 
6.6 Summary of the chapter 
DNA is damaged many times during each cell cycle and these damages are repaired 
using DNA repair pathways. One of these repair pathways is HR and the two of the 
most important genes in these pathways are BRCA1 and BRCA2. The other DNA 
repair pathway is called base excision and PARP is an important protein in this 
pathway. A combination of defective HR and inhabited PARP is lethal to the cell. 
Therefor PARPi are effective in cancers with mutated BRCA1 and BRCA2 genes. As a 
result, a simple test that would identify tumours with defective HR would therefore 
identify a group of patients who would likely respond to a PARP inhibitor.  
For this analysis a dataset which was developed by Gynaecological Oncology team at 
Queen Elizabeth Hospital in Gateshead and NICR based in Newcastle University is 
used. Briefly this dataset consist of eight primary cultures that had already been 
classified as HR competent (n=4) and HR deficient (n=4). 
The feature selection techniques: TPP, IG and GA were employed for identification of 
the most important genes. The algorithms were used to identify the top 12 differently 
regulated genes between 84 available genes. The most important genes identified as 
LIG1 and POLD3. 
Furthermore, ANN, BN and DT models were employed to predict the HR based on the 
available dataset that described previously. ANN outperformed other methods 
(Accuracy: 75%, AUC: 0.8750). 
This analysis was performed using a small dataset and more cases are needed for 
analysis. Identified genes (LIG1 and POLD3) have to be prospectively validated using 
other conventional methods.  
On the other hand, this analysis highlights that the test done on RNA is easier to roll out 
into clinical practice than the current gold standard HR test.  
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Chapter 7 Conclusion and Future Works 
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7.1 Introduction 
This chapter draws conclusions on the work reported in this thesis. A brief summary of 
major contributions of this research is provided and suggestions for possible further 
studies are made.  
7.2 Conclusions of the Thesis 
This thesis presents an effective approach via machine learning and artificial 
intelligence to predict survival outcome in patients with ovarian cancer. The approach 
taken is novel in the field of ovarian cancer research. The main conclusions drawn from 
this thesis to answer the research questions are as follows: 
 AI and ML models can effectively predict overall survival rates of ovarian cancer 
patients.  
 Using AI and ML models made it possible to predict the outcome of the surgery. 
 Feature selection techniques can identify the most important factors to predict 
survival rates and outcome of the surgery. 
Some important conclusions derived from this study are as follows: 
AI and ML models in most cases outperform conventional statistical models. ANN 
demonstrated the optimal performance of all the investigated models. The prediction 
performance of the models may improve by increasing the available data for analysis.   
7.3 Summary of main contributions 
The main goal of this research was to investigate and employ AI and ML models in 
order to provide more effective tools for clinicians managing patients with ovarian 
cancer. This goal leads to two major contributions, which are reviewed in related 
literature and the solution for the prediction. 
7.3.1 The review of related problems 
The review of the literature was divided into two sections: computing and medicine 
literature. The existing ovarian cancer literature shows that the dominant types of 
prediction models are statistical models. The AI and ML models were used to predict 
different aspects in other cancers; however the dominant prediction models in the field 
of ovarian cancer have all been statistical models until now.  
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The review of the computing literature indicates that three types of models are used for 
prediction. The ANN models as AI models, the BN as probabilistic models and DT as 
ML models are widely used.  
The existing literature identifies several problems as follows: 
 There is no effective way available for clinicians to measure the survival rates of the 
patients in an accurate way. 
 Prediction of the outcome of the surgery remains an unsolved question and there is 
an essential need for this prediction.  
 There is a need for an expert computer system to analyse the new biomarkers and 
treatment pathways. 
 The developed models have to be easy to use.  
 As the number of patient data increases the model has to cope with the new data and 
improve itself.  
7.3.2 The solution for prediction 
Developing a solution for predicting the survival rates and outcome of the surgery are 
the most important contribution of this research, as the prediction of these outcomes 
may have a significant effect on the quality of life of the patients. Accurate prediction of 
survival would allow patients to make informed treatment option decisions, faced with a 
poor prognosis patients may be more prone to opt for palliation, whereas patients with a 
good overall prognosis would be more likely to tolerate invasive and toxic treatment 
knowing that this will result in a survival benefit. Such accurate tools have not been 
available to date, although prognostic tools are available which can be applied to 
populations they are not accurate enough to allow use in individual cases.  In this 
research the computation power of AI and ML models were demonstrated. Four main 
steps were used for the prediction: (a) collection of the relevant data; (b) development of 
variety of AI, ML and LR models; (c) analysis of the models by increasing the number 
of available data; (d) Identification of the most important variable for each prediction 
using all permutations search and feature selection methods;  
The main capabilities of developed models for survival prediction are as follows: 
The best developed model can predict the five year survival of the patient by 92.07% 
accuracy. The AUC of this model was 0.74. The accuracy of 92.07% is a very high 
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accuracy, however the AUC value is categorized as a good model and the model has to 
be improved to become an accurate enough model. 
The model can predict the survival rate for 64 categories (section 4.3.1). Although the 
prediction accuracy for 64 categories is very low (based on the available data), by 
improving number of cases, this prediction may provide clinicians useful information. 
The prediction accuracy of the model increased as the number of cases improved. 
 
The developed model outperforms the conventional statistical models. The prediction 
results of developed model are higher than currently available models in the field of 
ovarian cancer. The currently available model can only predict the five year survival 
however the developed model in this research can predict the survival for many 
categories. 
 
Prediction is still not accurate enough for use on an individual patient but the 
encouraging thing is that the systems improve with data entry so this may develop into 
an accurate enough model eventually. 
 
The main capabilities of developed models for outcome of the surgery prediction are as 
follows: 
 The model can predict the outcome of the surgery for three main categories: (a) 
complete or optimal or sub-optimal cytoreduction; (b) complete or optimal 
cytoreduction versus sub-optimal cytoreduction; (c) complete cytoreduction versus 
optimal or sub-optimal cytoreduction. 
 The developed model is a unique model for such prediction in the field of cancer 
research. 
7.3.3 The prototype implementation and evaluation 
The prototype of the models has been implemented using Java programming language 
in Windows environment (however it can be used on other platforms or web based). 
This prototype validates the approach used in this research and can be employed by 
clinicians for further use.  The prototype provided a fundamental basis for conducting 
the experimental study of this research. 
The developed prototype serves the following purposes: 
 The easy to use graphical interface which is useable for any researcher. 
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 The capability of showing the survival rate and the prediction of the outcome of the 
surgery in discussed categories. 
 The capability of adding and analysing new data to the dataset. 
 The ability of the prototype to record newly added data. 
7.4 Further work 
There are some areas to explore in further details as follows: 
 Analysis of other feature sets 
The datasets that were used in this research were taken from sequential patients 
who underwent primary surgery between 1995 and 2005 at the Northern 
Gynaecological Oncology Centre, Gateshead, UK, with appropriate ethical 
approval. For further work the suggestion is to expand the date range of the data 
that collected from this centre to include the data from 2005-2010.The gene 
analysis chapter (chapter 6) of thesis was based on a dataset that included 8 
patients. The complexity of the micro array datasets requires the collection of new 
such data for further analysis. Furthermore, for complete validation of this research 
the datasets that collected from other centres around the world and UK has to be 
included. The reason is that other centres have different surgical approaches and so 
data from one centre may not reflect findings in another (would future models have 
to cope with this, the treating centre may be a very important feature in its own 
right) this will need exploring and validating in future work. 
 Including the missing values 
As discussed previously (chapter 2) the datasets included a number of missing 
values. The original analysis was performed and the missing values were excluded 
from the datasets. For further research, it is suggested that such data be handled and 
included in the dataset. Semi supervised methods can be employed for handling the 
missing values.   
 Connection with DNA microarray dataset 
The analysis of DNA micro array data discovered potential genes involved in 
abrogation of an important DNA repair pathway in ovarian cancer. It can be 
suggested for the next step of this research to explore the connection(s) between 
discovered genes and the OS and outcome of the surgery of the patients.  
 Exploration of other models 
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This research included different models of ML and AI. There is a potential to 
expand these models to include further developed models in this (such as 
bootstrapping). The number of available new or improved models and packages 
(such as R) are growing, the investigation of new models are suggested. 
 Completion of the prototype 
The prototype may help clinicians to have a more clear idea of which treatment 
pathway to choose for a particular patient. Therefore, the completion of the 
prototype will be the next plan. This prototype (as discussed previously) may 
improve the quality of the life of the patients and a completed prototype may be 
employed by hospitals and clinicians for better management of ovarian cancer. It 
will also result in the generation of larger datasets which could be used for 
validating and further developing the models. Although the prototype has been 
made as easy to use as possible there will be a real challenge in encouraging busy 
clinicians to enter data in real time. As the validity of the prototype is demonstrated 
and the quality of the output data improve with time the hope is that the prototype 
becomes a clinically useful tool which clinicians will want to use. The hope is that 
the prototype act similar to ‘adjuvant online’, which is used all the time by breast 
cancer oncologists which doesn’t have the capability to capture any new data. 
Furthermore, the issues regarding the instituting this prototype in many centres such 
as security of data transfer and ethical considerations has to be investigated in future 
work. 
 Investigation of other survival data 
Cancer research scientists are investigating Event-free survival (EFS) and Relapse-
free survival (RFS) for cancer patients. These factors were not included in the 
present analysis as the data were not available for this analysis and also the priority 
that was set for this research was to investigate the overall survival. It would be very 
beneficial to generate, analyse and include RFS and EFS into this analysis. 
7.5 The overall achievement of the thesis 
The overall achievements of this research can be summarized as follows: 
The main achievement of this research is the presentation of a solution to predict the 
outcome in ovarian cancer. There are different models compared in this research and the 
most successful models were identified. Development of an AI system to predict the 
outcome of the surgery which has never been conducted before in the field of ovarian 
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cancer. Identification of the most important genes using TPP as a multivariate feature 
selection technique for the first time. Other achievement which is arguably novel, that 
is, developed model is able to predict the survival rates of the patients for 64 categories 
based on the median maximum survival value in the dataset. By improving the number 
of cases available in the dataset this model can effectively predict the survival rates in 
the range of a month. Lastly, this research presents a new pathway of using AI systems 
for helping clinicians to explore different treatment options for a patient.  
 
Overall, present research makes advances in the clinical decisions making area in the 
medicine. The developed models make a strong argument that such models can be 
employed by health care teams to explore different treatments for a patient. 
Furthermore, this approach has also demonstrated its efficiency in dealing with large 
amounts of clinical data and finding the associations between the different markers to 
predict outcomes in ovarian cancer. We believe that the findings presented in this thesis 
will draw more attention to the area and attract more research in this field. 
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Appendices 
Appendix 1 Prototype snapshot 
Following is the snap shot of the main page of the developed prototype in this research.  
1- User enters the data into the prototype 
2- User selects survival/surgery for the prediction of the survival/surgery. 
3- After the analysis user has the option to include this new data into the dataset. 
4- By using analysis option user can produce different results (ROC curves, LR 
prediction, other modelling results, …) 
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Appendix 2 class diagrams 
Following are some of the class diagrams for the (weka) codes that used in this research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GeneticSearch (weka) 
-m_starting : int[]  
-m_startRange : Range  
-m_hasClass : boolean  
-m_classIndex : int  
-m_numAttribs : int  
-m_popSize : int  
-m_bestFeatureCount : int 
 -m_lookupTableSize : int 
 -m_lookupTable : Hashtable 
 -m_random : Random 
 -m_seed : int  
-m_pCrossover : double  
-m_pMutation : double  
-m_sumFitness : double  
-m_maxFitness : double  
-m_minFitness : double  
-m_avgFitness : double  
-m_maxGenerations : int  
-m_reportFrequency : int  
-m_generationReports: StringBuffer  
-m_population : GABitSet[]  
-m_best : GABitSet 
 
+listOptions() : Enumeration 
+setOptions(options : String []) : void 
 +getOptions() : String [] 
+startSetTipText() : String 
+setStartSet(startSet : String) : void  
+getStartSet() : String +seedTipText() 
: String +setSeed(s : int) : void 
+getSeed() : int 
+reportFrequencyTipText() : String  
+setReportFrequency(f : int) : void 
 +getReportFrequency() : int 
+mutationProbTipText() : String  
+setMutationProb(m : double) : void  
+getMutationProb() : double 
+crossoverProbTipText() : String 
+setCrossoverProb(c : double) : void 
+getCrossoverProb() : double 
+maxGenerationsTipText() : String  
+setMaxGenerations(m : int) : void 
+getMaxGenerations() : int  
+populationSizeTipText() : String 
+setPopulationSize(p : int) : void 
+getPopulationSize() : int 
+globalInfo() : String 
+GeneticSearch() -startSetToString() : 
String +toString() : String 
+search(ASEval : ASEvaluation, data : 
Instances) : int [] -attributeList(group 
: BitSet) : int [] -checkBest() : boolean 
-countFeatures(featureSet : BitSet) : 
int -generation() : void -select() : int -
evaluatePopulation(ASEvaluator : 
SubsetEvaluator) : void -
initPopulation() : void -
populationStatistics() : void -
scalePopulation() : void -
populationReport(genNum : 
int) : String -
printPopMember(temp : BitSet) 
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InfoGain (weka) 
 
-m_missing_merge : Boolean 
-m_Binarize : boolean  
-m_InfoGains : double[] 
 
+globalInfo() : String 
+InfoGainAttributeEval() 
+listOptions() : Enumeration 
+setOptions(options : String []) : void 
+getOptions() : String [] 
+binarizeNumericAttributesTipText() 
: String 
+setBinarizeNumericAttributes(b : 
boolean) : void 
+getBinarizeNumericAttributes() : 
boolean 
+missingMergeTipText() : String 
+setMissingMerge(b : boolean) : void 
+getMissingMerge() : boolean 
+buildEvaluator(data : Instances) : 
void 
#resetOptions() : void 
+evaluateAttribute(attribute : int) : 
double 
+toString() : String 
NaiveBayes(weka) 
 
#m_Distributions : Estimator[][] 
#m_ClassDistribution : Estimator 
#m_UseKernelEstimator : boolean = 
false 
#m_UseDiscretization : boolean = 
false 
#m_NumClasses : int 
#m_Instances : Instances 
#DEFAULT_NUM_PRECISION : 
double = 0.01 
#m_Disc : Discretize = null 
 
 
+buildClassifier(instances : Instances) 
: void 
+updateClassifier(instance : Instance) 
: void 
+distributionForInstance(instance : 
Instance) : double [] 
+listOptions() : Enumeration 
+setOptions(options : String []) : void 
+getOptions() : String [] 
+toString() : String 
+getUseKernelEstimator() : boolean 
+setUseKernelEstimator(v : boolean) 
: void 
+getUseSupervisedDiscretization() : 
boolean 
+setUseSupervisedDiscretization(new
blah : boolean) : void 
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PCA (weka) 
 
m_trainInstances : Instances 
-m_trainCopy : Instances 
-m_transformedFormat : Instances 
-m_originalSpaceFormat : Instances 
-m_hasClass : boolean 
-m_classIndex : int 
-m_numAttribs : int 
-m_numInstances : int 
-m_correlation : double[][] 
-m_eigenvectors : double[][] 
-m_eigenvalues : double[] = null 
-m_sortedEigens : int[] 
-m_sumOfEigenValues : double = 0.0 
-m_replaceMissingFilter : 
ReplaceMissingValues 
-m_normalizeFilter : Normalize 
-m_nominalToBinFilter : 
NominalToBinary 
-m_attributeFilter : Remove 
-m_attribFilter : Remove 
-m_outputNumAtts : int = -1 
-m_normalize : boolean = true 
-m_coverVariance : double = 0.95 
-m_transBackToOriginal : boolean = 
false 
-m_eTranspose : double[][] 
 
 
+globalInfo() : String 
+listOptions() : Enumeration 
+setOptions(options : String []) : void 
-resetOptions() : void 
+normalizeTipText() : String 
+setNormalize(n : boolean) : void 
+getNormalize() : boolean 
+varianceCoveredTipText() : String 
+setVarianceCovered(vc : double) : 
void 
+getVarianceCovered() : double 
+transformBackToOriginalTipText() 
: String 
+setTransformBackToOriginal(b : 
boolean) : void 
+getTransformBackToOriginal() : 
boolean 
+getOptions() : String [] 
+buildEvaluator(data : Instances) : 
void 
-buildAttributeConstructor(data : 
Instances) : void 
+transformedHeader() : Instances 
+transformedData() : Instances 
+evaluateAttribute(att : int) : double 
-fillCorrelation() : void 
-principalComponentsSummary() : 
String 
+toString() : String 
-matrixToString(matrix : double [][]) 
: String 
-convertInstanceToOriginal(inst : 
Instance) : Instance 
+convertInstance(instance : Instance) 
: Instance 
-setOutputFormatOriginal() : 
Instances 
-setOutputFormat() : Instances 
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ANN (weka) 
 
-m_instances : Instances 
-m_currentInstance : Instan 
-m_numeric : boolean 
-m_attributeRanges : doub 
-m_attributeBases : double 
-m_numClasses : int = 0 
-m_numAttributes : int = 0 
-m_nextId : int 
-m_selected : FastVector 
-m_graphers : FastVector 
-m_numEpochs : int 
-m_stopIt : boolean 
-m_stopped : boolean 
-m_accepted : boolean 
-m_win : JFrame 
-m_autoBuild : boolean 
-m_gui : boolean 
-m_valSize : int 
-m_driftThreshold : int 
-m_randomSeed : long 
-m_random : Random 
-m_nominalToBinaryFilter : 
-m_hiddenLayers : String 
-m_normalizeAttributes : bo 
-m_decay : boolean 
-m_learningRate : double 
-m_momentum : double 
-m_epoch : int 
-m_error : double 
-m_reset : boolean 
-m_normalizeClass : boole 
-m_outputs : NeuralEnd[] 
-m_inputs : NeuralEnd[] 
-m_neuralNodes : NeuralC 
-m_nodePanel : NodePane 
-m_controlPanel : ControlP 
-m_sigmoidUnit : SigmoidU 
-m_linearUnit : LinearUnit 
 
+NeuralNetwork() 
+setDecay(d : boolean) : void 
+getDecay() : boolean 
+setReset(r : boolean) : void 
+getReset() : boolean 
+setNormalizeNumericClass(c : 
boolean) : void 
+getNormalizeNumericClass() : 
boolean 
+setNormalizeAttributes(a : boolean) 
: void 
+getNormalizeAttributes() : boolean 
+setNominalToBinaryFilter(f : 
boolean) : void 
+getNominalToBinaryFilter() : 
boolean 
+setRandomSeed(l : long) : void 
+getRandomSeed() : long 
+setValidationThreshold(t : int) : void 
+getValidationThreshold() : int 
+setLearningRate(l : double) : void 
+getLearningRate() : double 
+setMomentum(m : double) : void 
+getMomentum() : double 
+setAutoBuild(a : boolean) : void 
+getAutoBuild() : boolean 
+setHiddenLayers(h : String) : void 
+getHiddenLayers() : String 
+setGUI(a : boolean) : void 
+getGUI() : boolean 
+setValidationSetSize(a : int) : void 
+getValidationSetSize() : int 
+setTrainingTime(n : int) : void 
+getTrainingTime() : int 
-addNode(n : NeuralConnection) : 
void 
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